Loading organization details...
Loading organization details...
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2024
Total Revenue
▼$2.6M
Program Spending
93%
of total expenses go to program services
Total Contributions
$939.4K
Total Expenses
▼$2.7M
Total Assets
$1.6M
Total Liabilities
▼$732.2K
Net Assets
$892.5K
Officer Compensation
→N/A
Other Salaries
$868.4K
Investment Income
$838
Fundraising
▼N/A
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$117.3M
VA/DoD Award Count
13
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding (partial)
$2.8B
Awards Found
200+
Additional awards may exist. View all on USAspending.gov →
| Awarding Agency | Description | Amount | Fiscal Year | Period |
|---|---|---|---|---|
| Corporation for National and Community Service | THIS APPLICATION IS FOR NEW, RECOMPETING, OR CONTINUATION STATE COMMISSION APPLICANTS, INCLUDING TERRITORIES WITH COMMISSIONS, APPLYING FOR COST REIMBURSEMENT GRANTS. | $107.2M | FY2021 | Aug 2021 – Jul 2025 |
| Department of Health and Human Services | CASE COMPREHENSIVE CANCER CENTER SUPPORT GRANT | $105.9M | FY1997 | Aug 1997 – Mar 2030 |
| Department of Health and Human Services | EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC) | $90.4M | FY2011 | Sep 2011 – Jun 2027 |
| Corporation for National and Community Service | THIS AWARD FUNDS THE APPROVED 2024-2025 AMERICORPS STATE COMPETITIVE PROGRAMS, AS LISTED ON THE APPROVED PROGRAM AND FUNDING SUMMARY CHARTS. NO MEMBER MAY ENROLL PRIOR TO THE APPROVED START DATE OF THE MEMBER ENROLLMENT PERIOD. YOUR 2024-2025 REGULATORY MATCH IS 14.96% AND YOUR BUDGETARY MATCH IS 42.28%. THE MULTIYEAR FUNDING AWARDED TO THE BREAKTHROUGH TWIN CITIES PROGRAM ON THE 2023-24 GRANT WAS DEOBLIGATED FROM THE 21ACE GRANT AND REOBLIGATED ON THIS GRANT. | $79.8M | FY2024 | Aug 2024 – Jul 2027 |
| Department of Agriculture | THE FOOD FOR PROGRESS PROGRAM PROVIDES FOR THE DONATION OF U.S. COMMODITIES TO DEVELOPING COUNTRIES AND EMERGING DEMOCRACIES THAT ARE COMMITTED TO INTRODUCING OR EXPANDING FREE ENTERPRISE IN THEIR AGRICULTURAL ECONOMIES. THE PROGRAM HAS TWO PRIMARY STRATEGIC OBJECTIVES: (1) INCREASE AGRICULTURAL PRODUCTIVITY AND (2) EXPAND TRADE OF AGRICULTURAL PRODUCTS. THIS FOOD FOR PROGRESS PROGRAM IS BEING IMPLEMENTED IN BENIN. | $55M | FY2015 | Sep 2015 – Apr 2024 |
| Corporation for National and Community Service | N/A | $53.8M | FY2018 | Aug 2018 – Jul 2022 |
| Department of Agriculture | THE FOOD FOR PROGRESS PROGRAM PROVIDES FOR THE DONATION OF U.S. COMMODITIES TO DEVELOPING COUNTRIES AND EMERGING DEMOCRACIES THAT ARE COMMITTED TO INTRODUCING OR EXPANDING FREE ENTERPRISE IN THEIR AGRICULTURAL ECONOMIES. THE PROGRAM HAS TWO PRIMARY STRATEGIC OBJECTIVES: (1) INCREASE AGRICULTURAL PRODUCTIVITY AND (2) EXPAND TRADE OF AGRICULTURAL PRODUCTS. CENTRAL AMERICA AND PERU | $50.1M | FY2018 | Sep 2018 – Sep 2023 |
| Corporation for National and Community Service | COMMISSION STATE GRANTS ARE AWARDED TO ORGANIZATIONS THAT ARE PROPOSING A PROJECT THAT OPERATE IN ONLY ONE STATE AND THAT ARE PUT FORWARD TO CNCS BY | $49.7M | FY2015 | Aug 2015 – Aug 2019 |
| Department of Health and Human Services | CLINICAL AND TRANSLATIONAL SCIENCE COLLABORATIVE OF CLEVELAND | $48.8M | FY2007 | Sep 2007 – May 2018 |
| Department of Health and Human Services | CASE WESTERN RESERVE UNIVERSITY/CLEVELAND CLINIC CTSA (UL1) | $43M | FY2007 | Sep 2007 – Jun 2012 |
| Department of Agriculture | THE FOOD FOR PROGRESS PROGRAM PROVIDES FOR THE DONATION OF U.S. COMMODITIES TO DEVELOPING COUNTRIES AND EMERGING DEMOCRACIES THAT ARE COMMITTED TO INTRODUCING OR EXPANDING FREE ENTERPRISE IN THEIR AGRICULTURAL ECONOMIES. THE PROGRAM HAS TWO PRIMARY STRATEGIC OBJECTIVES: (1) INCREASE AGRICULTURAL PRODUCTIVITY AND (2) EXPAND TRADE OF AGRICULTURAL PRODUCTS. THIS FOOD FOR PROGRESS IS BEING IMPLEMENTED IN WEST AFRICA REGIONAL; | $42.5M | FY2021 | Oct 2020 – Sep 2025 |
| Department of Health and Human Services | CASE AIDS CLINICAL TRIALS UNIT | $40M | FY2007 | Feb 2007 – Nov 2027 |
| Department of Agriculture | AGRICULTURAL PRODUCTIVITY AND VALUE CHAIN DEVELOPMENT PROJECT | $36M | FY2015 | Sep 2015 – Sep 2020 |
| Department of Health and Human Services | CLINICAL AND TRANSLATIONAL SCIENCE COLLABORATIVE OF CLEVELAND | $35.5M | FY2018 | May 2018 – Sep 2023 |
| National Science Foundation | NSF CENTER FOR LAYERED POLYMERIC SYSTEMS | $34.2M | FY2006 | Aug 2006 – Jul 2018 |
| Department of Health and Human Services | CENTER FOR AIDS RESEARCH(CFAR) | $32.9M | FY1997 | Apr 1997 – Apr 2021 |
| Corporation for National and Community Service | AMERICORPS STATE | $31.4M | FY2009 | Aug 2009 – Dec 2012 |
| Corporation for National and Community Service | ENGAGES AMERICORPS MEMBERS IN FULL AND PART-TIME SERVICE TO MEET COMMUNITY NEEDS IN EDUCATION, THE ENVIRONMENT, HEALTH, VETERANS, AND OTHER AREAS | $28.9M | FY2012 | Aug 2012 – Dec 2015 |
| Department of Health and Human Services | ASTHMA INFLAMMATION RESEARCH (AIR) | $26.6M | FY2011 | Aug 2011 – Jun 2022 |
| Corporation for National and Community Service | AMERICORPS*STATE | $26.1M | FY2006 | Aug 2006 – Sep 2009 |
| Department of Health and Human Services | CASE GI SPORE | $24.5M | FY2011 | Sep 2011 – Jul 2023 |
| Department of Health and Human Services | CLINICAL AND TRANSLATIONAL SCIENCE COLLABORATIVE OF NORTHERN OHIO, CATALYZING LINKAGES TO EQUITY IN HEALTH (CLE HEALTH) - PROJECT SUMMARY/ABSTRACT FOR THE PAST 15 YEARS, THE CLINICAL AND TRANSLATIONAL SCIENCE COLLABORATIVE (CTSC) AT CASE WESTERN RESERVE UNIVERSITY (CWRU) HAS LINKED CLINICAL AND TRANSLATIONAL RESEARCH EFFORTS AT FIVE INDEPENDENT INSTITUTIONS— CWRU, CLEVELAND CLINIC, METROHEALTH SYSTEM, UNIVERSITY HOSPITALS OF CLEVELAND, AND LOUIS STOKES CLEVELAND VETERANS AFFAIRS MEDICAL CENTER. TWO NEW PARTNERS (UNIVERSITY OF TOLEDO SCHOOL OF MEDICINE AND NORTHEAST OHIO MEDICAL UNIVERSITY) ARE NOW BEING ADDED TO EXTEND THE CTSC’S REACH ACROSS NORTHERN OHIO. THE CWRU CTSC HAS A STRONG TRACK RECORD OF ENHANCING THE QUANTITY AND QUALITY OF CLINICAL AND TRANSLATIONAL SCIENCE (CTS) AMONG OUR PARTNERS BY FACILITATING NOVEL RESEARCH PARADIGMS, TECHNOLOGIES, AND TRAINING. OUR CTSC HAS DEVELOPED A NEW GENERATION OF RESEARCHERS, ENHANCED COLLABORATIONS AMONG INVESTIGATORS, STREAMLINED DISCOVERY BY BUILDING PARTNERSHIPS AMONG INDUSTRY AND COMMUNITY AND ORGANIZATIONAL PARTNERS, AND FACILITATED MANY SUCCESSFUL ENTREPRENEURIAL STARTUPS. BUILDING ON THIS SOLID FOUNDATION, THE CWRU CTSC PROPOSES AN EXPANDED FOCUS ON HEALTH EQUITY, REFLECTED IN THE PROJECT THEME CATALYZING LINKAGES TO EQUITY IN HEALTH (CLE HEALTH). SOCIAL, ECONOMIC, AND ENVIRONMENTAL DISADVANTAGES ARE LINKED TO POOR HEALTH OUTCOMES AND LEAD TO DISPARITIES IN LIFE EXPECTANCY, INFANT MORTALITY, AND RATES OF CHRONIC CONDITIONS. MINORITY GROUPS ARE OFTEN UNDERREPRESENTED IN CLINICAL TRIALS AS WELL, MEANING THERE CAN BE INSUFFICIENT DATA FOR UNDERSTANDING THE EFFECTIVENESS OR SAFETY OF NEW DRUGS, PROCEDURES, OR HEALTH INTERVENTIONS FOR DIFFERENT POPULATIONS. THE OVERALL GOALS OF THIS PROJECT ARE TO 1) UNDERSTAND THE FUNDAMENTAL BARRIERS TO OPTIMAL RECRUITMENT OF UNDERREPRESENTED GROUPS IN CLINICAL TRIALS AND TEST AND SCALE INTERVENTIONS AIMED AT BREAKING DOWN THESE BARRIERS TO DIVERSIFY STUDY ENGAGEMENT, 2) FACILITATE AND EXPEDITE INNOVATION IN MULTICENTER CLINICAL AND TRANSLATIONAL RESEARCH BY FULLY INTEGRATING COMMUNITY AND STAKEHOLDER PARTNERS AND ENSURING THAT THIS RESEARCH REPRESENTS THE EXPERIENCES OF ALL AND RESULTS IN HEALTH IMPROVEMENTS FOR ALL, 3) DISSEMINATE AND IMPLEMENT NOVEL AND RESPONSIVE RESEARCH PROGRAMS ACROSS CLINICAL AND COMMUNITY SETTINGS TO ADVANCE ACCESS TO HEALTH INTERVENTIONS THAT AIM TO PROMOTE HEALTH EQUITY, AND 4) CREATE AND DISSEMINATE INCLUSIVE AND HIGH IMPACT EDUCATIONAL AND TRAINING PROGRAMS FOR TRANSLATIONAL RESEARCH PROFESSIONALS OF ALL DISCIPLINES AND LEVELS, BOTH IN CLINICAL AND COMMUNITY SETTINGS. THE CTSC HAS DESIGNED A STRATEGIC MANAGEMENT CORE AND SIX CTS RESEARCH AND TRAINING ELEMENTS TO ACCOMPLISH THESE GOALS: WORKFORCE DEVELOPMENT, COMMUNITY & STAKEHOLDER ENGAGEMENT, RESOURCES & SERVICES, CTS PILOT, HEALTH INFORMATICS, AND CTS RESEARCH PROGRAM. WE ARE COMMITTED TO INNOVATIVE AND COLLABORATIVE PRACTICE AND DISSEMINATION OF RESULTS SO THAT EVERYONE IN NORTHERN OHIO—AND BEYOND—CAN BENEFIT FROM ADVANCES IN CTS IN OUR PROGRAMS AND DISCOVERIES. | $24M | FY2023 | Aug 2023 – Jun 2030 |
| Department of Agriculture | THE FOOD FOR PROGRESS PROGRAM PROVIDES FOR THE DONATION OF U.S. COMMODITIES TO DEVELOPING COUNTRIES AND EMERGING DEMOCRACIES THAT ARE COMMITTED TO INTRODUCING OR EXPANDING FREE ENTERPRISE IN THEIR AGRICULTURAL ECONOMIES. THE PROGRAM HAS TWO PRIMARY STRATEGIC OBJECTIVES: (1) INCREASE AGRICULTURAL PRODUCTIVITY AND (2) EXPAND TRADE OF AGRICULTURAL PRODUCTS. THIS FOOD FOR PROGRESS IS BEING IMPLEMENTED IN BURUNDI. | $23.5M | — | — – — |
| Department of Health and Human Services | MEDICAL SCIENTIST TRAINING PROGRAM | $22M | FY1975 | Jul 1975 – Jun 2025 |
| Department of Energy | BREAKTHROUGH ELECTROLYTES FOR ENERGY STORAGE (BEES) | $21.8M | FY2018 | Aug 2018 – Jul 2026 |
| Department of Health and Human Services | IFNS AND CYTOKINES: SIGNALING AND ACTION | $21.7M | FY1994 | Aug 1994 – Mar 2022 |
| Department of Health and Human Services | OXIDATION IN INFLAMMATION AND CARDIOVASCULAR DISEASE | $20.2M | FY2004 | Aug 2004 – Apr 2020 |
| Corporation for National and Community Service | AMERICORPS*STATE | $20M | FY2006 | Sep 2006 – Aug 2009 |
| Department of Health and Human Services | PULMONARY VASCULAR DISEASE PHENOMICS PROGRAM (PVDOMICS) DATA COORDINATING CENTER | $20M | FY2014 | Sep 2014 – Jul 2024 |
| Department of Health and Human Services | VASCULAR CELL FUNCTION AND ATHEROSCLEROSIS | $19.9M | FY1983 | Jul 1983 – Oct 2020 |
| Department of Agriculture | THE FOOD FOR PROGRESS PROGRAM PROVIDES FOR THE DONATION OF U.S. COMMODITIES TO DEVELOPING COUNTRIES AND EMERGING DEMOCRACIES THAT ARE COMMITTED TO INTRODUCING OR EXPANDING FREE ENTERPRISE IN THEIR AGRICULTURAL ECONOMIES. THE PROGRAM HAS TWO PRIMARY STRATEGIC OBJECTIVES: (1) INCREASE AGRICULTURAL PRODUCTIVITY AND (2) EXPAND TRADE OF AGRICULTURAL PRODUCTS. THIS FOOD FOR PROGRESS PROGRAM IS BEING IMPLEMENTED IN ETHIOPIA. | $19.8M | FY2020 | Oct 2019 – Sep 2024 |
| Department of Health and Human Services | STRUCTURE AND FUNCTION OF BETA3 INTEGRINS ON BLOOD CELLS | $19.8M | FY2004 | Apr 2004 – Mar 2020 |
| Corporation for National and Community Service | THIS AWARD FUNDS THE APPROVED 2022?23 PUBLIC HEALTH AMERICORPS PROGRAM(S), AS LISTED ON THE APPROVED PROGRAM AND FUNDING SUMMARY CHARTS. NO MEMBER MAY ENROLL PRIOR TO THE APPROVED START DATE OF THE MEMBER ENROLLMENT PERIOD. YOUR 2022?23 REGULATORY MATCH IS 0%. READING & MATH, INC. PROPOSES TO HAVE 150 AMERICORPS MEMBERS WHO WILL PROVIDE CAPACITY-BUILDING SUPPORT IN PUBLIC HEALTH AGENCIES ACROSS THE STATE OF MINNESOTA. AT THE END OF THE FIRST PROGRAM YEAR, THE AMERICORPS MEMBERS WILL BE RESPONSIBLE FOR SUPPORTING 67 ORGANIZATIONS TO INCREASE THEIR EFFICIENCY, EFFECTIVENESS AND/OR PROGRAM REACH. AFTER THEIR YEAR OF SERVICE, 90 AMERICORPS MEMBERS WILL PURSUE FUTURE ENGAGEMENT IN THE PUBLIC HEALTH SECTOR. | $19.3M | FY2022 | Aug 2022 – Aug 2025 |
| Agency for International Development | ALLIANCE FOR INCLUSIVE AND NUTRITIOUS FOOD PROCESSING (AINFP) | $18.2M | FY2018 | Mar 2018 – Jun 2024 |
| Department of Health and Human Services | HEALTH CENTER CLUSTER | $17.9M | FY2014 | Nov 2013 – Jan 2027 |
| Department of Health and Human Services | ACUTE HUMORAL REJECTION OF RENAL ALLOGRAFTS | $17.2M | FY2010 | Jun 2010 – May 2021 |
| Agency for International Development | FEED THE FUTURE LOCAL FOOD SYSTEMS | $16.6M | FY2024 | Aug 2024 – Jul 2029 |
| Department of Agriculture | THE FOOD FOR PROGRESS PROGRAM PROVIDES FOR THE DONATION OF U.S. COMMODITIES TO DEVELOPING COUNTRIES AND EMERGING DEMOCRACIES THAT ARE COMMITTED TO INTRODUCING OR EXPANDING FREE ENTERPRISE IN THEIR AGRICULTURAL ECONOMIES. THE PROGRAM HAS TWO PRIMARY STRATEGIC OBJECTIVES: (1) INCREASE AGRICULTURAL PRODUCTIVITY AND (2) EXPAND TRADE OF AGRICULTURAL PRODUCTS. | $16.5M | FY2017 | Sep 2017 – Sep 2022 |
| Department of Health and Human Services | INNATE IMMUNITY END EXPERIMENTAL CROHN'S DISEASE | $16.5M | FY2011 | Aug 2011 – Jul 2023 |
| Department of Health and Human Services | ALCOHOL AND TISSUE INJURY FROM MECHANISMS TO TREATMENTS | $16.4M | FY2016 | Apr 2016 – Mar 2026 |
| Department of Health and Human Services | CWRU CENTER FOR EXCELLENCE ON THE IMPACT OF SUBSTANCE USE ON HIV - PROJECT SUMMARY - OVERVIEW THE NEWLY DEVELOPED CWRU (CASE WESTERN RESERVE UNIVERSITY) CENTER FOR EXCELLENCE ON THE IMPACT OF SUBSTANCE USE ON HIV WAS CONCEIVED IN AUGUST 2017 AND WAS INITIATED TO EFFECTIVELY PROMOTE EXCELLENCE IN BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH CONCERNING THE INTERSECTION BETWEEN SUBSTANCE USE AND HIV. THE CENTER FOR EXCELLENCE INCLUDES 12 NIDA-FUNDED INVESTIGATORS WHO COLLECTIVELY HOLD 9 R01, 2 DP1, 3 R34, 2 R44, 1 U01, AND 2 K01 DRAWN FROM THE CWRU SCHOOL OF MEDICINE, UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER, METROHEALTH MEDICAL CENTER, THE CLEVELAND CLINIC FOUNDATION, THE LOUIS STOKES CLEVELAND VETERANS ADMINISTRATION MEDICAL CENTER, THE CWRU MANDEL SCHOOL OF APPLIED SOCIAL SCIENCES, THE BEGUN CENTER FOR VIOLENCE PREVENTION RESEARCH AND EDUCATION, AND THE CUYAHOGA COUNTY, LORAIN COUNTY, AND CITY OF CLEVELAND DEPARTMENTS OF HEALTH. MAJOR RESEARCH STRENGTHS IN THE CENTER FOR EXCELLENCE INCLUDE IMPACT OF DRUG USE ON HIV IMMUNOPATHOGENESIS, HIV LATENCY AND CURE, NEUROAIDS, GASTROINTESTINAL DYSFUNCTION, SEXUAL RISK BEHAVIOR, AND HIV AND HCV CO-INFECTIONS. OUR STUDIES ARE ANCHORED BY ADVANCED COMPUTATIONAL, SYSTEMS BIOLOGY, BIOMIMETIC MODELS, AND INDUCED PLURIPOTENT STEM CELL (IPSC) TECHNOLOGIES THAT PROVIDE THE OPPORTUNITY TO PERFORM META-OMICS ANALYSES OF THE IMPACT OF OPIOID, METHAMPHETAMINE, CANNABIS, AND COCAINE MISUSE ON SEVERAL CLINICAL, VIROLOGICAL, IMMUNOLOGICAL, BEHAVIORAL, AND NEUROLOGICAL OUTCOMES OF HIV DISEASE. THE CENTER FOR EXCELLENCE HAS THE FOLLOWING SPECIFIC AIMS: - PROVIDE SCIENTIFIC LEADERSHIP TO POSITION THE CENTER AT THE FOREFRONT OF SUBSTANCE USE DISORDER RESEARCH AND FUNCTION AS A NATIONAL RESEARCH RESOURCE FOR THE STUDY OF DRUG USE IN PERSONS WITH HIV. - ESTABLISH AN ADMINISTRATIVE INFRASTRUCTURE THAT MAINTAINS FISCAL AND MANAGEMENT OVERSIGHT OF THE CORES. - APPLY ADVANCED COMPUTATIONAL BIOLOGY, PRIMARY CELLS, BIOMIMETIC MODELS, AND IPSC- DERIVED CELLS TO STUDY OF THE IMPACT OF SUBSTANCE USE ON HIV DISEASE. - SUPPORT TRANSLATIONAL, CLINICAL, AND BEHAVIORAL RESEARCH THROUGH ACCESS TO UNIQUE CLINICAL COHORTS OF PERSONS WITH SUBSTANCE USE DISORDER WITH HIV AND AT RISK FOR HIV. - ACCELERATE JUNIOR FACULTY DEVELOPMENT AND ENCOURAGE EXPERIENCED FACULTY TO ENTER THE SUBSTANCE USE RESEARCH ARENA TO SUPPORT THE NEXT GENERATION OF INVESTIGATORS. - PARTICIPATE IN COMMUNITY OUTREACH. | $16.2M | FY2021 | Sep 2021 – May 2027 |
| Department of Health and Human Services | CONTINUING ENHANCED NATIONAL SURVEILLANCE FOR PRION DISEASES IN THE UNITED STATES | $16M | FY2017 | Sep 2017 – Sep 2022 |
| Department of Health and Human Services | HYALURONAN MATRICES IN VASCULAR PATHOLOGIES | $16M | FY2011 | Jul 2011 – May 2019 |
| Department of Health and Human Services | CLEVELAND ALZHEIMERS DISEASE RESEARCH CENTER - PROJECT SUMMARY THE CLEVELAND ALZHEIMER'S DISEASE RESEARCH CENTER (CADRC) IS A COLLABORATIVE EFFORT OF PHYSICIANS AND INVESTIGATORS FROM CASE WESTERN RESERVE UNIVERSITY (CWRU), CLEVELAND CLINIC FOUNDATION (CCF), METROHEALTH SYSTEM (MHS), UNIVERSITY HOSPITALS (UH), AND THE LOUIS STOKES CLEVELAND VA MEDICAL CENTER (LSCVAMC), TO FOSTER EXCELLENCE IN RESEARCH AND FACILITATE DISCOVERY AS AN ESTABLISHED NATIONAL INSTITUTE ON AGING (NIA) FUNDED ALZHEIMER'S DISEASE RESEARCH CENTER. THE CADRC REPRESENTS A RICH CLINICAL AND RESEARCH COMMUNITY AND AN ESTIMATED 220,000 OHIOANS WHO SUFFER FROM ALZHEIMER'S DISEASE (AD) OR AD-RELATED DEMENTIAS (ADRD). THE CADRC HAS 8 CORES AND A RESEARCH EDUCATION COMPONENT DESIGNED TO CREATE THE FOUNDATION THAT WILL ENHANCE THE RESEARCH EFFORTS OF THE NORTHEAST OHIO AD/ADRD RESEARCH COMMUNITY, AS WELL AS ADD UNIQUE VALUE TO THE NATIONAL ALZHEIMER'S DISEASE RESEARCH CENTERS (ADRC) PROGRAM AND OTHER NATIONAL AND INTERNATIONAL RESEARCH PROGRAMS. THE CADRC IS FOCUSED ON PARTICIPANTS THAT WILL HELP US UNDERSTAND THE PATHOBIOLOGY OF CLINICAL AND PATHOLOGICAL HETEROGENEITY OBSERVED IN DEMENTIA INCLUDING ATYPICAL AND AMNESTIC AD, DEMENTIA WITH LEWY BODIES, COGNITIVELY NORMAL INDIVIDUALS WITH DIFFERENT LEVELS OF GENETIC RISK FOR AD, AND DIVERSITY OF PARTICIPANT POPULATIONS (CLINICAL AND OUTREACH, RECRUITMENT, AND ENGAGEMENT CORES). TO SUPPORT THE CADRC GOALS, THE FOCUS WILL BE ON DEEP PHENOTYPING OF PARTICIPANTS WITH LONGITUDINAL AND SYSTEMATIC COGNITIVE, BEHAVIORAL AND MOTOR CHARACTERIZATION (CLINICAL CORE), GENETIC AND BIOFLUID BIOMARKER COLLECTION AND ANALYSIS (BIOMARKER CORE), IMAGING (NEUROIMAGING CORE), AND AUTOPSY AFTER DEATH (NEUROPATHOLOGY CORE). RESULTS WILL BE SHARED WITH THE RESEARCH COMMUNITY IN A TIMELY AND REGULAR MANNER TO ALLOW OTHER INVESTIGATORS TO BENEFIT FROM THE CADRC EFFORTS (DATA MANAGEMENT AND STATISTICS CORE). IN ADDITION, THE CADRC WILL TRAIN THE NEXT GENERATION OF INVESTIGATORS UTILIZING A RIGOROUS AND WELL-DESIGNED RESEARCH EDUCATION COMPONENT, SUPPORT TRANSLATION OF NEW LABORATORY FINDINGS THROUGH THE TRANSLATIONAL THERAPEUTICS CORE, AND SUPPORT HIGH RISK/HIGH GAIN PROJECTS THROUGH THE DEVELOPMENTAL PROGRAM AS A PART OF THE ADMINISTRATIVE CORE. THE ULTIMATE GOALS ARE TO ADVANCE THE PRECISION MEDICINE APPROACH TO DEMENTIA DIAGNOSIS AND TREATMENT, SUPPORT THE DEVELOPMENT OF EARLY STAGE INVESTIGATORS, ASSIST ALL STAGES OF INVESTIGATORS WITH TOOLS FOR PERFORMING HUMAN-BASED RESEARCH, AND BETTER ENGAGE UNDERREPRESENTED POPULATIONS IN AD/ADRD RESEARCH. | $15.4M | FY2021 | Sep 2021 – Jun 2026 |
| Department of Agriculture | AGRICULTURAL PRODUCTIVITY AND VALUE CHAIN DEVELOPMENT PROJECT | $15.1M | FY2013 | Sep 2013 – Sep 2017 |
| Department of Agriculture | THE FOOD FOR PROGRESS PROGRAM PROVIDES FOR THE DONATION OF U.S. COMMODITIES TO DEVELOPING COUNTRIES AND EMERGING DEMOCRACIES THAT ARE COMMITTED TO INTRODUCING OR EXPANDING FREE ENTERPRISE IN THEIR AGRICULTURAL ECONOMIES. THE PROGRAM HAS TWO PRIMARY STRATEGIC OBJECTIVES: (1) INCREASE AGRICULTURAL PRODUCTIVITY AND (2) EXPAND TRADE OF AGRICULTURAL PRODUCTS. THIS FOOD FOR PROGRESS PROGRAM IS BEING IMPLEMENTED IN MOZAMBIQUE. | $15.1M | FY2013 | Sep 2013 – Dec 2018 |
| Department of Commerce | PURPOSE: THE ASSOCIATION TO PRESERVE CAPE COD WILL WORK WITH AN ARRAY OF PARTNERS TO LEAD THE COLLABORATIVE PLANNING, DESIGN, AND IMPLEMENTATION OF PROJECTS TO RESTORE RIVERS, RETIRED CRANBERRY BOGS, AND SALT MARSHES ON CAPE COD IN MASSACHUSETTS. THESE EFFORTS WILL SUPPORT IMPORTANT SPECIES LIKE RIVER HERRING AND AMERICAN EEL. THEY WILL ALSO PROVIDE BENEFITS TO COMMUNITIES SUCH AS INCREASED CLIMATE RESILIENCE AND PROTECTION FROM FLOODING. | $15M | FY2025 | Oct 2024 – Sep 2028 |
| Department of Health and Human Services | CLEVELAND OPEN SOURCE MODULAR IMPLANT INNOVATORS COMMUNITY (COSMIIC) - THE OVERALL GOAL OF THE CLEVELAND OPEN SOURCE MODULAR IMPLANT INNOVATORS COMMUNITY (COSMIIC) IS TO ESTABLISH AN OPEN SOURCE, MODULAR NETWORK OF ACTIVE IMPLANTABLE DEVICES FOR USE IN EARLY FEASIBILITY HUMAN RESEARCH AND TO PROVIDE ONGOING SUPPORT FOR THIS TECHNOLOGY THROUGH A VIBRANT, SUSTAINABLE COMMUNITY OF ACTIVE USERS. OUR TEAM IS POISED TO SUCCESSFULLY ACHIEVE ALL OF THE GOALS OF THE HORNET PROGRAM BECAUSE OUR PROPOSED CONCEPT IS BASED ON OUR ESTABLISHED PLATFORM ECOSYSTEM, THE NETWORKED NEUROPROSTHESIS (NNP). THIS PROVIDES A SOLID TECHNOLOGICAL PLATFORM WITH KNOWN REGULATORY STATUS FOR OUR COSMIIC HORNET PROJECT. CRITICALLY, ALL TECHNOLOGY DESCRIBED IN THIS PROPOSAL WAS INVENTED BY THE INVESTIGATIVE TEAM AND THEREFORE WE ARE ABLE TO FULLY EMBRACE THE OPEN SOURCE IDEOLOGY FOR THE END-TO-END TECHNOLOGY. THE PROPOSED COSMIIC HORNET SYSTEM, WHICH WILL BE ESTABLISHED ON THE PLATFORM NNP SYSTEM, IS A SYSTEM OF INTEROPERABLE AND INTEGRATED MODULES THAT CAN SIMULTANEOUSLY ELECTRICALLY ACTIVATE, BLOCK, AND SENSE THROUGHOUT THE BODY. THE SYSTEM CAN RECORD AND PROCESS ELECTRONEUROGRAM (ENG), ELECTROMYOGRAM (EMG), INTRACORTICAL SIGNALS, ELECTROCARDIOGRAM (EKG), KINEMATIC VARIABLES, PHOTOPLETHYSMOGRAM (PPG), AND TEMPERATURE. EACH MODULE CAN DIRECTLY COMMUNICATE WITH ALL OTHER MODULES THROUGH AN ESTABLISHED NETWORK COMMUNICATION PROTOCOL. THE SYSTEM CAN PROCESS SIGNALS TO IMPLEMENT COMPLEX CLOSED-LOOP CONTROL WITHOUT REQUIRING NON-IMPLANTED HARDWARE. IMPORTANTLY, THE EXISTING NNP PLATFORM COMPONENTS (POWER MODULE, STIMULATOR MODULE, BIOPOTENTIAL RECORDING MODULE, NETWORK CABLE, ELECTRODES) ALREADY HAVE IDE APPROVAL FROM THE FDA AND HAVE BEEN SUCCESSFULLY IMPLANTED AND IMPLEMENTED IN HUMAN RESEARCH PARTICIPANTS. THUS, THE COSMIIC HORNET SYSTEM HAS THE NECESSARY FEATURES TO PROVIDE THE MODULAR PLATFORM ECOSYSTEM FOR USE BY THE BIOELECTRONIC COMMUNITY FOR THE FORESEEABLE FUTURE. AIM #1. DISSEMINATION. WE WILL ESTABLISH THE COSMIIC COMMUNITY WITH FULL OPEN-SOURCE ACCESS TO AN ESTABLISHED MODULAR IMPLANTABLE DEVICE FOR USE IN THE PERIPHERAL AND CENTRAL NERVOUS SYSTEM. ACCESS WILL BE GIVEN FOR ALL CIRCUIT DESIGNS AND LAYOUTS; MECHANICAL DRAWINGS FOR ALL ENCLOSURES AND CONNECTORS AND CABLING; THE ANNOTATED CODE FOR ALL OPERATING SOFTWARE, FIRMWARE, AND BOOTLOADER; WRITTEN INSTRUCTIONS AND VIDEOS OF FABRICATION TECHNIQUES; AND ALL REGULATORY DOCUMENTS AND TEST DATA, INCLUDING OUR APPROVED IDE DOCUMENT. AIM #2. SUSTAINABILITY. WE WILL DEVELOP A SUSTAINABLE OPEN SOURCE MODEL THROUGH THE DEVELOPMENT OF TECHNOLOGY THAT ATTRACTS A BROAD INVESTIGATIVE TEAM TO ESTABLISH A CRITICAL MASS OF COSMIIC USERS. WE WILL PROVIDE ONGOING SUPPORT OF THE TECHNOLOGY AND PARTNER WITH COMMERCIAL PARTNERS TO CREATE A SUSTAINABLE BUSINESS PLAN SO THAT THE COSMIIC COMMUNITY REMAINS INDEPENDENTLY VIBRANT AND ACTIVE AFTER THREE YEARS. | $14.8M | FY2022 | Sep 2022 – Aug 2026 |
| Department of Health and Human Services | THE ALZHEIMER DISEASE SEQUENCE ANALYSIS COLLABORATIVE | $14.6M | FY2018 | Sep 2018 – Aug 2025 |
| Department of Health and Human Services | CONTINUING AN ENHANCED AND MULTIFACETED NATIONAL SURVEILLANCE PROGRAM FOR HUMAN PRION DISEASES | $14.5M | FY2022 | Sep 2022 – Aug 2027 |
| Department of Health and Human Services | THE CLEVELAND CLINIC INNOVATION ACCELERATOR | $14.4M | FY2013 | Sep 2013 – Jul 2022 |
| Department of Health and Human Services | PATHOBIOLOGY OF ASTHMA | $14M | FY2006 | Apr 2006 – Jan 2021 |
| Department of Health and Human Services | GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA | $14M | FY2011 | Sep 2011 – Apr 2023 |
| VA/DoDDepartment of Veterans Affairs | THE SSVF PROGRAM'S PURPOSE IS TO PROVIDE SUPPORTIVE SERVICES GRANTS TO PRIVATE NON-PROFIT ORGANIZATIONS AND CONSUMER COOPERATIVES, WHO WILL COORDINATE OR PROVIDE SUPPORTIVE SERVICES TO VERY LOW-INCOME VETERAN FAMILIES WHO ARE RESIDING IN PERMANENT HOUSING, ARE HOMELESS AND SCHEDULED TO BECOME RESIDENTS OF PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD; OR AFTER EXITING PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD, ARE SEEKING OTHER HOUSING THAT IS RESPONSIVE TO SUCH VERY LOW-INCOME VETERAN FAMILY'S NEEDS AND PREFERENCES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. | $13.9M | — | — – Sep 2025 |
| VA/DoDDepartment of Veterans Affairs | THE SSVF PROGRAM'S PURPOSE IS TO PROVIDE SUPPORTIVE SERVICES GRANTS TO PRIVATE NON-PROFIT ORGANIZATIONS AND CONSUMER COOPERATIVES, WHO WILL COORDINATE OR PROVIDE SUPPORTIVE SERVICES TO VERY LOW-INCOME VETERAN FAMILIES WHO ARE RESIDING IN PERMANENT HOUSING, ARE HOMELESS AND SCHEDULED TO BECOME RESIDENTS OF PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD; OR AFTER EXITING PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD, ARE SEEKING OTHER HOUSING THAT IS RESPONSIVE TO SUCH VERY LOW-INCOME VETERAN FAMILY'S NEEDS AND PREFERENCES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. | $13.9M | FY2025 | Sep 2025 – Sep 2026 |
| Corporation for National and Community Service | THIS AWARD FUNDS THE APPROVED 2023-2024 AMERICORPS FORMULA PROGRAMS, AS LISTED ON THE APPROVED PROGRAM AND FUNDING SUMMARY CHARTS. NO MEMBER MAY ENROLL PRIOR TO THE APPROVED START DATE OF THE MEMBER ENROLLMENT PERIOD. YOUR 2023-2024 BUDGETARY MATCH IS 32%. CLIMATE IMPACT CORPS: EXPAND CURRENT ACTIVITIES. TO DO THIS, WE WILL AWARD $1,222,857. CONSERVATION CORPS MINNESOTA: EXPAND CURRENT ACTIVITIES. TO DO THIS, WE WILL AWARD $576,000. | $13.7M | FY2023 | Aug 2023 – Dec 2026 |
| Agency for International Development | USAID COFFEE ALLIANCE FOR EXCELLENCE | $13.2M | FY2018 | Nov 2017 – Nov 2024 |
| Department of Health and Human Services | THE CLEVELAND DIGESTIVE DISEASES RESEARCH CORE CENTER (DDRCC) | $13.2M | FY2015 | Feb 2015 – Aug 2025 |
| Department of Health and Human Services | PHARMACOLOGICAL TREATMENT OF RETINAL DISEASES | $12.8M | FY2010 | Sep 2010 – Aug 2015 |
| Department of Health and Human Services | COHORT STUDY OF CHRONIC RENAL INSUFFICIENCY | $12.7M | FY2001 | Sep 2001 – Jun 2026 |
| Agency for International Development | TO PROVIDE OPERATIONAL SUPPORT TO FIELD MISSIONS AND OTHER OPERATING UNITS OF THE U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID), CONTRIBUTING TO THE GOALS OF THE GLOBAL FOOD SECURITY STRATEGY THROUGH THE IMPLEMENTATION OF PROGRAMMING ALIGNED WITH THE AGENCY’S LSFF RESULTS FRAMEWORK. REFLECTING PRIORITIES IN THE REVISED GFSS 2022- 2026, USAID AND IMPLEMENTING PARTNERS WILL USE THIS ACTIVITY TO ADVANCE A COMPREHENSIVE FOOD SYSTEMS APPROACH, WHILE PROACTIVELY COUNTERING THE COVID-19 PANDEMIC AND OTHER GLOBAL CRISES’ LONG-TERM EFFECTS ON NUTRITION. | $12.5M | FY2022 | Sep 2022 – Aug 2027 |
| Department of Health and Human Services | IBUDILAST PHASE II TRIAL IN PROGRESSIVE MS | $12.5M | FY2013 | Jul 2013 – Jun 2020 |
| Department of Education | HIGHER EDUCATION EMERGENCY RELIEF FUND-INSTITUTIONAL PORTION CARES ACT | $12.4M | FY2020 | May 2020 – Jun 2022 |
| Department of Health and Human Services | HEAD START | $12.4M | FY2019 | Jul 2019 – Mar 2025 |
| Department of Health and Human Services | CASE AIDS CLINICAL TRIALS UNIT | $12.3M | FY2007 | Feb 2007 – Nov 2013 |
| Department of Health and Human Services | TARGETING OBESITY AND BLOOD PRESSURE IN URBAN YOUTH | $12.2M | FY2010 | Aug 2010 – Apr 2019 |
| Department of Health and Human Services | GUT MICROBIOTA AND CARDIOMETABOLIC DISEASES | $12.1M | FY2019 | Sep 2019 – Jul 2025 |
| Department of Health and Human Services | CELL ADHESION AND SIGNALING IN BLOOD AND VASCULAR CELLS - PROJECT SUMMARY THIS APPLICATION HAS AS ITS THEME THE INTEGRINS, THEIR REGULATION AND THEIR CONTRIBUTION TO THE FUNCTIONAL RESPONSES OF BLOOD AND VASCULAR CELLS. THE INTEGRINS OF FOCUS ARE AMSS2 (MAC-1), AIIBSS3, AVSS3, AND A5SS1 BUT FINDINGS SHOULD APPLY TO BROADLY INTEGRINS. THE CELLS OF EMPHASIS ARE VASCULAR CELLS- ENDOTHELIAL CELLS, SMOOTH MUSCLE CELLS AND PERICYTES- AND BLOOD CELLS- LEUKOCYTES AND PLATELETS. ON THE BLOOD CELLS, THE CONJUGATION OF MAC-1 ON LEUKOCYTES AND GPIB ON PLATELETS WILL BE CONSIDERED. MAJOR EMPHASIS WILL BE PLACED ON THE MOLECULES THAT REGULATE INTEGRIN FUNCTION- KINDLINS, TALIN AND PAXILLIN- TO DETERMINE HOW THEY COLLABORATE TO REGULATE INTEGRIN ACTIVATION. THE FUNCTION OF THESE CYTOSKELETAL PROTEINS INDEPENDENT OF INTEGRIN ACTIVATING ACTIVITY WILL ALSO BE DISSECTED. THE PROGRAM CONSISTS OF THREE PROJECTS, EACH DIRECTED BY AN ACCOMPLISHED FACULTY MEMBER AT THEIR HOME INSTITUTIONS, CLEVELAND CLINIC, UNIVERSITY HOSPITALS OF CLEVELAND AND CASE WESTERN RESERVE UNIVERSITY WHICH ARE ALL CLOSELY LOCATED AND GOVERNED BY INTERINSTITUTIONAL AGREEMENTS. DR. EDWARD F. PLOW, PH.D. WILL SERVE AS PROGRAM DIRECTOR AND LEAD PROJECT 1. THIS PROJECT DEALS WITH THE MECHANISMS BY WHICH KINDLIN-2 REGULATES BOTH INTEGRIN-DEPENDENT AND INDEPENDENT RESPONSES OF BLOOD VESSEL CELLS. MOLECULAR, CELLULAR AND UNIQUE MOUSE MODELS ARE ALL BROUGHT TO BEAR TO DETERMINE HOW KINDLIN-2 SERVES AS A MASTER REGULATOR OF VASCULAR CELL RESPONSES. IN PROJECT 2, DR. JUN QIN WILL USE HIGH RESOLUTION STRUCTURAL APPROACHES IN COMBINATION WITH MUTAGENESIS AND CELLULAR STUDIES TO DETERMINE HOW TALIN REGULATE INTEGRIN ACTIVATION AND COOPERATES WITH KINDLINS AND PAXILLIN TO GAIN SUCH NOVEL INSIGHTS. HE WILL DETERMINE HOW TALIN INTERACTS WITH ACTIN TO CONTROL ORGANIZATION OF THE CYTOSKELETON. DR. DANIEL SIMON, M.D. WILL LEAD PROJECT 3 AND WILL CONSIDER HOW ENGAGEMENT OF INTEGRIN MAC-1 ON LEUKOCYTES AND GPIB ON PLATELETS REGULATES THE PARTICIPATION OF THESE CELLS IN INFLAMMATION AND THROMBOSIS. HIS STUDIES RANGE FROM BASIC STRUCTURAL APPROACHES TO TRANSLATIONAL STUDIES IN MICE AND TO HUMANS TO PROVIDE INSIGHTS INTO THEIR THROMBOTIC AND INFLAMMATORY CONTRIBUTIONS TO SYSTEMIC LUPUS ERYTHEMATOSUS. THE PROGRAM IS SUPPORTED BY TWO SCIENTIFIC CORES, PROTEIN EXPRESSION AND PURIFICATION (CORE B), AND ANIMAL MODELS AND TISSUE ANALYSIS (CORE C) AS WELL AS BY AN ADMINISTRATIVE CORE (AC1). A COMMON OBJECTIVE OF THE PROGRAM IS TO CONTINUE AND CREATE NEW COLLABORATIONS AMONG THE PROJECTS AND THEIR LEADERS TO RESOLVE THE STRUCTURAL AND BIOLOGICAL MECHANISMS THAT REGULATE THE FUNCTIONS OF INTEGRINS IN BLOOD AND VASCULAR CELLS. THE INFORMATION DERIVED FROM THESE STUDIES WILL PROVIDE INSIGHTS INTO BIOLOGICALLY IMPORTANT RESPONSES REGULATED BY INTEGRINS AND THEIR ACTIVATION THAT ARE RELEVANT TO THROMBOSIS AND CARDIOVASCULAR DISEASES. | $12.1M | FY2021 | Sep 2021 – Nov 2026 |
| Department of Health and Human Services | HDL STRUCTURE AND ITS FUNCTION IN ATHEROSCLEROSIS | $12.1M | FY2010 | Sep 2010 – May 2017 |
| Corporation for National and Community Service | AMERICORPS*STATE | $12M | FY2006 | Aug 2006 – Aug 2009 |
| Department of Health and Human Services | P30 - CORE GRANT FOR VISION RESEARCH | $11.9M | FY1998 | Apr 1998 – Jun 2027 |
| Department of Health and Human Services | CWRU CENTER FOR MULTIMODAL EVALUATION OF ENGINEERED CARTILAGE | $11.7M | FY2016 | Jun 2016 – May 2027 |
| Department of Health and Human Services | DEVELOPMENT OF NEW DIAGNOSTIC METHODS/SURVEILLANCE PROGRAM | $11.6M | FY2007 | Sep 2007 – Sep 2012 |
| Department of Health and Human Services | FRMI OF THE PERSON IDENTITY NETWORK: AGING AND APOE | $11.6M | FY2003 | May 2003 – May 2023 |
| Department of Energy | GRANT AWARD TO CASE WESTERN RESERVE UNIVERSITY (CWRU) CONTRIBUTES TO NNSA’S STOCKPILE STEWARDSHIP MISSION BY ESTABLISHING A UNIQUE PUBLIC-PRIVATE PARTNERSHIP MERGING MATERIALS SCIENCE WITH NOVEL COMPUTER SCIENCE AND DATA SCIENCE TO ADVANCE THE UNDERSTANDING OF FUNDAMENTAL MECHANISMS OF MATERIALS DEGRADATION AND FAILURE IN OUR NUCLEAR STOCKPILE MATERIALS AND COMPONENTS, THROUGH COMBINED RESEARCH AND EDUCATIONAL MULTI-DISCIPLINARY VISION. PROJECT TITLE: CENTER TO MATERIALS DATA SCIENCE FOR STOCKPILE STEWARDSHIP (MDS3) COE | $11.4M | FY2022 | Sep 2022 – Sep 2027 |
| Department of Health and Human Services | ATRIAL FIBRILLATION POST-GWAS: MECHANISMS TO TREATMENT - OVERALL COMPONENT PROJECT/SUMMARY ABSTRACT ATRIAL FIBRILLATION (AF), THE MOST COMMON CARDIAC ARRHYTHMIA, AFFLICTS THE U.S. AND WORLD WITH INCREASING PREVALENCE. AF INCIDENCE, PROGRESSION TO PERSISTENT AF, AND AF COMPLICATIONS, INCLUDING STROKE, ARE FED BY INCREASING OBESITY AND AGE. CURRENT THERAPIES ARE LIMITED BY RISKS AND LIMITED EFFICACY, WORSE AS AF PROGRESSES, BUT NO NEW PHARMACOLOGIC AGENTS HAVE BEEN APPROVED FOR AF IN >10 YEARS. WITH IDENTIFICATION OF >100 GENETIC LOCI THAT PREDISPOSE TO AF RISK IN GENOME-WIDE ASSOCIATION STUDIES (GWAS), THE HOPE HAS BEEN THAT GENETICS WOULD YIELD NOVEL THERAPEUTIC TARGETS. HOWEVER, EVEN FOR THE TOP LOCUS ON CHR. 4Q25 NEAR PITX2, A GENE INVOLVED IN FORMATION OF PULMONARY VEINS, THE TARGET OF AF ABLATION, MECHANISMS LINKING VARIANTS TO AF REMAIN ELUSIVE. GENETIC FINDINGS HAVE SO FAR FAILED TO YIELD CLINICALLY ACTIONABLE RESULTS. TO FILL THESE GAPS, WE SEEK TO GO BEYOND GWAS FINDINGS TO IDENTIFY DIRECT GENOMIC MECHANISMS UNDERLYING AF AND BETTER UNDERSTAND THEIR INTERACTIONS WITH ENVIRONMENT, COMORBIDITIES OR CELL STRESSORS. OUR LONG-TERM GOAL IS TO USE GENOMIC FINDINGS TO PERSONALIZE PREVENTIVE AND THERAPEUTIC STRATEGIES FOR AF. OUR OVERALL P01 THEME IS TO TRANSLATE AF GENETIC DISCOVERIES TOWARDS THE BEDSIDE, FOCUSING ON GENES TO MECHANISMS, GENES TO DRUGS, AND INTERACTIONS OF GENES WITH METABOLISM AND ENVIRONMENT. WE BUILD ON STRONG PRELIMINARY DATA AND COALESCE UNIQUE HUMAN ATRIAL TISSUE BIOREPOSITORY AND GENOMIC DATA RESOURCES, NOVEL CELL AND ANIMAL MODELS, AND COMPLEMENTARY EXPERTISE FROM OUR MULTIDISCIPLINARY TEAM WITH A STRONG COLLABORATION HISTORY. OUR CENTRAL HYPOTHESIS IS THAT GENOMIC MECHANISTIC DISCOVERIES IN AF CELLULAR AND ANIMAL MODELS WILL TRANSLATE TO HUMAN THERAPIES. OUR THEMATIC AIMS INCLUDE: 1) IDENTIFY CAUSAL GENES AND FUNCTIONAL MECHANISMS WITH A GOAL TOWARDS IDENTIFICATION OF NEW THERAPEUTIC APPROACHES FOR AF; 2) INVESTIGATE METABOLIC AND INFLAMMATORY MECHANISMS, IMPLICATED BY GENOMICS STUDIES TO BE IMPORTANT IN AF PATHOPHYSIOLOGY, TO IDENTIFY NEW THERAPEUTIC TARGETS FOR AF PREVENTION AND TREATMENT; AND 3) IDENTIFY CANDIDATE NOVEL DRUGS FOR AF AND DEVELOP A PIPELINE FOR IN VITRO AND IN VIVO FUNCTIONAL TESTING OF CANDIDATE THERAPIES. PROJECT 1 GENES TO FUNCTION WILL DETERMINE CAUSAL GENES, VARIANTS AND MECHANISMS UNDERLYING TWO AF GWAS LOCI. PROJECT 2 GENES AND METABOLISM WILL STUDY THE CONTRIBUTION OF MITOCHONDRIAL DYSFUNCTION TO AF ONSET AND PROGRESSION. EARLY STAGE INVESTIGATOR PROJECT GENES AND NUTRITION BUILDS ON NOVEL ASSOCIATIONS OF AF WITH TRIMETHYLAMINE N-OXIDE (TMAO), PRODUCED BY GUT MICROBIOTA FROM PRECURSORS SUCH AS CHOLINE FOUND IN EGGS, MEATS AND CHEESES. PROJECT 4 GENES TO OMICS-INFORMED DRUGS WILL IDENTIFY MECHANISMS AND REPURPOSABLE DRUGS TO PREVENT AF PROGRESSION. PROJECTS ARE SUPPORTED BY 4 CORES PROVIDING ADMINISTRATION, ENGINEERED HEART TISSUE AND ATRIAL PHENOTYPING, ELECTROPHYSIOLOGY, AND NETWORK AND SYSTEMS BIOLOGY ANALYTICS SUPPORT THAT SYNERGIZE DISCOVERY AND TRANSLATION IN AF AND INCREASE THE SCOPE AND IMPACT OF EACH PROJECT. ALL P01 COMPONENTS AIM TO BRIDGE BASIC RESEARCH IN AF TOWARDS CLINICAL UTILITY, THEREBY ADVANCING GENOMIC DATA AND RESEARCH TOWARDS THE BEDSIDE TO HELP OUR PATIENTS SUFFERING FROM ATRIAL FIBRILLATION. | $11.3M | FY2022 | Jul 2022 – Jun 2027 |
| Department of Health and Human Services | RESISTANCE TO MTB INFECTION IN HIV INFECTED INDIVIDUALS IN UGANDA AND S. AFRICA | $11.3M | FY2016 | Jun 2016 – May 2022 |
| Department of Health and Human Services | CONTINUING THE DEVELOPMENT OF NEW DIAGNOSTIC METHODS/SURVEILLANCE PROGRAM | $11.2M | FY2012 | Sep 2012 – Sep 2017 |
| Corporation for National and Community Service | No description available | $11.1M | FY2017 | Aug 2017 – Dec 2020 |
| Department of Health and Human Services | CASE COMPREHENSIVE CANCER CENTER NCTN LEAD ACADEMIC PARTICIPATING SITE | $11.1M | FY2019 | Mar 2019 – Feb 2032 |
| Department of Health and Human Services | CLINICAL AND TRANSLATIONAL SCIENCE COLLABORATIVE OF CLEVELAND | $11M | FY2007 | Sep 2007 – May 2018 |
| VA/DoDDepartment of Veterans Affairs | THE SSVF PROGRAM'S PURPOSE IS TO PROVIDE SUPPORTIVE SERVICES GRANTS TO PRIVATE NON-PROFIT ORGANIZATIONS AND CONSUMER COOPERATIVES, WHO WILL COORDINATE OR PROVIDE SUPPORTIVE SERVICES TO VERY LOW-INCOME VETERAN FAMILIES WHO ARE RESIDING IN PERMANENT HOUSING, ARE HOMELESS AND SCHEDULED TO BECOME RESIDENTS OF PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD; OR AFTER EXITING PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD, ARE SEEKING OTHER HOUSING THAT IS RESPONSIVE TO SUCH VERY LOW-INCOME VETERAN FAMILY'S NEEDS AND PREFERENCES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. | $10.9M | — | — – — |
| Department of Health and Human Services | DEFINING THE PATHOGENESIS OF IMMUNE DEFICIENCY IN CHRONIC HIV INFECTION | $10.9M | FY2008 | Aug 2008 – Jul 2013 |
| Department of Health and Human Services | SELF REGULATING CONTINUOUS FLOW TOTAL ARTIFICIAL HEART | $10.9M | FY2010 | Apr 2010 – Jun 2022 |
| Department of Health and Human Services | GUT FLORA METABOLISM OF DIETARY PHOSPHATIDYLCHOLINE AND CARDIOVASCULAR DISEASE | $10.8M | FY2010 | Aug 2010 – Apr 2026 |
| Agency for International Development | FEED THE FUTURE MOZAMBIQUE PROMOTING INNOVATIVE AND RESILIENT AGRICULTURAL MARKET SYSTEMS WILL SUPPORT INCLUSIVE AND RESILIENT AGRICULTURE-LED MARKET SYSTEMS GROWTH IN THE NAMPULA AND ZAMBEZIA PROVINCES AND SOUTHERN NIASSA AND CABO DELGADO PROVINCES (NACALA CORRIDOR) THAT WILL INCENTIVIZE RESPONSIBLE PRIVATE INVESTMENT, IMPROVE ACCESS TO FINANCE, IMPROVE BUSINESS TRANSACTIONS AND RELATIONSHIPS TO BE MORE MARKET RESPONSIVE, SUPPORT VALUE ADDITION, ENHANCE RISK MANAGEMENT, BUILD THE CAPACITY OF SMALLHOLDER PRODUCERS AND SMALL AND MEDIUM AGRIBUSINESSES, AND EXPAND JOBS, INCOMES AND ENTREPRENEURSHIP OPPORTUNITIES FOR YOUNG WOMEN AND MEN. | $10.7M | FY2022 | Jun 2022 – Jun 2027 |
| Department of Health and Human Services | CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM (CORP) | $10.6M | FY1997 | Sep 1997 – Jun 2024 |
| Department of Health and Human Services | SEX-BASED DIFFERENCES IN GLIOMA | $10.4M | FY2020 | Sep 2020 – Dec 2026 |
| Department of Education | HIGHER EDUCATION EMERGENCY RELIEF FUND CARES ACT | $10.4M | FY2020 | May 2020 – Jun 2022 |
| Department of Health and Human Services | RESEARCH TO CONTROL AND ELIMINATE MALARIA IN SE ASIA AND SW PACIFIC | $10.4M | FY2010 | Jul 2010 – Jun 2018 |
| Agency for International Development | SOLUTIONS FOR AFRICAN FOOD ENTERPRISES (SAFE) | $10.4M | FY2012 | Sep 2012 – Jan 2018 |
| Department of Transportation | WRTA SECTION 5307 CARES ACT OPERATING ASSISTANCE | $10.4M | FY2020 | Jun 2020 – May 2021 |
| Department of Transportation | APPLICATION PURPOSE: THE PURPOSE OF THIS AWARD IS TO PROVIDE ASSISTANCE FOR ONE YEAR OF ARCHITECTURE AND ENGINEERING DESIGN ONE YEAR OF TIRE LEASE FUNDING FOR PREVENTIVE MAINTENANCE TO KEEP FIXED ASSETS IN A GOOD STATE OF REPAIR FUNDING FOR THE REHAB OF THE ADMINISTRATION FACILITY FUNDING TO PURCHASE ONE (1) NON-REVENUE SERVICE TRUCK AND FUNDING FOR THE PURCHASE OF SIX (6) REPLACEMENT 35 BATTERY ELECTRIC BUSES.; ACTIVITIES PERFORMED: FUNDS WILL BE USED FOR ARCHITECTURE AND ENGINEERING DESIGN TO ASSIST WRTA STAFF WITH SPECIFICATION DEVELOPMENT AND PROJECT OVERSIGHT ON VARIOUS TECHNICAL AND CONSTRUCTION PROJECTS. FUNDS WILL BE USED FOR PREVENTIVE MAINTENANCE TO KEEP OUR ASSETS IN A GOOD STATE OF REPAIR FUNDS WILL BE USED FOR THE PURCHASE OF SIX (6) REPLACEMENT 35 BUSES AND ONE (1) REPLACEMENT NON-REVENUE SERVICE VEHICLES. FUNDS WILL BE USED FOR THE REHABILITATION OF THE ADMINISTRATION FACILITY TO ACCOMMODATE THE GROWTH IN OUR WORKFORCE.; EXPECTED OUTCOMES: THE BENEFITS FROM THESE FUNDS WILL ASSIST IN THE REHABILITATION OF OUR ADMINISTRATION FACILITY. THE PURCHASE OF REPLACEMENT BUSES WILL REPLACE VEHICLES THAT ARE BEYOND THEIR USEFUL LIFE SO THAT WRTA CAN PROVIDE BETTER SERVICE WITH NEWER VEHICLES FOR OUR PASSENGERS. THE REPLACEMENT OF A SERVICE VEHICLE THAT IS BEYOND ITS USEFUL LIFE. THE CONTINUED MAINTENANCE OF OUR ASSETS IS IN A STATE OF GOOD REPAIR.; INTENDED BENEFICIARIES: WRTA AND OUR PASSENGERS THAT RELY ON OUR SERVICE WILL BENEFIT FROM CONTINUED SERVICES PERMITTING WORKERS TO GET TO JOBS MEDICAL TRIPS EDUCATION OPPORTUNITIES SHOPPING AND OTHER DESTINATIONS. PLUS WRTA WILL BE ABLE TO REDUCE OUR CARBON FOOTPRINT THAT WILL HELP THE ENVIRONMENT.; SUBRECIPIENT ACTIVITIES: NONE | $9.9M | FY2025 | Jul 2025 – Mar 2029 |
| VA/DoDDepartment of Defense | PILOT RANDOMIZED CONTROLLED TRIAL OF THE ISENS SYSTEM FOR SENSORIMOTOR RESTORATION AFTER LIMB LOSS | $9.9M | FY2025 | Jul 2025 – Jun 2029 |
| VA/DoDDepartment of Defense | EMBODIED ROBOTICS FOR REMOTE OPERATIONS | $9.7M | FY2024 | Oct 2023 – Dec 2026 |
| Department of Health and Human Services | INFLAMMASOME AND GASDERMIN SIGNALING NETWORKS FOR REGULATION OF PYROPTOSIS AND CYTOKINE RELEASE | $9.4M | FY2020 | Jul 2020 – Jun 2026 |
| Department of Health and Human Services | NASH PROJECT | $9.2M | FY2002 | Jun 2002 – Jun 2027 |
| Department of Health and Human Services | OXIDIZED PHOSPHOLIPIDS IN VASCULAR PATHOBIOLOGY | $9.2M | FY2007 | Aug 2007 – Apr 2012 |
| Department of Health and Human Services | PATHOGENETIC MECHANISMS OF PRION DISEASE | $9.1M | FY1997 | Jun 1997 – Aug 2014 |
| Corporation for National and Community Service | AMERICORPS*STATE | $9.1M | FY2004 | Aug 2004 – Oct 2007 |
| VA/DoDDepartment of Defense | NEW CA CWRU | $9.1M | FY2020 | Jun 2020 – Dec 2025 |
| Department of Health and Human Services | ORAL MUCOSAL IMMUNITY IN VULNERABLE HIV INFECTED POPULATIONS | $9M | FY2009 | Jun 2009 – Apr 2015 |
| Department of Health and Human Services | ALLIANCE OF RANDOMIZED TRIALS OF MEDICINE VS METABOLIC SURGERY IN TYPE 2 DIABETES - (ARMMS-T2D) | $8.8M | FY2017 | Jul 2017 – Jun 2025 |
| Department of Health and Human Services | CELLULAR S-NITROSOTHIOL SIGNALING IN RESPIRATORY BIOLOGY | $8.7M | FY2011 | Apr 2011 – Mar 2016 |
| Corporation for National and Community Service | THIS APPLICATION IS FOR NEW, RECOMPETING, OR CONTINUATION STATE COMMISSION APPLICANTS, INCLUDING TERRITORIES WITH COMMISSIONS, APPLYING FOR COST REIMBURSEMENT GRANTS. | $8.6M | FY2020 | Aug 2020 – Jul 2024 |
| Department of Health and Human Services | ENGAGING COMMUNITIES AND INSTITUTIONS TO REDUCE HEALTH DISPARITIES IN CLEVELAND | $8.5M | FY2007 | Sep 2007 – Sep 2017 |
| Department of Health and Human Services | CASE CENTER FOR SYNCHROTRON BIOSCIENCES | $8.4M | FY2009 | Sep 2009 – Aug 2020 |
| Department of Health and Human Services | HEALTH CENTER CLUSTER | $8.3M | FY2014 | Nov 2013 – Jan 2019 |
| Department of Health and Human Services | PROTECTIVE GENETIC VARIANTS FOR ALZHEIMER DISEASE IN THE AMISH | $8.2M | FY2017 | Sep 2017 – Aug 2022 |
| Department of Health and Human Services | COCAINE EXPOSED CHILDREN AT SCHOOL AGE | $8.1M | FY1994 | Jan 1994 – Nov 2019 |
| Department of Health and Human Services | RESTORATION OF GRASP AND REACH IN CERVICAL SPINAL CORD INJURY | $8.1M | FY2018 | Mar 2018 – Aug 2025 |
| Agency for International Development | ECONOMIC DEVELOPMENT ALLIANCE FOR SAN MARTIN REGION | $8.1M | FY2011 | Oct 2010 – Dec 2017 |
| National Science Foundation | NEURONEX: COMMUNICATION, COORDINATION, AND CONTROL IN NEUROMECHANICAL SYSTEMS (C3NS) | $8.1M | FY2020 | Sep 2020 – Aug 2025 |
| VA/DoDDepartment of Defense | YOUNGSTOWN-WARREN REGIONAL AIRPORT TAXIWAY H REHABILITATION | $8M | FY2023 | Sep 2023 – Oct 2025 |
| Department of Health and Human Services | REGULATION OF CNS VIRAL PERSISTENCE | $7.9M | FY2009 | Sep 2009 – Aug 2014 |
| Department of Health and Human Services | GENETIC AND CELLULAR DETERMINANTS OF ARTERIAL THROMBOSIS | $7.9M | FY2006 | Mar 2006 – Feb 2011 |
| Department of Health and Human Services | MECHANISMS OF TRANSMISSIBILITY IN PRION DISEASES | $7.7M | FY2014 | Sep 2014 – Aug 2020 |
| Department of Transportation | APPLICATION PURPOSE: THE PURPOSE OF THIS AWARD IS TO PROVIDE ASSISTANCE FOR ONE YEAR OF PLANNING ASSISTANCE ONE YEAR OF ARCHITECTURE AND ENGINEERING DESIGN EXPANSION OF THE ADMIN/MAINTENANCE FACILITY THE PURCHASE OF THREE REPLACEMENT MINIVANS VEHICLES ONE YEAR OF OPERATING ASSISTANCE FUNDS FOR PREVENTIVE MAINTENANCE TO KEEP FIXED ASSETS IN A GOOD STATE OF REPAIR THE INSTALLATION OF A BACK-UP GENERATOR A PHONE SYSTEM UPGRADE AND FUNDING FOR THE PURCHASE OF FOUR REPLACEMENT NON-REVENUE ELECTRIC VEHICLES.; ACTIVITIES PERFORMED: FUNDS WILL BE USED TO COVER TRANSIT PLANNING ACTIVITIES FOR THE DEVELOPMENT AND UPDATE OF OUR SERVICE PLANS TRANSPORTATION IMPROVEMENT PROGRAMS ONGOING ANALYSIS AND EVALUATION OF POLICIES PROCEDURES AND STANDARDS IN THE AREAS OF SERVICE. FUNDS WILL BE USED FOR ARCHITECTURE AND ENGINEERING DESIGN TO ASSIST WRTA STAFF WITH SPECIFICATION DEVELOPMENT AND PROJECT OVERSIGHT ON VARIOUS TECHNICAL AND CONSTRUCTION PROJECTS. FUNDS WILL BE USED FOR PREVENTIVE MAINTENANCE TO KEEP OUR ASSETS IN A GOOD STATE OF REPAIR FUNDS WILL BE USED FOR THE PURCHASE OF THREE REPLACEMENT MINIVAN VEHICLES AND FOUR REPLACEMENT NON-REVENUE VEHICLES. FUNDS WILL BE USED FOR THE CONSTRUCTION OF THE EXPANSION OF OFFICE SPACE AND MAINTENANCE BAYS TO ACCOMMODATE THE GROWTH IN OUR WORKFORCE. FUNDS WILL BE USED FOR THE INSTALLATION OF A BACK-UP GENERATOR AT OUR DOWNTOWN PASSENGER TERMINAL AND FUNDS WILL BE USED TO REPLACE OUR BEYOND USEFUL LIFE PHONE SYSTEM.; EXPECTED OUTCOMES: THE BENEFITS FROM THESE FUNDS WILL ALLOW WRTA TO PLAN AND DEVELOP ROUTES TO BETTER SERVE OUR COMMUNITY ASSIST IN THE CONSTRUCTION OF THE EXPANSION OF OUR ADMIN/MAINTENANCE FACILITY. THE PURCHASE OF REPLACEMENT MINIVANS VEHICLES WILL REPLACE VEHICLES THAT ARE BEYOND THEIR USEFUL LIFE SO THAT WRTA CAN PROVIDE A BETTER SERVICE WITH NEWER VEHICLES FOR OUR PASSENGERS. THE REPLACEMENT OF BEYOND USEFUL LIFE NON-REVENUE VEHICLES WITH NEWER MORE ENVIRONMENTALLY SUSTAINABLE VEHICLES. THE INSTALLATION OF A BACK-UP GENERATOR TO MAKE SURE OUR TRANSIT CENTER CAN REMAIN OPERATING DURING POWER OUTAGES. THE CONTINUED MAINTENANCE OF OUR ASSETS IN A STATE OF GOOD REPAIR. WITH THE UPGRADE TO THE PHONE SYSTEM WE WILL HAVE A MORE RELIABLE SYSTEM ALONG WITH ADDITIONAL FEATURES TO MAKE IT EASIER TO ANSWER CALLS FOR SERVICE.; INTENDED BENEFICIARIES: WRTA AND OUR PASSENGERS THAT RELY ON OUR SERVICE WILL BENEFIT FROM CONTINUED SERVICES PERMITTING WORKERS TO GET TO JOBS MEDICAL TRIPS EDUCATION OPPORTUNITIES SHOPPING AND OTHER DESTINATIONS. PLUS WRTA WILL BE ABLE TO REDUCE OUR CARBON FOOTPRINT THAT WILL HELP THE ENVIRONMENT.; SUBRECIPIENT ACTIVITIES: NONE | $7.7M | FY2024 | Sep 2024 – Mar 2029 |
| Corporation for National and Community Service | AMERICORPS*STATE | $7.6M | FY2007 | Aug 2007 – Sep 2011 |
| Department of Health and Human Services | HEMODIALYSIS FISTULA MATURATION CONSORTIUM DATA COORDINATING CENTER | $7.6M | FY2008 | Sep 2008 – May 2015 |
| Department of Health and Human Services | TISSUE INJURY AND INFLAMMATION IN MULTIPLE SCLEROSIS | $7.6M | FY2000 | Dec 1999 – Dec 2015 |
| Department of Health and Human Services | MOLECULAR DISSECTION OF CYTOKINE CROSSTALK IN THE TUMOR MICROENVIRONMENT - PROJECT SUMMARY DESPITE RECOGNITION OF THE BROAD CONSEQUENCES OF INFLAMMATION IN CANCER BIOLOGY, THE MECHANISTIC IMPACT ON THE TUMOR LANDSCAPE REMAINS INCOMPLETELY UNDERSTOOD. INDEED, INNATE AND ADAPTIVE IMMUNE FUNCTIONS IN CANCER CAN BE BENEFICIAL OR DETRIMENTAL AND THE OPPOSING ROLES HIGHLIGHT THE GAP OF KNOWLEDGE IN OUR UNDERSTANDING OF HOW INFLAMMATION SCULPTS THE TUMOR MICROENVIRONMENT (TME). THIS PROGRAM PROJECT WILL ADDRESS THIS GAP OF KNOWLEDGE BY DEFINING AND DELINEATING HOW CYTOKINES MODULATE THE FUNCTIONS OF THE MULTIPLE CELL TYPES COMPOSING THE TUMOR MICROENVIRONMENT. OUR PREVIOUS WORK HAS REVEALED THE POTENTIAL FOR THESE INFLAMMATORY CYTOKINES TO REGULATE A SPECTRUM OF CANCER CELL PHENOTYPES, INCLUDING THEIR SELF-RENEWAL AND CELLULAR HIERARCHY OR STEMNESS, THAT ARE ASSOCIATED WITH THE EPITHELIAL-MESENCHYMAL TRANSITION (EMT). MOREOVER, THESE PHENOTYPES ARE COMMONLY ASSOCIATED WITH CANCER PROGRESSION THROUGH MODULATION OF DIFFERENTIATION POTENTIAL, CELL-CELL INTERACTIONS AND MOBILITY, FIBROSIS, AND SENSITIVITY TO MULTIPLE THERAPEUTIC MODALITIES. THE PROGRAM IS NOW CENTERED ON TWO MAJOR THEMES. THE FIRST IS TO DEFINE THE SIGNALING MECHANISMS THAT GOVERN HOW CYTOKINES (TYPE I IFNS, IL- 17,TGFSS) MODULATE (BOTH POSITIVELY AND NEGATIVELY) THE EMT PROCESS. THE CELLULAR TARGETS INCLUDE STEM-LIKE TUMOR CELLS AS WELL AS THE NON-TUMOR DERIVED POPULATIONS, INCLUDING FIBROBLASTS AND IMMUNE CELLS. THE SECOND THEME RELATES THESE CELL-SPECIFIC EMT RESPONSES TO SPECIFIC EFFECTS ON METASTASIS, FIBROSIS, AND RESISTANCE TO MULTIPLE THERAPEUTIC STRATEGIES. OUR MAJOR GOAL IS TO PARLAY OUR IMPROVED UNDERSTANDING OF CYTOKINE EFFECTS IN THE TME INTO SPECIFIC IMPROVEMENTS IN CANCER THERAPY. COLLECTIVELY THE THREE PROJECTS IN THE APPLICATION WILL TEST THE FOLLOWING OVERARCHING HYPOTHESIS: CYTOKINE SIGNALS HAVE DISTINCT AND SOMETIMES CONFLICTING MECHANISTIC ROLES IN CANCER PROGRESSION THOUGH ALTERATIONS IN EMT AND CANCER STEM CELL DEVELOPMENT. SUCH MECHANISMS LEAD TO CRITICAL PHENOTYPIC PROPERTIES RESPONSIBLE FOR CONTINUOUS METASTATIC SPREAD AND RESISTANCE TO MULTIPLE THERAPEUTIC MODALITIES (CHEMOTHERAPY, IMMUNE THERAPY). THIS HYPOTHESIS WILL BE TESTED BY (1) DEFINING THE SIGNALING EVENTS INITIATED BY TGFSS, IL-17, AND/OR TYPE I IFNS AND THE ENDPOINT CHANGES IN SPECIFIC GENE EXPRESSION THAT ARE CAUSALLY LINKED WITH CONTROL OF TME AND CANCER CELL PHENOTYPES, (2) DETERMINATION OF HOW THESE SPECIFIC SIGNALING PATHWAYS AND GENE EXPRESSION EVENTS ARE MECHANISTICALLY RESPONSIBLE FOR ACQUISITION OF THERAPEUTIC RESISTANCE AND (3) EVALUATION OF THE DISTINCT CELL TYPE CONTRIBUTIONS TO TUMOR PHENOTYPES AND THERAPEUTIC RESISTANCE, WITH EMPHASIS ON TUMOR CELL INTRINSIC MECHANISMS, IMMUNE CELL INFILTRATES AND ACTIVITIES, AND STROMAL CELL CONTROL OF TUMOR ACCESS. | $7.5M | FY2022 | Sep 2022 – Aug 2027 |
| Department of Health and Human Services | PROGNOSIS AND PREDICTORS OF ACL RECONSTRUCTION: A MULTICENTER COHORT STUDY | $7.5M | FY2006 | Sep 2006 – Apr 2022 |
| VA/DoDDepartment of Defense | MOLECULAR MECHANISMS AND PATHWAYS FOR GAS TRANSPORT ACROSS BIOLOGICAL MEMBRANES AND IMPLICATIONS FOR PHYSIOLOGY AND PERFORMANCE MURI 2016 | $7.5M | FY2016 | Jul 2016 – Jul 2022 |
| Corporation for National and Community Service | GRANTS WILL BE AWARDED TO ORGANIZATIONS PROPOSING TO ENGAGE AMERICORPS MEMBERS TO STRENGTHEN COMMUNITIES. | $7.4M | FY2016 | Jul 2016 – Jun 2019 |
| Department of Health and Human Services | CYCLE-AD: RANDOMIZED CONTROLLED TRIAL TO ASSESS THE EFFICACY OF INDOOR CYCLING IN SLOWING DISEASE PROGRESSION IN HEALTHY OLDER PERSONS AT GENETIC RISK FOR ALZHEIMER?S DISEASE - PROJECT SUMMARY/ABSTRACT THE APOLIPOPROTEIN E EPSILON 4 (APOE 4) ALLELE IS THE MOST IMPORTANT GENETIC RISK FACTOR FOR LATE ONSET ALZHEIMER'S DISEASE (AD). A RECENT REVIEW BY THE WORLD HEALTH ORGANIZATION HIGHLIGHTED THE POTENTIAL PROTECTIVE ROLE OF PHYSICAL ACTIVITY AND EXERCISE AGAINST COGNITIVE DECLINE, ALL-CAUSE DEMENTIA, AD, AND VASCULAR DEMENTIA IN HEALTHY INDIVIDUALS. IN AN 18-MONTH LONGITUDINAL OBSERVATIONAL STUDY, WE SHOWED THAT SEDENTARY 4 CARRIERS EXPERIENCE SIGNIFICANT DECLINES IN EPISODIC MEMORY AND HIPPOCAMPAL VOLUME COMPARED TO 4 CARRIERS WHO ENGAGED IN MODERATE PA. IMPORTANTLY, AMONG 4 NON-CARRIERS, NO SIGNIFICANT LONGITUDINAL CHANGES IN COGNITION AND BRAIN IMAGING WERE OBSERVED WHETHER THE NON-CARRIERS WERE SEDENTARY OR ENGAGED IN MODERATE PA, SUGGESTING THAT PA HAS A SPECIFIC NEUROPROTECTIVE ROLE IN DELAYING THE PROGRESSION OF AD IN 4 CARRIERS. BASED ON OUR RESULTS, A PRAGMATIC, RANDOMIZED CONTROLLED TRIAL WITH BLINDED CLINICAL AND IMAGING OUTCOMES IS PROPOSED TO DETERMINE THE IMPACT OF A HOME BASED, HIGH INTENSITY EXERCISE INTERVENTION IN HEALTHY, COGNITIVELY INTACT 4 CARRIERS BETWEEN THE AGES OF 65 AND 80 YEARS. THE CYCLE-AD (CYCLING TO CEASE OR LIMIT THE EFFECTS OF ALZHEIMER'S DISEASE) TRIAL WILL RECRUIT OTHERWISE HEALTHY SEDENTARY CARRIERS RANDOMIZED TO ONE OF TWO GROUPS (N=75 EACH): 1) AN INDOOR CYCLING (IC) GROUP THAT PARTICIPATES IN HIGH-INTENSITY INTERVAL TRAINING (HIIT; 60-90% OF HEART RATE RESERVE) IN THEIR HOME VIA THE COMMERCIALLY AVAILABLE PELOTON® CYCLING SYSTEM OR 2) A USUAL AND CUSTOMARY CARE (UCC) GROUP, IN WHICH PARTICIPANTS ENGAGE IN THEIR HABITUAL LEVEL OF PA. WE HYPOTHESIZE THAT AN 18-MONTH HIGH-INTENSITY AEROBIC EXERCISE REGIMEN WILL SLOW AD-RELATED DISEASE PROGRESSION IN SEDENTARY ELDERS AT GENETIC RISK FOR AD. PARTICIPANTS IN THE INTERVENTION GROUP WILL ENGAGE IN EXERCISE 3X/WEEK (MINIMUM 90 MINUTES/WEEK) FOR 18 MONTHS. PRIMARY OUTCOME MEASURES, OBTAINED AT STUDY ENTRY AND AT 18 MONTHS, WILL INCLUDE COMPREHENSIVE COGNITIVE TESTING AND BRAIN MR IMAGING TO ASSESS DISEASE PROGRESSION AND A COMPREHENSIVE PA/FITNESS ASSESSMENT TO MEASURE THE DEGREE OF CHANGE IN PHYSICAL FITNESS DUE TO HIGH INTENSITY AEROBIC EXERCISE. THE OVERALL GOAL OF THE CYCLE-AD TRIAL IS TO DETERMINE THE ROLE OF LONG-TERM, HIGH INTENSITY EXERCISE IN SLOWING OR DELAYING THE ONSET OF COGNITIVE AND AD-RELATED BRAIN CHANGES IN 4 CARRIERS. SUCCESSFUL TRANSLATION AND DEMONSTRATION OF THE EFFECTIVENESS OF A SCALABLE HOME-BASED EXERCISE INTERVENTION CAPABLE OF SLOWING OR DELAYING DISEASE ONSET WILL TRANSFORM AD TREATMENT, IMPROVE PATIENT OUTCOMES AND QUALITY OF LIFE, AND REDUCE HEALTH CARE COSTS. | $7.4M | FY2021 | Jan 2021 – Dec 2026 |
| VA/DoDDepartment of Veterans Affairs | HOMELESS PREVENTION | $7.4M | — | — – — |
| Department of Health and Human Services | POST-TRANSPLANT INFLAMMATORY RESPONSE | $7.3M | FY1997 | Apr 1997 – Nov 2029 |
| Corporation for National and Community Service | ENGAGES AMERICORPS MEMBERS IN FULL AND PART-TIME SERVICE TO MEET COMMUNITY NEEDS IN EDUCATION, THE ENVIRONMENT, HEALTH, VETERANS, AND OTHER AREAS. NA | $7.3M | FY2014 | Aug 2014 – Dec 2017 |
| Department of Health and Human Services | CAPTURING SPATIAL PATTERNS OF NEW M. TUBERCULOSIS INFECTION IN KAMPALA, UGANDA | $7.3M | FY2019 | Aug 2019 – Jul 2025 |
| VA/DoDDepartment of Veterans Affairs | CARES 2.0 FUNDING FOR COVID19. THE SSVF PROGRAM'S PURPOSE IS TO PROVIDE SUPPORTIVE SERVICES GRANTS TO PRIVATE NON-PROFIT ORGANIZATIONS AND CONSUMER COOPERATIVES, WHO WILL COORDINATE OR PROVIDE SUPPORTIVE SERVICES TO VERY LOW-INCOME VETERAN FAMILIES WHO ARE RESIDING IN PERMANENT HOUSING, ARE HOMELESS AND SCHEDULED TO BECOME RESIDENTS OF PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD; OR AFTER EXITING PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD, ARE SEEKING OTHER HOUSING THAT IS RESPONSIVE TO SUCH VERY LOW-INCOME VETERAN FAMILY'S NEEDS AND PREFERENCES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. | $7.3M | FY2020 | Apr 2020 – — |
| Corporation for National and Community Service | N/A | $7.3M | FY2017 | Aug 2017 – Aug 2020 |
| Department of Transportation | WRTA SECTION 5307 ARPA OPERATING ASSISTANCE | $7.2M | FY2021 | Jun 2021 – Apr 2022 |
| Department of Health and Human Services | MULTI-FUNCTIONAL NEUROPROSTHETIC SYSTEMS FOR RESTORATION OF MOTOR FUNCTION | $7.1M | FY2010 | Jun 2010 – May 2018 |
| Department of Health and Human Services | CENTRAL VEIN SIGN: A DIAGNOSTIC BIOMARKER IN MULTIPLE SCLEROSIS | $7.1M | FY2020 | Jul 2020 – Jun 2026 |
| Department of Health and Human Services | INVOLVING COMMUNITIES IN DELIVERING AND DISSEMINATING HEALTH DISPARITY INTERVENTIONS | $7.1M | FY2007 | Jul 2007 – Apr 2024 |
| Department of Health and Human Services | REGULATION OF GENE EXPRESSION DURING STRESS | $7.1M | FY1998 | Jan 1998 – Jul 2023 |
| Department of Health and Human Services | CASE WESTERN RESERVE UNIVERSITY/CLEVELAND CLINIC CTSA (KL2) | $7.1M | FY2007 | Sep 2007 – Jun 2012 |
| Department of Health and Human Services | MOLECULAR BASIS OF ILK SIGNALING IN CELL ADHESION | $7.1M | FY1999 | Jan 1999 – Mar 2028 |
| Department of Health and Human Services | TOWARDS PRECISION IMMUNO-ONCOLOGY: UNRAVELING THE GENOMIC DETERMINANTS AND MECHANISMS UNDERLYING IMMUNOTHERAPY EFFICACY AND RESISTANCE | $7M | FY2018 | Sep 2018 – Aug 2025 |
| Department of Health and Human Services | NEI CENTER CORE GRANT FOR VISION RESEARCH | $7M | FY2016 | Sep 2016 – Jun 2030 |
| Agency for International Development | THE GORILLA COFFEE ALLIANCE BRINGS TOGETHER DEVELOPMENT AND CONSERVATION ORGANIZATIONS IN PARTNERSHIP WITH AGRICULTURE COMPANIES TO IDENTIFY INNOVATIVE AND SCALABLE SOLUTIONS THAT ENHANCE THE WAYS THAT COMMUNITIES AROUND KAHUZI BIEGA NATIONAL PARK BENEFIT FROM THE REGION’S PRODUCTION POTENTIAL WHILE PROTECTING THE PARK’S VULNERABLE SPECIES AND LANDSCAPES. | $7M | FY2021 | Aug 2021 – Aug 2026 |
| Department of Transportation | CAPITAL PLANNING VEHICLE PURCHASE | $7M | — | — – May 2021 |
| Department of Health and Human Services | PATHOGENESIS OF NEUROLOGICAL DISABILITY IN PRIMARY DISEASES OF MYELIN | $6.9M | FY2017 | Dec 2016 – Nov 2025 |
| VA/DoDDepartment of Veterans Affairs | THE SSVF PROGRAM'S PURPOSE IS TO PROVIDE SUPPORTIVE SERVICES GRANTS TO PRIVATE NON-PROFIT ORGANIZATIONS AND CONSUMER COOPERATIVES, WHO WILL COORDINATE OR PROVIDE SUPPORTIVE SERVICES TO VERY LOW-INCOME VETERAN FAMILIES WHO ARE RESIDING IN PERMANENT HOUSING, ARE HOMELESS AND SCHEDULED TO BECOME RESIDENTS OF PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD; OR AFTER EXITING PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD, ARE SEEKING OTHER HOUSING THAT IS RESPONSIVE TO SUCH VERY LOW-INCOME VETERAN FAMILY'S NEEDS AND PREFERENCES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. | $6.9M | FY2020 | Oct 2019 – Sep 2020 |
| Department of Health and Human Services | INSTITUTIONAL CAREER DEVELOPMENT CORE | $6.9M | FY2018 | May 2018 – Apr 2024 |
| Department of Health and Human Services | MOLECULAR DETERMINANTS OF CORONARY ARTERY DISEASE | $6.8M | FY2005 | Feb 2005 – Dec 2010 |
| VA/DoDDepartment of Veterans Affairs | HOMELESS PREVENTION | $6.8M | — | — – — |
| Department of Health and Human Services | PREVENTION RESEARCH CENTER FOR HEALTHY NEIGHBORHOODS | $6.7M | FY2014 | Sep 2014 – Sep 2019 |
| Department of Health and Human Services | IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM | $6.7M | FY2010 | Aug 2010 – Sep 2022 |
| Department of Health and Human Services | CLEVELAND CLINIC CARDIOTHORACIC COLLABORATIVE CLINICAL CENTER (C6) | $6.7M | FY2007 | Jul 2007 – Feb 2027 |
| Department of Health and Human Services | PATHWAYS OF INJURY AND REPAIR IN BARRETT'S CARCINOGENESIS - PROGRAM SUMMARY THE CENTRAL HYPOTHESIS OF THIS PROGRAM PROJECT IS THAT “ALTERED SQUAMOUS EPITHELIAL INTEGRITY (PRJ 1) AND INFLAMMATORY INJURY (PRJ 2) ACTIVATE SIGNALING PATHWAYS INCLUDING EPHB2 (PRJ 3) THAT AFFECT PRECURSOR CELLS AT THE SQUAMOCOLUMNAR JUNCTION (SCJ) TRANSITION, ESOPHAGEAL SUBMUCOSAL GLAND (ESMG), AND BASAL SQUAMOUS NICHES, RESULTING IN THE ALTERATION OF REGULATORY FACTORS THAT INCLUDE NOTCH, MYC, P63, AND SOX9, LEADING TO ACINAR DUCTAL METAPLASIA (ADM), MULTI-LAYERED EPITHELIUM (MLE), BARRETT'S ESOPHAGUS (BE), AND ULTIMATELY ESOPHAGEAL ADENOCARCINOMA (EAC).” THE SPECIFIC AIMS OF OUR PROGRAM ARE: 1) TO ELUCIDATE SIGNALING PATHWAYS BY WHICH MUTATED VSIG10L ALTERS EPITHELIAL INTEGRITY LEADING TO MLE AND BE LIKE METAPLASIA ON NOVEL MOUSE MODELS. 2) TO DEFINE THE SPATIAL AND TEMPORAL PATTERN OF CXCL8 (IL-8) IN ESMG FOLLOWING ESOPHAGEAL INJURY AND PHENOTYPE THE INFLAMMATORY INFILTRATE THAT LEADS TO THE DEVELOPMENT OF ACINAR DUCTAL METAPLASIA (ADM) IN ESMG ASSOCIATED WITH BE/EAC. 3)TO IDENTIFY MEDIATORS OF EPHB2 SIGNALING THAT LEAD TO C-MYC ACTIVATION AND METAPLASTIC CELLULAR DIFFERENTIATION AFTER INJURY IN THE DEVELOPMENT OF BE AND ITS PROGRESSION TO EAC. 4) TO DEFINE HOW ALTERED EPITHELIAL INTEGRITY, INFLAMMATORY CELLS, AND ALTERATION OF SIGNALING MOLECULES THAT CONTROL DIFFERENTIATION (EPHB2) LEAD TO METAPLASIA BY ALTERING TRANSCRIPTION FACTORS. 5) INTEGRATE PROJECTS BY PROVIDING INVESTIGATORS EFFECTIVE SUPPORT THROUGH CORE RESOURCES WITH STATE-OF-THE-ART BIOREPOSITORY, BIOINFORMATICS, AND ADMINISTRATIVE SERVICES. THESE OBJECTIVES BUILD AND SYNERGIZE ON THE CONSIDERABLE CLINICAL, BASIC SCIENCE, AND TRANSLATIONAL EXPERTISE AVAILABLE AT OUR INSTITUTIONS, 1) TO FOCUS LABORATORY RESEARCH ON UNDERSTANDING THE GENETIC SUSCEPTIBILITY AND MOLECULAR CHANGES THAT INFLUENCE THE DEVELOPMENT OF BE AND EAC; AND 2) TO THEN TRANSLATE LABORATORY DISCOVERIES INTO CLINICAL APPLICATIONS FOR EFFECTIVE DETECTION, MOLECULAR RISK STRATIFICATION, AND PREVENTION OF PROGRESSION FROM BE TO EAC. | $6.6M | FY2023 | Sep 2023 – Aug 2028 |
| Department of Health and Human Services | TARGETING 15-PROSTAGLANDIN DEHYDROGENASE (15-PGDH) IN CANCER RISK, PREVENTION, AND TREATMENT | $6.6M | FY2017 | Dec 2016 – Nov 2023 |
| Department of Health and Human Services | SIGNIFICANCE OF CYP46A1 AND OTHER P450S IN RETINAL FUNCTION | $6.5M | FY2007 | Sep 2007 – Mar 2025 |
| Department of Health and Human Services | PSORIASIS CENTER OF RESEARCH TRANSLATION | $6.5M | FY2017 | Sep 2017 – Aug 2024 |
| Department of Health and Human Services | PHOTOTRANSDUCTION IN HEALTH AND DISEASE | $6.5M | FY2011 | Sep 2011 – Mar 2030 |
| Department of Health and Human Services | OPTICAL TOOLS TO ASSESS THE ROLE OF HEMODYNAMICS IN THE DEVELOPMENT OF CONGENITAL HEART DEFECTS | $6.4M | FY2015 | Jul 2015 – Feb 2027 |
| Department of Health and Human Services | TRANSLATIONAL RESEARCH IN CYSTIC FIBROSIS | $6.4M | FY1983 | Jan 1983 – Mar 2015 |
| Department of Health and Human Services | CIRCUIT ARCHITECTURE AND DYNAMICS REPRESENTATION IN ODOR PERCEPTION | $6.4M | FY2015 | Jul 2015 – Apr 2027 |
| Department of Health and Human Services | PROTECTIVE GENETIC VARIANTS FOR ALZHEIMER DISEASE IN THE AMISH - RENEWAL - ALZHEIMER DISEASE (AD) IS A DEVASTATING NEURODEGENERATIVE DISORDER THAT AFFECTS MILLIONS OF INDIVIDUALS IN THE U.S. IT HAS SO FAR RESISTED ATTEMPTS TO DEVELOP EFFECTIVE THERAPIES DESPITE NUMEROUS (FAILED) CLINICAL TRIALS BASED ON KNOWN TARGETS, MOST IDENTIFIED OVER 20 YEARS AGO. WHILE GENOMIC RESEARCH (E.G. THE ALZHEIMER’S DISEASE SEQUENCING PROJECT; ADSP) HAS IDENTIFIED NUMEROUS ADDITIONAL RISK LOCI, THESE RESULTS DERIVE PRIMARILY FROM CASE- CONTROL DATASETS. IN CONTRAST, COHORTS DESIGNED TO IDENTIFY VARIANTS THAT MAY PROTECT FROM AD, AND THOSE USING COMPLEMENTARY STUDY DESIGNS, ARE FEW. WE USED OUR EXTENSIVE EXPERIENCE WITH THE AMISH COMMUNITIES IN INDIANA AND OHIO TO ESTABLISH A COHORT OF OLDER INDIVIDUALS AT HIGH RISK OF DEVELOPING AD BUT WHO ARE COGNITIVELY UNIMPAIRED (CU). THE AMISH PROVIDE A UNIQUE OPPORTUNITY TO IDENTIFY PROTECTIVE VARIANTS FOR AD BECAUSE OF THEIR REDUCED BACKGROUND GENETIC VARIATION AND ENVIRONMENTAL RISK FACTORS. THEIR SMALL FOUNDING POPULATION AND ENDOGAMY PROVIDES ENRICHMENT FOR RARE VARIANTS. FOUNDER POPULATIONS ALSO ENABLE TESTING FOR NON-ADDITIVE ALLELIC EFFECTS AND CAN MAGNIFY SUB-SIGNIFICANT ASSOCIATION SIGNALS IDENTIFIED IN CASE-CONTROL STUDIES. THE STABILITY AND ENGAGEMENT OF OUR AMISH PARTICIPANTS ENABLES LONGITUDINAL ASSESSMENTS OF COGNITION AND BIOMARKERS. OUR PRIMARY GOALS ARE TO IDENTIFY AD PROTECTIVE LOCI AND CHARACTERIZE PRE-CLINICAL BIOMARKERS OF PROGRESSION TO COGNITIVE IMPAIRMENT. BUILDING ON OUR EXISTING LARGE COHORT, OUR REPLICATED PROTECTIVE LOCUS AND SEVERAL SUGGESTIVE PROTECTIVE LOCI, AND OUR EXISTING BIOBANK OF DNA AND PLASMA AND DATABANK OF GWAS AND WGS, WE PROPOSE TO: 1) PERFORM LONGITUDINAL ASSESSMENT OF COGNITION IN OUR FAMILY-BASED AMISH COHORT; 2) IDENTIFY PROTECTIVE FACTORS FOR AD AND PREDICTORS OF PROGRESSION TO COGNITIVE IMPAIRMENT BY ANALYZING GENOMIC AND LONGITUDINAL COGNITIVE, BIOMARKER, AND SDOH DATA; AND 3) EXAMINE THE FUNCTIONAL IMPLICATIONS OF CURRENT AND NOVEL GENES AND VARIANTS BY PRIORITIZING LOCI USING IN SILICO ANNOTATION FOR FUNCTIONAL CONSEQUENCES FOLLOWED BY IN VITRO FUNCTIONAL CHARACTERIZATION. OUR RESULTS WILL IDENTIFY POTENTIAL DRUGGABLE TARGETS AND ACCELERATE THE DEVELOPMENT OF BETTER TREATMENTS FOR AD. | $6.4M | FY2022 | Sep 2022 – May 2027 |
| Corporation for National and Community Service | AMERICORPS STATE | $6.3M | FY2009 | Jul 2009 – Aug 2012 |
| Department of Health and Human Services | GENOMIC AND MICROENVIRONMENTAL DETERMINANTS, TEMPORAL DYNAMICS, AND TREATMENT EFFICACY OF RADIATION-BASED COMBINATION THERAPIES - PROJECT SUMMARY OVERALL SECTION OUR ROBIN CENTER FOCUSES ON ELUCIDATING THE GENOMIC AND MICROENVIRONMENTAL DETERMINANTS, AND TEMPORAL DYNAMICS UNDERLYING EFFICACY OF RADIATION-BASED COMBINATION THERAPIES. RADIOTHERAPY (RT), ALONE OR IN COMBINATION WITH OTHER TREATMENTS, IS USED TO TREAT ABOUT TWO-THIRDS OF ALL CANCER PATIENTS. DESPITE THE WIDESPREAD USE OF RADIATION THERAPY IN ONCOLOGY, OUR UNDERSTANDING OF THE MECHANISMS DRIVING RESPONSE AND RESISTANCE REMAINS POOR. OUR LONG-TERM GOAL IS TO UNDERSTAND THE MECHANISMS THAT UNDERLIE EFFICACY AND RESISTANCE OF RADIATION-BASED THERAPIES. NEW EFFORTS TO IMPROVE TREATMENT FOR MANY CANCER TYPES NOW FOCUS ON USING COMBINATION THERAPIES IN WHICH RADIATION IS USED WITH SYSTEMIC AGENTS, HIGHLIGHTING THE URGENT NEED TO UNDERSTAND THE DRIVERS OF EFFICACY. AMONG THE MOST PROMISING NEW BIOLOGICS BEING STUDIED FOR USE WITH RADIATION ARE ANTIBODY-DRUG CONJUGATES (ADC) AND IMMUNE CHECKPOINT INHIBITORS (ICI). WE WILL USE AN INNOVATIVE MOLECULAR CHARACTERIZATION TRIAL TESTING RADIATION PLUS ADC IN BLADDER CANCER AND RADIATION PLUS ICI IN HEAD AND NECK CANCER TO CHARACTERIZE THE MECHANISTIC DRIVERS UNDERLYING THESE NEXT GENERATION RT-BASED COMBINATIONS. THE CENTRAL HYPOTHESIS OF THIS U54 APPLICATION IS THAT SPECIFIC GENETIC AND IMMUNOLOGIC MECHANISMS UNDERLIE SENSITIVITY AND RESISTANCE TO RADIATION-BASED COMBINATION THERAPIES. WE WILL ADDRESS THESE QUESTIONS THROUGH 3 SPECIFIC AIMS. IN AIM 1, WE WILL WORK TO UNDERSTAND THE MOLECULAR MECHANISMS THAT UNDERLIE EFFICACY OF TREATMENT WITH RADIATION PLUS ADC. HERE, OUR WORKING HYPOTHESIS IS THAT SPECIFIC GENETIC AND IMMUNOLOGIC EVENTS UNDERLIE RESPONSE TO RT PLUS SACITUZUMAB GOVITECAN (SG) TREATMENT. WE WILL LEVERAGE OUR MOLECULAR CHARACTERIZATION TRIAL (PART A) INVESTIGATING THE USE OF RT AND SACITUZUMAB FOR BLADDER PRESERVATION THERAPY. WE WILL DETERMINE THE DIFFERENTIAL MOLECULAR EFFECTS WITH STANDARD-OF-CARE RT + CISPLATIN VERSUS RT + SG. IN AIM 2, WE WILL IMPROVE IDENTIFICATION OF PATIENTS WHO ARE SENSITIVE OR RESISTANT TO RT-BASED THERAPIES BASED ON NEW INSIGHTS INTO TRANSCRIPTIONAL DYNAMICS AND TEMPORAL REPROGRAMMING DURING TREATMENT WITH RADIATION-BASED THERAPIES. HERE, WE WILL LEVERAGE OUR MOLECULAR CHARACTERIZATION TRIAL TREATING HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) OR BLADDER CANCER PATIENTS WITH RT + CHEMOTHERAPY VERSUS RT + SG OR ICI. WE WILL BUILD ON RECENT EXPERIMENTAL AND CLINICAL BREAKTHROUGHS LED BY OUR RESEARCH GROUPS, WHICH HAVE IDENTIFIED HIGHLY REFINED GENE EXPRESSION PROGRAMS ASSOCIATED WITH RT SENSITIVITY AND DELTA RADIOMICS. IN AIM 3, WE WILL IDENTIFY THE DIFFERENTIAL MECHANISMS UNDERLYING THE ANTI-TUMOR ACTIVITIES OF RT + CISPLATIN VERSUS RT + IMMUNE CHECKPOINT BLOCKADE. HERE, USING OUR HEAD AND NECK TRIAL (PART B), WE WILL UNCOVER THE UNIQUE GENETIC AND IMMUNOLOGIC FACTORS THAT GOVERN RESPONSE TO RT WHEN COMBINED WITH THESE TWO CLASSES OF AGENTS. WE WILL ELUCIDATE THE DIFFERENTIAL MOLECULAR EFFECTS OF THE TWO APPROACHES, IMMUNE REPROGRAMMING, AND MECHANISMS OF ACQUIRED RESISTANCE. OUR STUDIES WILL HELP BUILD A FOUNDATION TO OPTIMIZE MULTIMODAL, RADIATION- BASED DEFINITIVE TREATMENT STRATEGIES. | $6.3M | FY2022 | Sep 2022 – Jul 2027 |
| Department of Health and Human Services | MULTIDRUG RESISTANT ACINETOBACTER BAUMANNII, | $6.3M | FY2007 | Aug 2007 – Mar 2029 |
| Department of Health and Human Services | A FAMILIAL STUDY OF SEVERE PHONOLOGY DISORDERS | $6.2M | FY1999 | Jan 1999 – Aug 2020 |
| Agency for International Development | 1-INCREASE THE TOTAL ESTIMATED AMOUNT OF THE AGREEMENT BY $256,000.00 FROM $9,608,453.00 TO $9,864,453.00;2-PROVIDE INCREMENTAL FUNDING IN THE AMOU | $6.2M | FY2007 | Dec 2006 – May 2009 |
| Department of Transportation | PURPOSE: REHABILITATE RUNWAY. ACTIVITIES TO BE PERFORMED/EXPECTED OUTCOMES: THIS PROJECT REHABILITATES 9,003 FEET OF EXISTING PAVED RUNWAY 14/32 TO MAINTAIN THE STRUCTURAL INTEGRITY AND MINIMIZE FOREIGN OBJECT DEBRIS TO EXTEND ITS USEFUL LIFE. THIS GRANT FUNDS PHASE 3, WHICH CONSISTS OF REHABILITATION OF 4,575 FEET OF PAVEMENT. INTENDED BENEFICIARY: THIS GRANT WILL PROVIDE FEDERAL FUNDING FOR AIRPORTS ASSOCIATED WITH YOUNGSTOWN, OHIO. | $6.2M | FY2025 | Aug 2025 – Aug 2029 |
| Department of Health and Human Services | MOLECULAR BASIS OF KSHV ONCOGENESIS | $6.1M | FY2016 | Mar 2016 – Feb 2023 |
| Department of Health and Human Services | MECHANISMS OF TUBULAR ATROPHY IN RENAL DISEASE | $6.1M | FY2005 | Aug 2005 – Jun 2026 |
| VA/DoDDepartment of Defense | AN INTEGRATED COMPUTATIONAL AND EXPERIMENTAL APPROACH TOWARD THE DESIGN OF MATERIALS FOR FUEL CELLS SYSTEMS | $6.1M | FY2003 | Jun 2003 – Aug 2009 |
| Department of Health and Human Services | FUNCTIONAL GENOMICS OF ATRIAL FIBRILLATION IN HUMAN ATRIA | $6.1M | FY2012 | Jul 2012 – Apr 2021 |
| Department of Health and Human Services | CWRU CASE COMPREHENSIVE CANCER CENTER NCTN LEAD ACADEMIC PARTICIPATING SITE | $6M | FY2014 | Jun 2014 – Feb 2019 |
| Department of Health and Human Services | BEAR-MOON: A TWO ARM NONINFERIORITY BLINDED RANDOMIZED CLINICAL TRIAL COMPARING ACL REPAIR WITH BEAR DEVICE VS. STANDARD OF CARE AUTOGRAFT PATELLAR TENDON ACL RECONSTRUCTION | $6M | FY2018 | Aug 2018 – Jul 2026 |
| Department of Health and Human Services | RANDOMIZED TRIAL OF ASSISTED AMBULATION TO IMPROVE HEALTH OUTCOMES FOR OLDER MEDICAL INPATIENTS - PROJECT SUMMARY/ABSTRACT FOR OLDER ADULTS, PROLONGED HOSPITALIZATION CAN LEAD TO A DEVASTATING LOSS OF MOBILITY AND INDEPENDENCE. EACH YEAR, 12 MILLION ADULTS OVER THE AGE OF 65 ARE HOSPITALIZED, AND 30% ARE DISCHARGED TO A POST-ACUTE CARE FACILITY. ONE OF THE RISKS OF HOSPITALIZATION IS BED REST, WHICH IS ASSOCIATED WITH A NUMBER OF HOSPITAL-ACQUIRED COMPLICATIONS, INCLUDING FALLS, DELIRIUM, VENOUS THROMBOSIS AND SKIN BREAKDOWN. HOSPITAL MOBILITY PROGRAMS ATTEMPT TO AMBULATE PATIENTS UP TO THREE TIMES DAILY, BUT THIS WORK IS GENERALLY ASSIGNED TO NURSES, WHO HAVE MANY COMPETING AND OFTEN MORE PRESSING TASKS. CONSEQUENTLY, AMBULATING PATIENTS IS THE MOST FREQUENTLY OVERLOOKED NURSING DUTY. THIS PROBLEM HAS BEEN EXACERBATED BY THE COVID-19 PANDEMIC AND THE RESULTING NURSING SHORTAGE. SMALL STUDIES HAVE EXAMINED THE BENEFITS OF MOBILITY TECHNICIANS (MTS), WHOSE SOLE JOB IS TO SAFELY AMBULATE PATIENTS. THESE STUDIES HAVE DEMONSTRATED THAT MTS CAN INCREASE STEPS TAKEN, BUT THEY ARE TOO SMALL TO PROVE THE IMPACT OF MTS ON OTHER OUTCOMES, SUCH AS WHETHER PATIENTS HAVE IN-HOSPITAL COMPLICATIONS OR WHETHER THEY CAN GO HOME INSTEAD OF TO A POST-ACUTE CARE FACILITY. HOSPITALS ARE HESITANT TO ADOPT MT PROGRAMS BECAUSE THEY PERCEIVE THEM TO BE EXPENSIVE AND UNPROVEN. WE PROPOSE TO CONDUCT A LARGE RANDOMIZED TRIAL TO TEST THE IMPACT OF MTS ON SHORT AND INTERMEDIATE TERM OUTCOMES FOR 3000 PATIENTS AGED 65 YEARS AND OLDER AT 5 HOSPITALS IN 2 HEALTH SYSTEMS. PATIENTS WILL BE RANDOMIZED TO RECEIVE SUPERVISED AMBULATION UP TO 3 TIMES DAILY WITH A MT OR TO RECEIVE USUAL CARE. ALL PARTICIPANTS WILL WEAR AN ACCELEROMETER ON THEIR WRIST TO TRACK THEIR MOVEMENT THROUGHOUT THE HOSPITAL STAY. THE STUDY HAS 3 AIMS. FIRST, WE WILL COMPARE THE MOBILITY OF PATIENTS AT DISCHARGE (OR 10 DAYS) TO ASSESS THE IMPACT OF THE MTS ON THIS OUTCOME. WE ARE PARTICULARLY INTERESTED IN WHETHER THE USE OF MTS WILL INCREASE THE PROPORTION OF PATIENTS WHO CAN GO HOME VS. POST-ACUTE CARE, AND WHETHER THE IMPROVEMENTS IN MOBILITY ARE SUSTAINED AT 30 DAYS. SECOND, WE WILL USE PREDICTIVE MODELING TO IDENTIFY WHICH PATIENTS ARE MOST LIKELY TO BENEFIT FROM THIS INTERVENTION. THIRD, WE WILL ASSESS THE IMPACT OF THE INTERVENTION ON OVERALL COSTS ASSOCIATED WITH THE EPISODE OF CARE, INCLUDING INPATIENT COSTS AND THE 30 DAYS AFTER DISCHARGE. THIS INFORMATION WILL BE IMPORTANT TO CONVINCE HEALTH SYSTEMS TO ADOPT THIS APPROACH. | $6M | FY2022 | Aug 2022 – Jun 2027 |
| Department of Health and Human Services | TISSUE ENGINEERED CARTILAGE REPAIR | $6M | FY2008 | Aug 2008 – Jul 2013 |
| Department of Health and Human Services | ENSURING PATIENTS' INFORMED ACCESS TO NONINVASIVE PRENATAL TESTING | $5.9M | FY2017 | Sep 2017 – Feb 2027 |
| Department of Health and Human Services | FUNCTION OF THE PET-1 ETS FACTOR IN THE MAMMALIAN 5-HT SYSTEM | $5.9M | FY2001 | Dec 2000 – Jan 2022 |
| Department of Health and Human Services | ACTIVATION OF BLOOD AND ENDOTHELIAL CELL A5B3 INTEGRIN | $5.8M | FY2003 | Jul 2003 – Jun 2024 |
| Corporation for National and Community Service | ENGAGES AMERICORPS MEMBERS IN FULL AND PART-TIME SERVICE TO MEET COMMUNITY NEEDS IN EDUCATION, THE ENVIRONMENT, HEALTH, VETERANS, AND OTHER AREAS. CO | $5.7M | FY2014 | Aug 2014 – Aug 2018 |
| Department of Health and Human Services | BASIC AND COMPARATIVE STUDIES OF CCR5 INHIBITION TO PREVENT HIV TRANSMISSION | $5.7M | FY2008 | Jun 2008 – May 2012 |
| Corporation for National and Community Service | AMERICORPS*STATE | $5.7M | FY2006 | Aug 2006 – Apr 2010 |
| Department of Health and Human Services | EFFECTS OF IL-6 BLOCKADE IN TREATED HIV INFECTION | $5.7M | FY2013 | Feb 2013 – Jan 2020 |
| Department of Health and Human Services | DEFINING THE VIRAL PTMOME: TOWARDS THE DEVELOPMENT OF NOVEL ANTIVIRAL APPROACHES - PROJECT SUMMARY OVER THE PAST SEVERAL DECADES, THE TRADITIONAL APPROACH TO COMBATING VIRAL INFECTIOUS DISEASES HAS BEEN TO TARGET THE VIRUS ITSELF, IN MOST CASES BY EITHER BLOCKING VIRUS-ENCODED ENZYMES THAT ARE REQUIRED FOR VIRAL REPLICATION, OR BY PREVENTING THE VIRUS FROM ENTERING HOST CELLS. ONE OF THE MAJOR CAVEATS OF THESE APPROACHES HAS BEEN THE ABILITY OF THE VIRUS TO READILY MUTATE AND THEREBY BECOME RESISTANT TO THESE CLASSICAL TYPES OF ANTIVIRAL THERAPIES. IN FACT, THIS IS A SERIOUS PROBLEM FOR THE THERAPY OF RNA VIRUS INFECTIONS, SUCH AS HIV OR INFLUENZA VIRUS, WHICH ARE KNOWN TO RAPIDLY MUTATE AND THEREBY ESCAPE ANTIVIRAL DRUGS. ADDITIONALLY, TRADITIONAL ANTIVIRAL APPROACHES ARE DESIGNED TO TARGET A SPECIFIC VIRUS, AND THEREFORE ARE INEFFECTIVE AGAINST ANY NEW VIRUS THAT MAY EMERGE IN THE FUTURE, AND IT IS IMPOSSIBLE TO PREDICT WHAT VIRUS WILL CAUSE THE NEXT OUTBREAK OR PANDEMIC. THEREFORE, THERE IS THE URGENT NEED TO DEVELOP NEW WAYS FOR TARGETING VIRAL PATHOGENS, WHICH WILL REQUIRE CREATIVE AND INNOVATIVE RESEARCH. LIKE HUMAN PROTEINS, VIRAL PROTEINS ROBUSTLY UNDERGO POSTTRANSLATIONAL MODIFICATIONS (PTMS) FOR THEIR REGULATION AND PROPER FUNCTIONING IN THE VIRUS LIFE CYCLE. IN MOST CASES, VIRAL PTMS ARE DYNAMICALLY REGULATED BY HUMAN ENZYMES, SUCH AS KINASES/PHOSPHATASES, UBIQUITIN E3 LIGASES/DEUBIQUITINATING ENZYMES, OR ACETYL TRANSFERASES/DEACETYLASES. THUS, CELLULAR ENZYMES PLAY AN IMPORTANT ROLE IN CONTROLLING THE ABILITY OF THE VIRUS TO REPLICATE AND TO CAUSE DISEASE. THIS PROPOSAL’S OVERARCHING GOAL IS TO COMPREHENSIVELY MAP THE ‘VIRAL PTMOME’ TO IDENTIFY THE PTMS THAT ARE ESSENTIAL FOR VIRUS REPLICATION AND PATHOGENESIS. WE WILL COMBINE PROTEOMICS SCREENS AND MOLECULAR VIROLOGY APPROACHES INCLUDING REVERSE GENETICS TECHNIQUES WITH CUTTING- EDGE MOLECULAR, BIOCHEMICAL AND BIOPHYSICAL STUDIES. THIS WILL ALLOW US TO IDENTIFY AND CHARACTERIZE VIRAL PTMS AND THE RESPONSIBLE HOST MODIFYING ENZYMES, AS WELL AS TO DETERMINE THEIR ROLES FOR EFFECTIVE VIRAL REPLICATION AND PATHOGENESIS. THIS POWERFUL APPROACH, COMBINED WITH COLLABORATIVE STUDIES TO DESIGN AND TEST CHEMICAL INHIBITORS TO BLOCK THE ENZYMES THAT REGULATE CRITICAL VIRAL PTMS, WILL NOT ONLY PROVIDE UNIQUE MECHANISTIC INSIGHT INTO HOST CONTROL OF VIRUS REPLICATION BUT WILL ALSO LAY THE GROUNDWORK FOR DEVELOPING NEW ANTIVIRALS FOR A RANGE OF EMERGING VIRAL INFECTIOUS DISEASES. | $5.6M | FY2021 | Sep 2021 – Jul 2026 |
| Department of Health and Human Services | NERVE RESHAPING FOR IMPROVED ELECTRODE SELECTIVITY | $5.6M | FY1994 | Jun 1994 – Jun 2024 |
| Department of Health and Human Services | EFFECT OF CORNEAL PRESERVATION TIME ON LONG-TERM GRAFT SUCCESS (CPTS) | $5.6M | FY2011 | Sep 2011 – Aug 2018 |
| Department of Health and Human Services | UNDERSTANDING NEURAL CONTROL OF THE OCULAR SURFACE - PROJECT SUMMARY CURRENTLY OUR UNDERSTANDING OF HOW THE NERVOUS SYSTEM MAINTAINS OCULAR SURFACE HOMEOSTASIS IS EXTREMELY LIMITED. NEW TECHNOLOGIES, METHODS AND MODELS ARE NEEDED TO ADVANCE OUR SCIENTIFIC UNDERSTANDING AND ADDRESS KNOWLEDGE GAPS. THE OCULAR SURFACE AND TEAR FILM-SECRETING GLANDS (INCLUDING THE LACRIMAL AND MEIBOMIAN GLANDS, AS WELL AS THE GOBLET CELLS) ARE CAREFULLY CONTROLLED TO PROVIDE AN OPTICALLY SMOOTH, LOW-SCATTERING SURFACE WITH APPROPRIATE IMMUNE AND INJURY RESPONSES. SENSORY FEEDBACK TO MAINTAIN THE STRUCTURAL AND FUNCTIONAL INTEGRITY OF THE OCULAR SURFACE IS PROVIDED BY THE CORNEAL NERVES, WHICH SEND FEEDBACK FROM STIMULI (CHEMICAL, THERMAL, MECHANICAL) TO GANGLIA (E.G., TRIGEMINAL) AND BRAIN REGIONS (E.G., VENTRAL POSTEROMEDIAL THALAMUS) TO DRIVE PRODUCTION OF TEAR FILM COMPONENTS AS WELL AS THE BLINK REFLEX. THIS DELICATE BALANCE OF NEURAL CONTROL IS DISRUPTED BY DAMAGE, PERIPHERAL NEUROPATHIES, INFLAMMATION AND FURTHER COMPLICATED BY A WIDE ARRAY OF IMMUNE RESPONSES TO VARIOUS DISEASES. DYSFUNCTION OF THIS FEEDBACK LOOP CAN LEAD TO A DOWNWARD SPIRAL OF FURTHER DYSREGULATION. ABERRANT NEURAL CONTROL OF THE OCULAR SURFACE CAN LEAD TO ABNORMAL SENSATION AND PAIN, WHICH IN THE WORST CASES CAN BE DISABLING. TO FIND REMEDIES, IT IS FIRST ESSENTIAL TO UNDERSTAND THE UNDERLYING NEURAL CONTROL SYSTEM AND HOW IT ADAPTS TO ITS ENVIRONMENT. IN THIS PROPOSAL, WE AIM TO BRING NEW TOOLS AND MODELS TO STUDY MOLECULAR, CELLULAR, AND FUNCTIONAL INTERACTIONS ACROSS SYSTEMS RESPONSIBLE FOR NEURAL CONTROL OF THE OCULAR SURFACE AND EXAMINE HOW THEY CHANGE UNDER DIFFERENT INFLAMMATORY AND PAIN CONDITIONS. WE HAVE ASSEMBLED AN EXCELLENT TEAM WITH EXPERTISE ACROSS MULTIPLE FIELDS INCLUDING ADVANCED 3D MICROSCOPY, NEUROSCIENCE, ELECTROPHYSIOLOGY, PAIN, OCULAR IMMUNOLOGY, OCULAR LIPID METABOLISM, OCULAR SURFACE DISORDERS, SPATIAL STATISTICS, AND MACHINE/DEEP LEARNING. HERE, WE WILL UTILIZE CUTTING EDGE TECHNIQUES AND TECHNOLOGIES INCLUDING OPTICAL CLEARING, TRACT TRACING, ETHOLOGICALLY-VALID BEHAVIOR ANALYSIS, MACHINE/DEEP LEARNING, SPATIAL STATISTICS, GENETICALLY ENCODED CALCIUM IMAGING, LIGHT-SHEET MICROSCOPY, MULTIPLEXED 3D FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IMAGING, AND MULTI-ARRAY ELECTRODES IMPLANTED IN THE BRAIN. THESE TOOLS WILL HELP US ASSESS MOLECULAR, CELLULAR, AND FUNCTIONAL INTERACTIONS ACROSS ORGANS AND BEGIN TO UNDERSTAND OCULAR SURFACE CONTROL AT THE ORGANISM LEVEL. WE WILL ALSO EMPLOY SEVERAL RELEVANT ANIMAL MODELS TO ASSESS OCULAR SURFACE CONTROL UNDER DIFFERENT INFLAMMATORY AND PAIN CONDITIONS. MODELS INCLUDE AWAT2 DEFICIENT MICE THAT MIMIC EVAPORATIVE DRY EYE DISEASE (DED), DIABETIC MICE, AN EPITHELIAL DEBRIDEMENT MODEL WITH PSEUDOMONAS AERUGINOSA THAT MIMICS BACTERIAL KERATITIS, AND HUMAN DONOR EYES. THE MOUSE MODELS ALL HAVE GCAMP6F EXPRESSED IN CORNEAL NERVES ALLOWING FUNCTIONAL IMAGING OF CALCIUM TRANSIENTS. WITH THESE MODELS WE WILL STUDY BOTH INNATE AND ADAPTIVE IMMUNITY AS WELL AS NOCICEPTIVE AND NEUROPATHIC PAIN RESPONSES. IN ADDITION, WE WILL APPLY NERVE GROWTH FACTOR (NGF) TO OUR MODELS TO STUDY HOW A POTENTIAL TREATMENT OPTION ALTERS THE OCULAR SURFACE CONTROL SYSTEM. | $5.6M | FY2022 | Sep 2022 – Aug 2027 |
| Department of Health and Human Services | ACTIVATION OF THE BETA-3 INTEGRINS: ROLE OF THE KINDLINS | $5.6M | FY2009 | Jul 2009 – Mar 2023 |
| Department of Health and Human Services | MULTI-LEVEL INTERVENTIONS TO REDUCE CARIES DISPARITIES IN PRIMARY CARE SETTINGS | $5.5M | FY2017 | Sep 2017 – Feb 2024 |
| Department of Transportation | APPLICATION PURPOSE: THE PURPOSE OF THIS AWARD IS TO PROVIDE ASSISTANCE FOR ONE YEAR OF OPERATING PLANNING ASSISTANCE PREVENTIVE MAINTENANCE ADA SERVICE LEASE OF CAPITAL MAINTENANCE ITEMS AND ARCHITECTURE AND ENGINEERING DESIGN THE PURCHASE OF FOUR REPLACEMENT VEHICLES FUND TO REHAB BUS STOP SIGNS PURCHASE OF COMPUTER EQUIPMENT AND SOFTWARE.; ACTIVITIES PERFORMED: FUNDS WILL BE USED TO COVER TRANSIT PLANNING ACTIVITIES FOR THE DEVELOPMENT AND UPDATE OF OUR SERVICE PLANS TRANSPORTATION IMPROVEMENT PROGRAMS ONGOING ANALYSIS AND EVALUATION OF POLICIES PROCEDURES AND STANDARDS IN THE AREAS OF SERVICE. FUNDS WILL BE USED FOR ARCHITECTURE AND ENGINEERING DESIGN TO ASSIST WRTA STAFF WITH SPECIFICATION DEVELOPMENT AND PROJECT OVERSIGHT ON VARIOUS TECHNICAL AND CONSTRUCTION PROJECTS. FUNDS WILL BE USED FOR THE PURCHASE OF COMPUTER HARDWARE AND SOFTWARE. FUNDS WILL BE USED TO SUPPORT OPERATING AND ADA SERVICES. FUNDS WILL BE USED FOR PREVENTIVE MAINTENANCE TO KEEP OUR ASSETS IN A GOOD STATE OF REPAIR FUNDS WILL BE USED FOR THE PURCHASE OF FOUR REPLACEMENT VEHICLES.; EXPECTED OUTCOMES: THE BENEFITS FROM THESE FUNDS WILL ALLOW WRTA TO PLAN AND DEVELOP ROUTES TO BETTER SERVE OUR COMMUNITY ASSIST IN THE CONSTRUCTION OF THE EXPANSION OF OUR ADMIN/MAINTENANCE FACILITY. THE PURCHASE OF REPLACEMENT VEHICLES WILL REPLACE VEHICLES THAT ARE BEYOND THEIR USEFUL LIFE SO THAT WRTA CAN PROVIDE A BETTER SERVICE WITH NEWER VEHICLES FOR OUR PASSENGERS. THE CONTINUED MAINTENANCE OF OUR ASSETS IN A STATE OF GOOD REPAIR. CONTINUED ABILITY TO MAINTAIN ADA AND FIXED ROUTE SERVICE.; INTENDED BENEFICIARIES: WRTA AND OUR PASSENGERS THAT RELY ON OUR SERVICE WILL BENEFIT FROM CONTINUED SERVICES PERMITTING WORKERS TO GET TO JOBS MEDICAL TRIPS EDUCATION OPPORTUNITIES SHOPPING AND OTHER DESTINATIONS. PLUS WRTA WILL BE ABLE TO REDUCE OUR CARBON FOOTPRINT THAT WILL HELP THE ENVIRONMENT.; SUBRECIPIENT ACTIVITIES: NONE | $5.5M | FY2018 | May 2018 – May 2025 |
| Department of Transportation | APPLICATION PURPOSE: THE PURPOSE OF THIS AWARD IS TO PROVIDE FUNDING THE PURCHASE OF THREE REPLACEMENT BATTERY ELECTRIC LTV BUSES CHARGING EQUIPMENT TO BE INSTALLED IN A BUS STORAGE BARN PROJECT ADMINISTRATION AND BUS BARN RENOVATION.; ACTIVITIES PERFORMED: FUNDS WILL BE USED FOR THE PURCHASE OF THREE REPLACEMENT BATTERY ELECTRIC LTV BUSES CHARGING EQUIPMENT TO BE USED TO FUEL ELECTRIC VEHICLES PROJECT ADMINISTRATION AND THE RENOVATION OF A BUS BARN.; EXPECTED OUTCOMES: THE BENEFITS FROM THESE FUNDS WILL ALLOW WRTA TO BEGIN THE CONVERSION OF OUR FLEET FROM DIESEL TO A MORE SUSTAINABLE POWER SOURCE THAT WILL REDUCE CARBON EMISSIONS. THE PURCHASE OF REPLACEMENT BATTERY ELECTRIC LTV BUSES WILL REPLACE VEHICLES THAT ARE BEYOND THEIR USEFUL LIFE SO THAT WRTA CAN PROVIDE A BETTER SERVICE WITH NEWER VEHICLES FOR OUR PASSENGERS. THE REPLACEMENT OF BEYOND USEFUL LIFE REVENUE VEHICLES WITH NEWER MORE ENVIRONMENTALLY SUSTAINABLE VEHICLES. THE RENOVATION OF OLD UNDERUTILIZED BUS BARN TO PROVIDE ADDITIONAL BUS STORAGE.; INTENDED BENEFICIARIES: WRTA AND OUR PASSENGERS THAT RELY ON OUR SERVICE WILL BENEFIT FROM CONTINUED SERVICES PERMITTING WORKERS TO GET TO JOBS MEDICAL TRIPS EDUCATION OPPORTUNITIES SHOPPING AND OTHER DESTINATIONS. PLUS WRTA WILL BE ABLE TO REDUCE OUR CARBON FOOTPRINT THAT WILL HELP THE ENVIRONMENT.; SUBRECIPIENT ACTIVITIES: N/A | $5.5M | FY2024 | Sep 2024 – Mar 2029 |
| Department of Health and Human Services | NOVEL THERAPIES FOR ALCOHOLIC HEPATITIS | $5.5M | FY2012 | Sep 2012 – Jun 2018 |
| Department of Health and Human Services | DATA COORDINATING CENTER FOR PILOT STUDIES OF CANDIDATE THERAPIES FOR CKD | $5.4M | FY2013 | Sep 2013 – Jun 2020 |
| Department of Health and Human Services | DEVELOPMENT OF NETWORKED IMPLANTABLE NEUROPROSTHESES | $5.4M | FY2001 | Sep 2001 – Apr 2016 |
| Department of Health and Human Services | AUTOMATIC CONTROL OF STANDING BALANCE WITH FNS | $5.3M | FY2000 | Sep 2000 – Jul 2025 |
| Department of Health and Human Services | THERAPEUTIC IMPLICATIONS OF MOLECULAR DEFECTS IN BONE MARROW FAILURE | $5.3M | FY2017 | Jan 2017 – Jun 2024 |
| Department of Health and Human Services | LOCAL CIRCUITS IN THE OLFACTORY BULB | $5.3M | FY2000 | Dec 1999 – Jun 2029 |
| Department of Transportation | CAPITAL PLANNING | $5.2M | FY2019 | Jul 2019 – Dec 2026 |
| Department of Health and Human Services | NIAMS: CORT (PSORIASIS CENTER OF RESEARCH TRANSLATION) | $5.2M | FY2007 | Sep 2007 – Aug 2012 |
| Department of Health and Human Services | ER-TO-GOLGI TRANSPORT OF COAGULATION FACTORS V AND VIII | $5.1M | FY2009 | Dec 2008 – Jun 2024 |
| Department of Health and Human Services | INTERDISCIPLINARY BIOMEDICAL IMAGING TRAINING PROGRAM | $5.1M | FY2007 | Sep 2007 – Jun 2027 |
| Department of Health and Human Services | LRP4 SIGNALING IN NEUROMUSCULAR JUNCTION FORMATION | $5.1M | FY2013 | Jun 2013 – Jun 2024 |
Corporation for National and Community Service
$107.2M
THIS APPLICATION IS FOR NEW, RECOMPETING, OR CONTINUATION STATE COMMISSION APPLICANTS, INCLUDING TERRITORIES WITH COMMISSIONS, APPLYING FOR COST REIMBURSEMENT GRANTS.
Department of Health and Human Services
$105.9M
CASE COMPREHENSIVE CANCER CENTER SUPPORT GRANT
Department of Health and Human Services
$90.4M
EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC)
Corporation for National and Community Service
$79.8M
THIS AWARD FUNDS THE APPROVED 2024-2025 AMERICORPS STATE COMPETITIVE PROGRAMS, AS LISTED ON THE APPROVED PROGRAM AND FUNDING SUMMARY CHARTS. NO MEMBER MAY ENROLL PRIOR TO THE APPROVED START DATE OF THE MEMBER ENROLLMENT PERIOD. YOUR 2024-2025 REGULATORY MATCH IS 14.96% AND YOUR BUDGETARY MATCH IS 42.28%. THE MULTIYEAR FUNDING AWARDED TO THE BREAKTHROUGH TWIN CITIES PROGRAM ON THE 2023-24 GRANT WAS DEOBLIGATED FROM THE 21ACE GRANT AND REOBLIGATED ON THIS GRANT.
Department of Agriculture
$55M
THE FOOD FOR PROGRESS PROGRAM PROVIDES FOR THE DONATION OF U.S. COMMODITIES TO DEVELOPING COUNTRIES AND EMERGING DEMOCRACIES THAT ARE COMMITTED TO INTRODUCING OR EXPANDING FREE ENTERPRISE IN THEIR AGRICULTURAL ECONOMIES. THE PROGRAM HAS TWO PRIMARY STRATEGIC OBJECTIVES: (1) INCREASE AGRICULTURAL PRODUCTIVITY AND (2) EXPAND TRADE OF AGRICULTURAL PRODUCTS. THIS FOOD FOR PROGRESS PROGRAM IS BEING IMPLEMENTED IN BENIN.
Corporation for National and Community Service
$53.8M
N/A
Department of Agriculture
$50.1M
THE FOOD FOR PROGRESS PROGRAM PROVIDES FOR THE DONATION OF U.S. COMMODITIES TO DEVELOPING COUNTRIES AND EMERGING DEMOCRACIES THAT ARE COMMITTED TO INTRODUCING OR EXPANDING FREE ENTERPRISE IN THEIR AGRICULTURAL ECONOMIES. THE PROGRAM HAS TWO PRIMARY STRATEGIC OBJECTIVES: (1) INCREASE AGRICULTURAL PRODUCTIVITY AND (2) EXPAND TRADE OF AGRICULTURAL PRODUCTS. CENTRAL AMERICA AND PERU
Corporation for National and Community Service
$49.7M
COMMISSION STATE GRANTS ARE AWARDED TO ORGANIZATIONS THAT ARE PROPOSING A PROJECT THAT OPERATE IN ONLY ONE STATE AND THAT ARE PUT FORWARD TO CNCS BY
Department of Health and Human Services
$48.8M
CLINICAL AND TRANSLATIONAL SCIENCE COLLABORATIVE OF CLEVELAND
Department of Health and Human Services
$43M
CASE WESTERN RESERVE UNIVERSITY/CLEVELAND CLINIC CTSA (UL1)
Department of Agriculture
$42.5M
THE FOOD FOR PROGRESS PROGRAM PROVIDES FOR THE DONATION OF U.S. COMMODITIES TO DEVELOPING COUNTRIES AND EMERGING DEMOCRACIES THAT ARE COMMITTED TO INTRODUCING OR EXPANDING FREE ENTERPRISE IN THEIR AGRICULTURAL ECONOMIES. THE PROGRAM HAS TWO PRIMARY STRATEGIC OBJECTIVES: (1) INCREASE AGRICULTURAL PRODUCTIVITY AND (2) EXPAND TRADE OF AGRICULTURAL PRODUCTS. THIS FOOD FOR PROGRESS IS BEING IMPLEMENTED IN WEST AFRICA REGIONAL;
Department of Health and Human Services
$40M
CASE AIDS CLINICAL TRIALS UNIT
Department of Agriculture
$36M
AGRICULTURAL PRODUCTIVITY AND VALUE CHAIN DEVELOPMENT PROJECT
Department of Health and Human Services
$35.5M
CLINICAL AND TRANSLATIONAL SCIENCE COLLABORATIVE OF CLEVELAND
National Science Foundation
$34.2M
NSF CENTER FOR LAYERED POLYMERIC SYSTEMS
Department of Health and Human Services
$32.9M
CENTER FOR AIDS RESEARCH(CFAR)
Corporation for National and Community Service
$31.4M
AMERICORPS STATE
Corporation for National and Community Service
$28.9M
ENGAGES AMERICORPS MEMBERS IN FULL AND PART-TIME SERVICE TO MEET COMMUNITY NEEDS IN EDUCATION, THE ENVIRONMENT, HEALTH, VETERANS, AND OTHER AREAS
Department of Health and Human Services
$26.6M
ASTHMA INFLAMMATION RESEARCH (AIR)
Corporation for National and Community Service
$26.1M
AMERICORPS*STATE
Department of Health and Human Services
$24.5M
CASE GI SPORE
Department of Health and Human Services
$24M
CLINICAL AND TRANSLATIONAL SCIENCE COLLABORATIVE OF NORTHERN OHIO, CATALYZING LINKAGES TO EQUITY IN HEALTH (CLE HEALTH) - PROJECT SUMMARY/ABSTRACT FOR THE PAST 15 YEARS, THE CLINICAL AND TRANSLATIONAL SCIENCE COLLABORATIVE (CTSC) AT CASE WESTERN RESERVE UNIVERSITY (CWRU) HAS LINKED CLINICAL AND TRANSLATIONAL RESEARCH EFFORTS AT FIVE INDEPENDENT INSTITUTIONS— CWRU, CLEVELAND CLINIC, METROHEALTH SYSTEM, UNIVERSITY HOSPITALS OF CLEVELAND, AND LOUIS STOKES CLEVELAND VETERANS AFFAIRS MEDICAL CENTER. TWO NEW PARTNERS (UNIVERSITY OF TOLEDO SCHOOL OF MEDICINE AND NORTHEAST OHIO MEDICAL UNIVERSITY) ARE NOW BEING ADDED TO EXTEND THE CTSC’S REACH ACROSS NORTHERN OHIO. THE CWRU CTSC HAS A STRONG TRACK RECORD OF ENHANCING THE QUANTITY AND QUALITY OF CLINICAL AND TRANSLATIONAL SCIENCE (CTS) AMONG OUR PARTNERS BY FACILITATING NOVEL RESEARCH PARADIGMS, TECHNOLOGIES, AND TRAINING. OUR CTSC HAS DEVELOPED A NEW GENERATION OF RESEARCHERS, ENHANCED COLLABORATIONS AMONG INVESTIGATORS, STREAMLINED DISCOVERY BY BUILDING PARTNERSHIPS AMONG INDUSTRY AND COMMUNITY AND ORGANIZATIONAL PARTNERS, AND FACILITATED MANY SUCCESSFUL ENTREPRENEURIAL STARTUPS. BUILDING ON THIS SOLID FOUNDATION, THE CWRU CTSC PROPOSES AN EXPANDED FOCUS ON HEALTH EQUITY, REFLECTED IN THE PROJECT THEME CATALYZING LINKAGES TO EQUITY IN HEALTH (CLE HEALTH). SOCIAL, ECONOMIC, AND ENVIRONMENTAL DISADVANTAGES ARE LINKED TO POOR HEALTH OUTCOMES AND LEAD TO DISPARITIES IN LIFE EXPECTANCY, INFANT MORTALITY, AND RATES OF CHRONIC CONDITIONS. MINORITY GROUPS ARE OFTEN UNDERREPRESENTED IN CLINICAL TRIALS AS WELL, MEANING THERE CAN BE INSUFFICIENT DATA FOR UNDERSTANDING THE EFFECTIVENESS OR SAFETY OF NEW DRUGS, PROCEDURES, OR HEALTH INTERVENTIONS FOR DIFFERENT POPULATIONS. THE OVERALL GOALS OF THIS PROJECT ARE TO 1) UNDERSTAND THE FUNDAMENTAL BARRIERS TO OPTIMAL RECRUITMENT OF UNDERREPRESENTED GROUPS IN CLINICAL TRIALS AND TEST AND SCALE INTERVENTIONS AIMED AT BREAKING DOWN THESE BARRIERS TO DIVERSIFY STUDY ENGAGEMENT, 2) FACILITATE AND EXPEDITE INNOVATION IN MULTICENTER CLINICAL AND TRANSLATIONAL RESEARCH BY FULLY INTEGRATING COMMUNITY AND STAKEHOLDER PARTNERS AND ENSURING THAT THIS RESEARCH REPRESENTS THE EXPERIENCES OF ALL AND RESULTS IN HEALTH IMPROVEMENTS FOR ALL, 3) DISSEMINATE AND IMPLEMENT NOVEL AND RESPONSIVE RESEARCH PROGRAMS ACROSS CLINICAL AND COMMUNITY SETTINGS TO ADVANCE ACCESS TO HEALTH INTERVENTIONS THAT AIM TO PROMOTE HEALTH EQUITY, AND 4) CREATE AND DISSEMINATE INCLUSIVE AND HIGH IMPACT EDUCATIONAL AND TRAINING PROGRAMS FOR TRANSLATIONAL RESEARCH PROFESSIONALS OF ALL DISCIPLINES AND LEVELS, BOTH IN CLINICAL AND COMMUNITY SETTINGS. THE CTSC HAS DESIGNED A STRATEGIC MANAGEMENT CORE AND SIX CTS RESEARCH AND TRAINING ELEMENTS TO ACCOMPLISH THESE GOALS: WORKFORCE DEVELOPMENT, COMMUNITY & STAKEHOLDER ENGAGEMENT, RESOURCES & SERVICES, CTS PILOT, HEALTH INFORMATICS, AND CTS RESEARCH PROGRAM. WE ARE COMMITTED TO INNOVATIVE AND COLLABORATIVE PRACTICE AND DISSEMINATION OF RESULTS SO THAT EVERYONE IN NORTHERN OHIO—AND BEYOND—CAN BENEFIT FROM ADVANCES IN CTS IN OUR PROGRAMS AND DISCOVERIES.
Department of Agriculture
$23.5M
THE FOOD FOR PROGRESS PROGRAM PROVIDES FOR THE DONATION OF U.S. COMMODITIES TO DEVELOPING COUNTRIES AND EMERGING DEMOCRACIES THAT ARE COMMITTED TO INTRODUCING OR EXPANDING FREE ENTERPRISE IN THEIR AGRICULTURAL ECONOMIES. THE PROGRAM HAS TWO PRIMARY STRATEGIC OBJECTIVES: (1) INCREASE AGRICULTURAL PRODUCTIVITY AND (2) EXPAND TRADE OF AGRICULTURAL PRODUCTS. THIS FOOD FOR PROGRESS IS BEING IMPLEMENTED IN BURUNDI.
Department of Health and Human Services
$22M
MEDICAL SCIENTIST TRAINING PROGRAM
Department of Energy
$21.8M
BREAKTHROUGH ELECTROLYTES FOR ENERGY STORAGE (BEES)
Department of Health and Human Services
$21.7M
IFNS AND CYTOKINES: SIGNALING AND ACTION
Department of Health and Human Services
$20.2M
OXIDATION IN INFLAMMATION AND CARDIOVASCULAR DISEASE
Corporation for National and Community Service
$20M
AMERICORPS*STATE
Department of Health and Human Services
$20M
PULMONARY VASCULAR DISEASE PHENOMICS PROGRAM (PVDOMICS) DATA COORDINATING CENTER
Department of Health and Human Services
$19.9M
VASCULAR CELL FUNCTION AND ATHEROSCLEROSIS
Department of Agriculture
$19.8M
THE FOOD FOR PROGRESS PROGRAM PROVIDES FOR THE DONATION OF U.S. COMMODITIES TO DEVELOPING COUNTRIES AND EMERGING DEMOCRACIES THAT ARE COMMITTED TO INTRODUCING OR EXPANDING FREE ENTERPRISE IN THEIR AGRICULTURAL ECONOMIES. THE PROGRAM HAS TWO PRIMARY STRATEGIC OBJECTIVES: (1) INCREASE AGRICULTURAL PRODUCTIVITY AND (2) EXPAND TRADE OF AGRICULTURAL PRODUCTS. THIS FOOD FOR PROGRESS PROGRAM IS BEING IMPLEMENTED IN ETHIOPIA.
Department of Health and Human Services
$19.8M
STRUCTURE AND FUNCTION OF BETA3 INTEGRINS ON BLOOD CELLS
Corporation for National and Community Service
$19.3M
THIS AWARD FUNDS THE APPROVED 2022?23 PUBLIC HEALTH AMERICORPS PROGRAM(S), AS LISTED ON THE APPROVED PROGRAM AND FUNDING SUMMARY CHARTS. NO MEMBER MAY ENROLL PRIOR TO THE APPROVED START DATE OF THE MEMBER ENROLLMENT PERIOD. YOUR 2022?23 REGULATORY MATCH IS 0%. READING & MATH, INC. PROPOSES TO HAVE 150 AMERICORPS MEMBERS WHO WILL PROVIDE CAPACITY-BUILDING SUPPORT IN PUBLIC HEALTH AGENCIES ACROSS THE STATE OF MINNESOTA. AT THE END OF THE FIRST PROGRAM YEAR, THE AMERICORPS MEMBERS WILL BE RESPONSIBLE FOR SUPPORTING 67 ORGANIZATIONS TO INCREASE THEIR EFFICIENCY, EFFECTIVENESS AND/OR PROGRAM REACH. AFTER THEIR YEAR OF SERVICE, 90 AMERICORPS MEMBERS WILL PURSUE FUTURE ENGAGEMENT IN THE PUBLIC HEALTH SECTOR.
Agency for International Development
$18.2M
ALLIANCE FOR INCLUSIVE AND NUTRITIOUS FOOD PROCESSING (AINFP)
Department of Health and Human Services
$17.9M
HEALTH CENTER CLUSTER
Department of Health and Human Services
$17.2M
ACUTE HUMORAL REJECTION OF RENAL ALLOGRAFTS
Agency for International Development
$16.6M
FEED THE FUTURE LOCAL FOOD SYSTEMS
Department of Agriculture
$16.5M
THE FOOD FOR PROGRESS PROGRAM PROVIDES FOR THE DONATION OF U.S. COMMODITIES TO DEVELOPING COUNTRIES AND EMERGING DEMOCRACIES THAT ARE COMMITTED TO INTRODUCING OR EXPANDING FREE ENTERPRISE IN THEIR AGRICULTURAL ECONOMIES. THE PROGRAM HAS TWO PRIMARY STRATEGIC OBJECTIVES: (1) INCREASE AGRICULTURAL PRODUCTIVITY AND (2) EXPAND TRADE OF AGRICULTURAL PRODUCTS.
Department of Health and Human Services
$16.5M
INNATE IMMUNITY END EXPERIMENTAL CROHN'S DISEASE
Department of Health and Human Services
$16.4M
ALCOHOL AND TISSUE INJURY FROM MECHANISMS TO TREATMENTS
Department of Health and Human Services
$16.2M
CWRU CENTER FOR EXCELLENCE ON THE IMPACT OF SUBSTANCE USE ON HIV - PROJECT SUMMARY - OVERVIEW THE NEWLY DEVELOPED CWRU (CASE WESTERN RESERVE UNIVERSITY) CENTER FOR EXCELLENCE ON THE IMPACT OF SUBSTANCE USE ON HIV WAS CONCEIVED IN AUGUST 2017 AND WAS INITIATED TO EFFECTIVELY PROMOTE EXCELLENCE IN BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH CONCERNING THE INTERSECTION BETWEEN SUBSTANCE USE AND HIV. THE CENTER FOR EXCELLENCE INCLUDES 12 NIDA-FUNDED INVESTIGATORS WHO COLLECTIVELY HOLD 9 R01, 2 DP1, 3 R34, 2 R44, 1 U01, AND 2 K01 DRAWN FROM THE CWRU SCHOOL OF MEDICINE, UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER, METROHEALTH MEDICAL CENTER, THE CLEVELAND CLINIC FOUNDATION, THE LOUIS STOKES CLEVELAND VETERANS ADMINISTRATION MEDICAL CENTER, THE CWRU MANDEL SCHOOL OF APPLIED SOCIAL SCIENCES, THE BEGUN CENTER FOR VIOLENCE PREVENTION RESEARCH AND EDUCATION, AND THE CUYAHOGA COUNTY, LORAIN COUNTY, AND CITY OF CLEVELAND DEPARTMENTS OF HEALTH. MAJOR RESEARCH STRENGTHS IN THE CENTER FOR EXCELLENCE INCLUDE IMPACT OF DRUG USE ON HIV IMMUNOPATHOGENESIS, HIV LATENCY AND CURE, NEUROAIDS, GASTROINTESTINAL DYSFUNCTION, SEXUAL RISK BEHAVIOR, AND HIV AND HCV CO-INFECTIONS. OUR STUDIES ARE ANCHORED BY ADVANCED COMPUTATIONAL, SYSTEMS BIOLOGY, BIOMIMETIC MODELS, AND INDUCED PLURIPOTENT STEM CELL (IPSC) TECHNOLOGIES THAT PROVIDE THE OPPORTUNITY TO PERFORM META-OMICS ANALYSES OF THE IMPACT OF OPIOID, METHAMPHETAMINE, CANNABIS, AND COCAINE MISUSE ON SEVERAL CLINICAL, VIROLOGICAL, IMMUNOLOGICAL, BEHAVIORAL, AND NEUROLOGICAL OUTCOMES OF HIV DISEASE. THE CENTER FOR EXCELLENCE HAS THE FOLLOWING SPECIFIC AIMS: - PROVIDE SCIENTIFIC LEADERSHIP TO POSITION THE CENTER AT THE FOREFRONT OF SUBSTANCE USE DISORDER RESEARCH AND FUNCTION AS A NATIONAL RESEARCH RESOURCE FOR THE STUDY OF DRUG USE IN PERSONS WITH HIV. - ESTABLISH AN ADMINISTRATIVE INFRASTRUCTURE THAT MAINTAINS FISCAL AND MANAGEMENT OVERSIGHT OF THE CORES. - APPLY ADVANCED COMPUTATIONAL BIOLOGY, PRIMARY CELLS, BIOMIMETIC MODELS, AND IPSC- DERIVED CELLS TO STUDY OF THE IMPACT OF SUBSTANCE USE ON HIV DISEASE. - SUPPORT TRANSLATIONAL, CLINICAL, AND BEHAVIORAL RESEARCH THROUGH ACCESS TO UNIQUE CLINICAL COHORTS OF PERSONS WITH SUBSTANCE USE DISORDER WITH HIV AND AT RISK FOR HIV. - ACCELERATE JUNIOR FACULTY DEVELOPMENT AND ENCOURAGE EXPERIENCED FACULTY TO ENTER THE SUBSTANCE USE RESEARCH ARENA TO SUPPORT THE NEXT GENERATION OF INVESTIGATORS. - PARTICIPATE IN COMMUNITY OUTREACH.
Department of Health and Human Services
$16M
CONTINUING ENHANCED NATIONAL SURVEILLANCE FOR PRION DISEASES IN THE UNITED STATES
Department of Health and Human Services
$16M
HYALURONAN MATRICES IN VASCULAR PATHOLOGIES
Department of Health and Human Services
$15.4M
CLEVELAND ALZHEIMERS DISEASE RESEARCH CENTER - PROJECT SUMMARY THE CLEVELAND ALZHEIMER'S DISEASE RESEARCH CENTER (CADRC) IS A COLLABORATIVE EFFORT OF PHYSICIANS AND INVESTIGATORS FROM CASE WESTERN RESERVE UNIVERSITY (CWRU), CLEVELAND CLINIC FOUNDATION (CCF), METROHEALTH SYSTEM (MHS), UNIVERSITY HOSPITALS (UH), AND THE LOUIS STOKES CLEVELAND VA MEDICAL CENTER (LSCVAMC), TO FOSTER EXCELLENCE IN RESEARCH AND FACILITATE DISCOVERY AS AN ESTABLISHED NATIONAL INSTITUTE ON AGING (NIA) FUNDED ALZHEIMER'S DISEASE RESEARCH CENTER. THE CADRC REPRESENTS A RICH CLINICAL AND RESEARCH COMMUNITY AND AN ESTIMATED 220,000 OHIOANS WHO SUFFER FROM ALZHEIMER'S DISEASE (AD) OR AD-RELATED DEMENTIAS (ADRD). THE CADRC HAS 8 CORES AND A RESEARCH EDUCATION COMPONENT DESIGNED TO CREATE THE FOUNDATION THAT WILL ENHANCE THE RESEARCH EFFORTS OF THE NORTHEAST OHIO AD/ADRD RESEARCH COMMUNITY, AS WELL AS ADD UNIQUE VALUE TO THE NATIONAL ALZHEIMER'S DISEASE RESEARCH CENTERS (ADRC) PROGRAM AND OTHER NATIONAL AND INTERNATIONAL RESEARCH PROGRAMS. THE CADRC IS FOCUSED ON PARTICIPANTS THAT WILL HELP US UNDERSTAND THE PATHOBIOLOGY OF CLINICAL AND PATHOLOGICAL HETEROGENEITY OBSERVED IN DEMENTIA INCLUDING ATYPICAL AND AMNESTIC AD, DEMENTIA WITH LEWY BODIES, COGNITIVELY NORMAL INDIVIDUALS WITH DIFFERENT LEVELS OF GENETIC RISK FOR AD, AND DIVERSITY OF PARTICIPANT POPULATIONS (CLINICAL AND OUTREACH, RECRUITMENT, AND ENGAGEMENT CORES). TO SUPPORT THE CADRC GOALS, THE FOCUS WILL BE ON DEEP PHENOTYPING OF PARTICIPANTS WITH LONGITUDINAL AND SYSTEMATIC COGNITIVE, BEHAVIORAL AND MOTOR CHARACTERIZATION (CLINICAL CORE), GENETIC AND BIOFLUID BIOMARKER COLLECTION AND ANALYSIS (BIOMARKER CORE), IMAGING (NEUROIMAGING CORE), AND AUTOPSY AFTER DEATH (NEUROPATHOLOGY CORE). RESULTS WILL BE SHARED WITH THE RESEARCH COMMUNITY IN A TIMELY AND REGULAR MANNER TO ALLOW OTHER INVESTIGATORS TO BENEFIT FROM THE CADRC EFFORTS (DATA MANAGEMENT AND STATISTICS CORE). IN ADDITION, THE CADRC WILL TRAIN THE NEXT GENERATION OF INVESTIGATORS UTILIZING A RIGOROUS AND WELL-DESIGNED RESEARCH EDUCATION COMPONENT, SUPPORT TRANSLATION OF NEW LABORATORY FINDINGS THROUGH THE TRANSLATIONAL THERAPEUTICS CORE, AND SUPPORT HIGH RISK/HIGH GAIN PROJECTS THROUGH THE DEVELOPMENTAL PROGRAM AS A PART OF THE ADMINISTRATIVE CORE. THE ULTIMATE GOALS ARE TO ADVANCE THE PRECISION MEDICINE APPROACH TO DEMENTIA DIAGNOSIS AND TREATMENT, SUPPORT THE DEVELOPMENT OF EARLY STAGE INVESTIGATORS, ASSIST ALL STAGES OF INVESTIGATORS WITH TOOLS FOR PERFORMING HUMAN-BASED RESEARCH, AND BETTER ENGAGE UNDERREPRESENTED POPULATIONS IN AD/ADRD RESEARCH.
Department of Agriculture
$15.1M
AGRICULTURAL PRODUCTIVITY AND VALUE CHAIN DEVELOPMENT PROJECT
Department of Agriculture
$15.1M
THE FOOD FOR PROGRESS PROGRAM PROVIDES FOR THE DONATION OF U.S. COMMODITIES TO DEVELOPING COUNTRIES AND EMERGING DEMOCRACIES THAT ARE COMMITTED TO INTRODUCING OR EXPANDING FREE ENTERPRISE IN THEIR AGRICULTURAL ECONOMIES. THE PROGRAM HAS TWO PRIMARY STRATEGIC OBJECTIVES: (1) INCREASE AGRICULTURAL PRODUCTIVITY AND (2) EXPAND TRADE OF AGRICULTURAL PRODUCTS. THIS FOOD FOR PROGRESS PROGRAM IS BEING IMPLEMENTED IN MOZAMBIQUE.
Department of Commerce
$15M
PURPOSE: THE ASSOCIATION TO PRESERVE CAPE COD WILL WORK WITH AN ARRAY OF PARTNERS TO LEAD THE COLLABORATIVE PLANNING, DESIGN, AND IMPLEMENTATION OF PROJECTS TO RESTORE RIVERS, RETIRED CRANBERRY BOGS, AND SALT MARSHES ON CAPE COD IN MASSACHUSETTS. THESE EFFORTS WILL SUPPORT IMPORTANT SPECIES LIKE RIVER HERRING AND AMERICAN EEL. THEY WILL ALSO PROVIDE BENEFITS TO COMMUNITIES SUCH AS INCREASED CLIMATE RESILIENCE AND PROTECTION FROM FLOODING.
Department of Health and Human Services
$14.8M
CLEVELAND OPEN SOURCE MODULAR IMPLANT INNOVATORS COMMUNITY (COSMIIC) - THE OVERALL GOAL OF THE CLEVELAND OPEN SOURCE MODULAR IMPLANT INNOVATORS COMMUNITY (COSMIIC) IS TO ESTABLISH AN OPEN SOURCE, MODULAR NETWORK OF ACTIVE IMPLANTABLE DEVICES FOR USE IN EARLY FEASIBILITY HUMAN RESEARCH AND TO PROVIDE ONGOING SUPPORT FOR THIS TECHNOLOGY THROUGH A VIBRANT, SUSTAINABLE COMMUNITY OF ACTIVE USERS. OUR TEAM IS POISED TO SUCCESSFULLY ACHIEVE ALL OF THE GOALS OF THE HORNET PROGRAM BECAUSE OUR PROPOSED CONCEPT IS BASED ON OUR ESTABLISHED PLATFORM ECOSYSTEM, THE NETWORKED NEUROPROSTHESIS (NNP). THIS PROVIDES A SOLID TECHNOLOGICAL PLATFORM WITH KNOWN REGULATORY STATUS FOR OUR COSMIIC HORNET PROJECT. CRITICALLY, ALL TECHNOLOGY DESCRIBED IN THIS PROPOSAL WAS INVENTED BY THE INVESTIGATIVE TEAM AND THEREFORE WE ARE ABLE TO FULLY EMBRACE THE OPEN SOURCE IDEOLOGY FOR THE END-TO-END TECHNOLOGY. THE PROPOSED COSMIIC HORNET SYSTEM, WHICH WILL BE ESTABLISHED ON THE PLATFORM NNP SYSTEM, IS A SYSTEM OF INTEROPERABLE AND INTEGRATED MODULES THAT CAN SIMULTANEOUSLY ELECTRICALLY ACTIVATE, BLOCK, AND SENSE THROUGHOUT THE BODY. THE SYSTEM CAN RECORD AND PROCESS ELECTRONEUROGRAM (ENG), ELECTROMYOGRAM (EMG), INTRACORTICAL SIGNALS, ELECTROCARDIOGRAM (EKG), KINEMATIC VARIABLES, PHOTOPLETHYSMOGRAM (PPG), AND TEMPERATURE. EACH MODULE CAN DIRECTLY COMMUNICATE WITH ALL OTHER MODULES THROUGH AN ESTABLISHED NETWORK COMMUNICATION PROTOCOL. THE SYSTEM CAN PROCESS SIGNALS TO IMPLEMENT COMPLEX CLOSED-LOOP CONTROL WITHOUT REQUIRING NON-IMPLANTED HARDWARE. IMPORTANTLY, THE EXISTING NNP PLATFORM COMPONENTS (POWER MODULE, STIMULATOR MODULE, BIOPOTENTIAL RECORDING MODULE, NETWORK CABLE, ELECTRODES) ALREADY HAVE IDE APPROVAL FROM THE FDA AND HAVE BEEN SUCCESSFULLY IMPLANTED AND IMPLEMENTED IN HUMAN RESEARCH PARTICIPANTS. THUS, THE COSMIIC HORNET SYSTEM HAS THE NECESSARY FEATURES TO PROVIDE THE MODULAR PLATFORM ECOSYSTEM FOR USE BY THE BIOELECTRONIC COMMUNITY FOR THE FORESEEABLE FUTURE. AIM #1. DISSEMINATION. WE WILL ESTABLISH THE COSMIIC COMMUNITY WITH FULL OPEN-SOURCE ACCESS TO AN ESTABLISHED MODULAR IMPLANTABLE DEVICE FOR USE IN THE PERIPHERAL AND CENTRAL NERVOUS SYSTEM. ACCESS WILL BE GIVEN FOR ALL CIRCUIT DESIGNS AND LAYOUTS; MECHANICAL DRAWINGS FOR ALL ENCLOSURES AND CONNECTORS AND CABLING; THE ANNOTATED CODE FOR ALL OPERATING SOFTWARE, FIRMWARE, AND BOOTLOADER; WRITTEN INSTRUCTIONS AND VIDEOS OF FABRICATION TECHNIQUES; AND ALL REGULATORY DOCUMENTS AND TEST DATA, INCLUDING OUR APPROVED IDE DOCUMENT. AIM #2. SUSTAINABILITY. WE WILL DEVELOP A SUSTAINABLE OPEN SOURCE MODEL THROUGH THE DEVELOPMENT OF TECHNOLOGY THAT ATTRACTS A BROAD INVESTIGATIVE TEAM TO ESTABLISH A CRITICAL MASS OF COSMIIC USERS. WE WILL PROVIDE ONGOING SUPPORT OF THE TECHNOLOGY AND PARTNER WITH COMMERCIAL PARTNERS TO CREATE A SUSTAINABLE BUSINESS PLAN SO THAT THE COSMIIC COMMUNITY REMAINS INDEPENDENTLY VIBRANT AND ACTIVE AFTER THREE YEARS.
Department of Health and Human Services
$14.6M
THE ALZHEIMER DISEASE SEQUENCE ANALYSIS COLLABORATIVE
Department of Health and Human Services
$14.5M
CONTINUING AN ENHANCED AND MULTIFACETED NATIONAL SURVEILLANCE PROGRAM FOR HUMAN PRION DISEASES
Department of Health and Human Services
$14.4M
THE CLEVELAND CLINIC INNOVATION ACCELERATOR
Department of Health and Human Services
$14M
PATHOBIOLOGY OF ASTHMA
Department of Health and Human Services
$14M
GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA
Department of Veterans Affairs
$13.9M
THE SSVF PROGRAM'S PURPOSE IS TO PROVIDE SUPPORTIVE SERVICES GRANTS TO PRIVATE NON-PROFIT ORGANIZATIONS AND CONSUMER COOPERATIVES, WHO WILL COORDINATE OR PROVIDE SUPPORTIVE SERVICES TO VERY LOW-INCOME VETERAN FAMILIES WHO ARE RESIDING IN PERMANENT HOUSING, ARE HOMELESS AND SCHEDULED TO BECOME RESIDENTS OF PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD; OR AFTER EXITING PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD, ARE SEEKING OTHER HOUSING THAT IS RESPONSIVE TO SUCH VERY LOW-INCOME VETERAN FAMILY'S NEEDS AND PREFERENCES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES.
Department of Veterans Affairs
$13.9M
THE SSVF PROGRAM'S PURPOSE IS TO PROVIDE SUPPORTIVE SERVICES GRANTS TO PRIVATE NON-PROFIT ORGANIZATIONS AND CONSUMER COOPERATIVES, WHO WILL COORDINATE OR PROVIDE SUPPORTIVE SERVICES TO VERY LOW-INCOME VETERAN FAMILIES WHO ARE RESIDING IN PERMANENT HOUSING, ARE HOMELESS AND SCHEDULED TO BECOME RESIDENTS OF PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD; OR AFTER EXITING PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD, ARE SEEKING OTHER HOUSING THAT IS RESPONSIVE TO SUCH VERY LOW-INCOME VETERAN FAMILY'S NEEDS AND PREFERENCES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES.
Corporation for National and Community Service
$13.7M
THIS AWARD FUNDS THE APPROVED 2023-2024 AMERICORPS FORMULA PROGRAMS, AS LISTED ON THE APPROVED PROGRAM AND FUNDING SUMMARY CHARTS. NO MEMBER MAY ENROLL PRIOR TO THE APPROVED START DATE OF THE MEMBER ENROLLMENT PERIOD. YOUR 2023-2024 BUDGETARY MATCH IS 32%. CLIMATE IMPACT CORPS: EXPAND CURRENT ACTIVITIES. TO DO THIS, WE WILL AWARD $1,222,857. CONSERVATION CORPS MINNESOTA: EXPAND CURRENT ACTIVITIES. TO DO THIS, WE WILL AWARD $576,000.
Agency for International Development
$13.2M
USAID COFFEE ALLIANCE FOR EXCELLENCE
Department of Health and Human Services
$13.2M
THE CLEVELAND DIGESTIVE DISEASES RESEARCH CORE CENTER (DDRCC)
Department of Health and Human Services
$12.8M
PHARMACOLOGICAL TREATMENT OF RETINAL DISEASES
Department of Health and Human Services
$12.7M
COHORT STUDY OF CHRONIC RENAL INSUFFICIENCY
Agency for International Development
$12.5M
TO PROVIDE OPERATIONAL SUPPORT TO FIELD MISSIONS AND OTHER OPERATING UNITS OF THE U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID), CONTRIBUTING TO THE GOALS OF THE GLOBAL FOOD SECURITY STRATEGY THROUGH THE IMPLEMENTATION OF PROGRAMMING ALIGNED WITH THE AGENCY’S LSFF RESULTS FRAMEWORK. REFLECTING PRIORITIES IN THE REVISED GFSS 2022- 2026, USAID AND IMPLEMENTING PARTNERS WILL USE THIS ACTIVITY TO ADVANCE A COMPREHENSIVE FOOD SYSTEMS APPROACH, WHILE PROACTIVELY COUNTERING THE COVID-19 PANDEMIC AND OTHER GLOBAL CRISES’ LONG-TERM EFFECTS ON NUTRITION.
Department of Health and Human Services
$12.5M
IBUDILAST PHASE II TRIAL IN PROGRESSIVE MS
Department of Education
$12.4M
HIGHER EDUCATION EMERGENCY RELIEF FUND-INSTITUTIONAL PORTION CARES ACT
Department of Health and Human Services
$12.4M
HEAD START
Department of Health and Human Services
$12.3M
CASE AIDS CLINICAL TRIALS UNIT
Department of Health and Human Services
$12.2M
TARGETING OBESITY AND BLOOD PRESSURE IN URBAN YOUTH
Department of Health and Human Services
$12.1M
GUT MICROBIOTA AND CARDIOMETABOLIC DISEASES
Department of Health and Human Services
$12.1M
CELL ADHESION AND SIGNALING IN BLOOD AND VASCULAR CELLS - PROJECT SUMMARY THIS APPLICATION HAS AS ITS THEME THE INTEGRINS, THEIR REGULATION AND THEIR CONTRIBUTION TO THE FUNCTIONAL RESPONSES OF BLOOD AND VASCULAR CELLS. THE INTEGRINS OF FOCUS ARE AMSS2 (MAC-1), AIIBSS3, AVSS3, AND A5SS1 BUT FINDINGS SHOULD APPLY TO BROADLY INTEGRINS. THE CELLS OF EMPHASIS ARE VASCULAR CELLS- ENDOTHELIAL CELLS, SMOOTH MUSCLE CELLS AND PERICYTES- AND BLOOD CELLS- LEUKOCYTES AND PLATELETS. ON THE BLOOD CELLS, THE CONJUGATION OF MAC-1 ON LEUKOCYTES AND GPIB ON PLATELETS WILL BE CONSIDERED. MAJOR EMPHASIS WILL BE PLACED ON THE MOLECULES THAT REGULATE INTEGRIN FUNCTION- KINDLINS, TALIN AND PAXILLIN- TO DETERMINE HOW THEY COLLABORATE TO REGULATE INTEGRIN ACTIVATION. THE FUNCTION OF THESE CYTOSKELETAL PROTEINS INDEPENDENT OF INTEGRIN ACTIVATING ACTIVITY WILL ALSO BE DISSECTED. THE PROGRAM CONSISTS OF THREE PROJECTS, EACH DIRECTED BY AN ACCOMPLISHED FACULTY MEMBER AT THEIR HOME INSTITUTIONS, CLEVELAND CLINIC, UNIVERSITY HOSPITALS OF CLEVELAND AND CASE WESTERN RESERVE UNIVERSITY WHICH ARE ALL CLOSELY LOCATED AND GOVERNED BY INTERINSTITUTIONAL AGREEMENTS. DR. EDWARD F. PLOW, PH.D. WILL SERVE AS PROGRAM DIRECTOR AND LEAD PROJECT 1. THIS PROJECT DEALS WITH THE MECHANISMS BY WHICH KINDLIN-2 REGULATES BOTH INTEGRIN-DEPENDENT AND INDEPENDENT RESPONSES OF BLOOD VESSEL CELLS. MOLECULAR, CELLULAR AND UNIQUE MOUSE MODELS ARE ALL BROUGHT TO BEAR TO DETERMINE HOW KINDLIN-2 SERVES AS A MASTER REGULATOR OF VASCULAR CELL RESPONSES. IN PROJECT 2, DR. JUN QIN WILL USE HIGH RESOLUTION STRUCTURAL APPROACHES IN COMBINATION WITH MUTAGENESIS AND CELLULAR STUDIES TO DETERMINE HOW TALIN REGULATE INTEGRIN ACTIVATION AND COOPERATES WITH KINDLINS AND PAXILLIN TO GAIN SUCH NOVEL INSIGHTS. HE WILL DETERMINE HOW TALIN INTERACTS WITH ACTIN TO CONTROL ORGANIZATION OF THE CYTOSKELETON. DR. DANIEL SIMON, M.D. WILL LEAD PROJECT 3 AND WILL CONSIDER HOW ENGAGEMENT OF INTEGRIN MAC-1 ON LEUKOCYTES AND GPIB ON PLATELETS REGULATES THE PARTICIPATION OF THESE CELLS IN INFLAMMATION AND THROMBOSIS. HIS STUDIES RANGE FROM BASIC STRUCTURAL APPROACHES TO TRANSLATIONAL STUDIES IN MICE AND TO HUMANS TO PROVIDE INSIGHTS INTO THEIR THROMBOTIC AND INFLAMMATORY CONTRIBUTIONS TO SYSTEMIC LUPUS ERYTHEMATOSUS. THE PROGRAM IS SUPPORTED BY TWO SCIENTIFIC CORES, PROTEIN EXPRESSION AND PURIFICATION (CORE B), AND ANIMAL MODELS AND TISSUE ANALYSIS (CORE C) AS WELL AS BY AN ADMINISTRATIVE CORE (AC1). A COMMON OBJECTIVE OF THE PROGRAM IS TO CONTINUE AND CREATE NEW COLLABORATIONS AMONG THE PROJECTS AND THEIR LEADERS TO RESOLVE THE STRUCTURAL AND BIOLOGICAL MECHANISMS THAT REGULATE THE FUNCTIONS OF INTEGRINS IN BLOOD AND VASCULAR CELLS. THE INFORMATION DERIVED FROM THESE STUDIES WILL PROVIDE INSIGHTS INTO BIOLOGICALLY IMPORTANT RESPONSES REGULATED BY INTEGRINS AND THEIR ACTIVATION THAT ARE RELEVANT TO THROMBOSIS AND CARDIOVASCULAR DISEASES.
Department of Health and Human Services
$12.1M
HDL STRUCTURE AND ITS FUNCTION IN ATHEROSCLEROSIS
Corporation for National and Community Service
$12M
AMERICORPS*STATE
Department of Health and Human Services
$11.9M
P30 - CORE GRANT FOR VISION RESEARCH
Department of Health and Human Services
$11.7M
CWRU CENTER FOR MULTIMODAL EVALUATION OF ENGINEERED CARTILAGE
Department of Health and Human Services
$11.6M
DEVELOPMENT OF NEW DIAGNOSTIC METHODS/SURVEILLANCE PROGRAM
Department of Health and Human Services
$11.6M
FRMI OF THE PERSON IDENTITY NETWORK: AGING AND APOE
Department of Energy
$11.4M
GRANT AWARD TO CASE WESTERN RESERVE UNIVERSITY (CWRU) CONTRIBUTES TO NNSA’S STOCKPILE STEWARDSHIP MISSION BY ESTABLISHING A UNIQUE PUBLIC-PRIVATE PARTNERSHIP MERGING MATERIALS SCIENCE WITH NOVEL COMPUTER SCIENCE AND DATA SCIENCE TO ADVANCE THE UNDERSTANDING OF FUNDAMENTAL MECHANISMS OF MATERIALS DEGRADATION AND FAILURE IN OUR NUCLEAR STOCKPILE MATERIALS AND COMPONENTS, THROUGH COMBINED RESEARCH AND EDUCATIONAL MULTI-DISCIPLINARY VISION. PROJECT TITLE: CENTER TO MATERIALS DATA SCIENCE FOR STOCKPILE STEWARDSHIP (MDS3) COE
Department of Health and Human Services
$11.3M
ATRIAL FIBRILLATION POST-GWAS: MECHANISMS TO TREATMENT - OVERALL COMPONENT PROJECT/SUMMARY ABSTRACT ATRIAL FIBRILLATION (AF), THE MOST COMMON CARDIAC ARRHYTHMIA, AFFLICTS THE U.S. AND WORLD WITH INCREASING PREVALENCE. AF INCIDENCE, PROGRESSION TO PERSISTENT AF, AND AF COMPLICATIONS, INCLUDING STROKE, ARE FED BY INCREASING OBESITY AND AGE. CURRENT THERAPIES ARE LIMITED BY RISKS AND LIMITED EFFICACY, WORSE AS AF PROGRESSES, BUT NO NEW PHARMACOLOGIC AGENTS HAVE BEEN APPROVED FOR AF IN >10 YEARS. WITH IDENTIFICATION OF >100 GENETIC LOCI THAT PREDISPOSE TO AF RISK IN GENOME-WIDE ASSOCIATION STUDIES (GWAS), THE HOPE HAS BEEN THAT GENETICS WOULD YIELD NOVEL THERAPEUTIC TARGETS. HOWEVER, EVEN FOR THE TOP LOCUS ON CHR. 4Q25 NEAR PITX2, A GENE INVOLVED IN FORMATION OF PULMONARY VEINS, THE TARGET OF AF ABLATION, MECHANISMS LINKING VARIANTS TO AF REMAIN ELUSIVE. GENETIC FINDINGS HAVE SO FAR FAILED TO YIELD CLINICALLY ACTIONABLE RESULTS. TO FILL THESE GAPS, WE SEEK TO GO BEYOND GWAS FINDINGS TO IDENTIFY DIRECT GENOMIC MECHANISMS UNDERLYING AF AND BETTER UNDERSTAND THEIR INTERACTIONS WITH ENVIRONMENT, COMORBIDITIES OR CELL STRESSORS. OUR LONG-TERM GOAL IS TO USE GENOMIC FINDINGS TO PERSONALIZE PREVENTIVE AND THERAPEUTIC STRATEGIES FOR AF. OUR OVERALL P01 THEME IS TO TRANSLATE AF GENETIC DISCOVERIES TOWARDS THE BEDSIDE, FOCUSING ON GENES TO MECHANISMS, GENES TO DRUGS, AND INTERACTIONS OF GENES WITH METABOLISM AND ENVIRONMENT. WE BUILD ON STRONG PRELIMINARY DATA AND COALESCE UNIQUE HUMAN ATRIAL TISSUE BIOREPOSITORY AND GENOMIC DATA RESOURCES, NOVEL CELL AND ANIMAL MODELS, AND COMPLEMENTARY EXPERTISE FROM OUR MULTIDISCIPLINARY TEAM WITH A STRONG COLLABORATION HISTORY. OUR CENTRAL HYPOTHESIS IS THAT GENOMIC MECHANISTIC DISCOVERIES IN AF CELLULAR AND ANIMAL MODELS WILL TRANSLATE TO HUMAN THERAPIES. OUR THEMATIC AIMS INCLUDE: 1) IDENTIFY CAUSAL GENES AND FUNCTIONAL MECHANISMS WITH A GOAL TOWARDS IDENTIFICATION OF NEW THERAPEUTIC APPROACHES FOR AF; 2) INVESTIGATE METABOLIC AND INFLAMMATORY MECHANISMS, IMPLICATED BY GENOMICS STUDIES TO BE IMPORTANT IN AF PATHOPHYSIOLOGY, TO IDENTIFY NEW THERAPEUTIC TARGETS FOR AF PREVENTION AND TREATMENT; AND 3) IDENTIFY CANDIDATE NOVEL DRUGS FOR AF AND DEVELOP A PIPELINE FOR IN VITRO AND IN VIVO FUNCTIONAL TESTING OF CANDIDATE THERAPIES. PROJECT 1 GENES TO FUNCTION WILL DETERMINE CAUSAL GENES, VARIANTS AND MECHANISMS UNDERLYING TWO AF GWAS LOCI. PROJECT 2 GENES AND METABOLISM WILL STUDY THE CONTRIBUTION OF MITOCHONDRIAL DYSFUNCTION TO AF ONSET AND PROGRESSION. EARLY STAGE INVESTIGATOR PROJECT GENES AND NUTRITION BUILDS ON NOVEL ASSOCIATIONS OF AF WITH TRIMETHYLAMINE N-OXIDE (TMAO), PRODUCED BY GUT MICROBIOTA FROM PRECURSORS SUCH AS CHOLINE FOUND IN EGGS, MEATS AND CHEESES. PROJECT 4 GENES TO OMICS-INFORMED DRUGS WILL IDENTIFY MECHANISMS AND REPURPOSABLE DRUGS TO PREVENT AF PROGRESSION. PROJECTS ARE SUPPORTED BY 4 CORES PROVIDING ADMINISTRATION, ENGINEERED HEART TISSUE AND ATRIAL PHENOTYPING, ELECTROPHYSIOLOGY, AND NETWORK AND SYSTEMS BIOLOGY ANALYTICS SUPPORT THAT SYNERGIZE DISCOVERY AND TRANSLATION IN AF AND INCREASE THE SCOPE AND IMPACT OF EACH PROJECT. ALL P01 COMPONENTS AIM TO BRIDGE BASIC RESEARCH IN AF TOWARDS CLINICAL UTILITY, THEREBY ADVANCING GENOMIC DATA AND RESEARCH TOWARDS THE BEDSIDE TO HELP OUR PATIENTS SUFFERING FROM ATRIAL FIBRILLATION.
Department of Health and Human Services
$11.3M
RESISTANCE TO MTB INFECTION IN HIV INFECTED INDIVIDUALS IN UGANDA AND S. AFRICA
Department of Health and Human Services
$11.2M
CONTINUING THE DEVELOPMENT OF NEW DIAGNOSTIC METHODS/SURVEILLANCE PROGRAM
Corporation for National and Community Service
$11.1M
No description available
Department of Health and Human Services
$11.1M
CASE COMPREHENSIVE CANCER CENTER NCTN LEAD ACADEMIC PARTICIPATING SITE
Department of Health and Human Services
$11M
CLINICAL AND TRANSLATIONAL SCIENCE COLLABORATIVE OF CLEVELAND
Department of Veterans Affairs
$10.9M
THE SSVF PROGRAM'S PURPOSE IS TO PROVIDE SUPPORTIVE SERVICES GRANTS TO PRIVATE NON-PROFIT ORGANIZATIONS AND CONSUMER COOPERATIVES, WHO WILL COORDINATE OR PROVIDE SUPPORTIVE SERVICES TO VERY LOW-INCOME VETERAN FAMILIES WHO ARE RESIDING IN PERMANENT HOUSING, ARE HOMELESS AND SCHEDULED TO BECOME RESIDENTS OF PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD; OR AFTER EXITING PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD, ARE SEEKING OTHER HOUSING THAT IS RESPONSIVE TO SUCH VERY LOW-INCOME VETERAN FAMILY'S NEEDS AND PREFERENCES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES.
Department of Health and Human Services
$10.9M
DEFINING THE PATHOGENESIS OF IMMUNE DEFICIENCY IN CHRONIC HIV INFECTION
Department of Health and Human Services
$10.9M
SELF REGULATING CONTINUOUS FLOW TOTAL ARTIFICIAL HEART
Department of Health and Human Services
$10.8M
GUT FLORA METABOLISM OF DIETARY PHOSPHATIDYLCHOLINE AND CARDIOVASCULAR DISEASE
Agency for International Development
$10.7M
FEED THE FUTURE MOZAMBIQUE PROMOTING INNOVATIVE AND RESILIENT AGRICULTURAL MARKET SYSTEMS WILL SUPPORT INCLUSIVE AND RESILIENT AGRICULTURE-LED MARKET SYSTEMS GROWTH IN THE NAMPULA AND ZAMBEZIA PROVINCES AND SOUTHERN NIASSA AND CABO DELGADO PROVINCES (NACALA CORRIDOR) THAT WILL INCENTIVIZE RESPONSIBLE PRIVATE INVESTMENT, IMPROVE ACCESS TO FINANCE, IMPROVE BUSINESS TRANSACTIONS AND RELATIONSHIPS TO BE MORE MARKET RESPONSIVE, SUPPORT VALUE ADDITION, ENHANCE RISK MANAGEMENT, BUILD THE CAPACITY OF SMALLHOLDER PRODUCERS AND SMALL AND MEDIUM AGRIBUSINESSES, AND EXPAND JOBS, INCOMES AND ENTREPRENEURSHIP OPPORTUNITIES FOR YOUNG WOMEN AND MEN.
Department of Health and Human Services
$10.6M
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM (CORP)
Department of Health and Human Services
$10.4M
SEX-BASED DIFFERENCES IN GLIOMA
Department of Education
$10.4M
HIGHER EDUCATION EMERGENCY RELIEF FUND CARES ACT
Department of Health and Human Services
$10.4M
RESEARCH TO CONTROL AND ELIMINATE MALARIA IN SE ASIA AND SW PACIFIC
Agency for International Development
$10.4M
SOLUTIONS FOR AFRICAN FOOD ENTERPRISES (SAFE)
Department of Transportation
$10.4M
WRTA SECTION 5307 CARES ACT OPERATING ASSISTANCE
Department of Transportation
$9.9M
APPLICATION PURPOSE: THE PURPOSE OF THIS AWARD IS TO PROVIDE ASSISTANCE FOR ONE YEAR OF ARCHITECTURE AND ENGINEERING DESIGN ONE YEAR OF TIRE LEASE FUNDING FOR PREVENTIVE MAINTENANCE TO KEEP FIXED ASSETS IN A GOOD STATE OF REPAIR FUNDING FOR THE REHAB OF THE ADMINISTRATION FACILITY FUNDING TO PURCHASE ONE (1) NON-REVENUE SERVICE TRUCK AND FUNDING FOR THE PURCHASE OF SIX (6) REPLACEMENT 35 BATTERY ELECTRIC BUSES.; ACTIVITIES PERFORMED: FUNDS WILL BE USED FOR ARCHITECTURE AND ENGINEERING DESIGN TO ASSIST WRTA STAFF WITH SPECIFICATION DEVELOPMENT AND PROJECT OVERSIGHT ON VARIOUS TECHNICAL AND CONSTRUCTION PROJECTS. FUNDS WILL BE USED FOR PREVENTIVE MAINTENANCE TO KEEP OUR ASSETS IN A GOOD STATE OF REPAIR FUNDS WILL BE USED FOR THE PURCHASE OF SIX (6) REPLACEMENT 35 BUSES AND ONE (1) REPLACEMENT NON-REVENUE SERVICE VEHICLES. FUNDS WILL BE USED FOR THE REHABILITATION OF THE ADMINISTRATION FACILITY TO ACCOMMODATE THE GROWTH IN OUR WORKFORCE.; EXPECTED OUTCOMES: THE BENEFITS FROM THESE FUNDS WILL ASSIST IN THE REHABILITATION OF OUR ADMINISTRATION FACILITY. THE PURCHASE OF REPLACEMENT BUSES WILL REPLACE VEHICLES THAT ARE BEYOND THEIR USEFUL LIFE SO THAT WRTA CAN PROVIDE BETTER SERVICE WITH NEWER VEHICLES FOR OUR PASSENGERS. THE REPLACEMENT OF A SERVICE VEHICLE THAT IS BEYOND ITS USEFUL LIFE. THE CONTINUED MAINTENANCE OF OUR ASSETS IS IN A STATE OF GOOD REPAIR.; INTENDED BENEFICIARIES: WRTA AND OUR PASSENGERS THAT RELY ON OUR SERVICE WILL BENEFIT FROM CONTINUED SERVICES PERMITTING WORKERS TO GET TO JOBS MEDICAL TRIPS EDUCATION OPPORTUNITIES SHOPPING AND OTHER DESTINATIONS. PLUS WRTA WILL BE ABLE TO REDUCE OUR CARBON FOOTPRINT THAT WILL HELP THE ENVIRONMENT.; SUBRECIPIENT ACTIVITIES: NONE
Department of Defense
$9.9M
PILOT RANDOMIZED CONTROLLED TRIAL OF THE ISENS SYSTEM FOR SENSORIMOTOR RESTORATION AFTER LIMB LOSS
Department of Defense
$9.7M
EMBODIED ROBOTICS FOR REMOTE OPERATIONS
Department of Health and Human Services
$9.4M
INFLAMMASOME AND GASDERMIN SIGNALING NETWORKS FOR REGULATION OF PYROPTOSIS AND CYTOKINE RELEASE
Department of Health and Human Services
$9.2M
NASH PROJECT
Department of Health and Human Services
$9.2M
OXIDIZED PHOSPHOLIPIDS IN VASCULAR PATHOBIOLOGY
Department of Health and Human Services
$9.1M
PATHOGENETIC MECHANISMS OF PRION DISEASE
Corporation for National and Community Service
$9.1M
AMERICORPS*STATE
Department of Defense
$9.1M
NEW CA CWRU
Department of Health and Human Services
$9M
ORAL MUCOSAL IMMUNITY IN VULNERABLE HIV INFECTED POPULATIONS
Department of Health and Human Services
$8.8M
ALLIANCE OF RANDOMIZED TRIALS OF MEDICINE VS METABOLIC SURGERY IN TYPE 2 DIABETES - (ARMMS-T2D)
Department of Health and Human Services
$8.7M
CELLULAR S-NITROSOTHIOL SIGNALING IN RESPIRATORY BIOLOGY
Corporation for National and Community Service
$8.6M
THIS APPLICATION IS FOR NEW, RECOMPETING, OR CONTINUATION STATE COMMISSION APPLICANTS, INCLUDING TERRITORIES WITH COMMISSIONS, APPLYING FOR COST REIMBURSEMENT GRANTS.
Department of Health and Human Services
$8.5M
ENGAGING COMMUNITIES AND INSTITUTIONS TO REDUCE HEALTH DISPARITIES IN CLEVELAND
Department of Health and Human Services
$8.4M
CASE CENTER FOR SYNCHROTRON BIOSCIENCES
Department of Health and Human Services
$8.3M
HEALTH CENTER CLUSTER
Department of Health and Human Services
$8.2M
PROTECTIVE GENETIC VARIANTS FOR ALZHEIMER DISEASE IN THE AMISH
Department of Health and Human Services
$8.1M
COCAINE EXPOSED CHILDREN AT SCHOOL AGE
Department of Health and Human Services
$8.1M
RESTORATION OF GRASP AND REACH IN CERVICAL SPINAL CORD INJURY
Agency for International Development
$8.1M
ECONOMIC DEVELOPMENT ALLIANCE FOR SAN MARTIN REGION
National Science Foundation
$8.1M
NEURONEX: COMMUNICATION, COORDINATION, AND CONTROL IN NEUROMECHANICAL SYSTEMS (C3NS)
Department of Defense
$8M
YOUNGSTOWN-WARREN REGIONAL AIRPORT TAXIWAY H REHABILITATION
Department of Health and Human Services
$7.9M
REGULATION OF CNS VIRAL PERSISTENCE
Department of Health and Human Services
$7.9M
GENETIC AND CELLULAR DETERMINANTS OF ARTERIAL THROMBOSIS
Department of Health and Human Services
$7.7M
MECHANISMS OF TRANSMISSIBILITY IN PRION DISEASES
Department of Transportation
$7.7M
APPLICATION PURPOSE: THE PURPOSE OF THIS AWARD IS TO PROVIDE ASSISTANCE FOR ONE YEAR OF PLANNING ASSISTANCE ONE YEAR OF ARCHITECTURE AND ENGINEERING DESIGN EXPANSION OF THE ADMIN/MAINTENANCE FACILITY THE PURCHASE OF THREE REPLACEMENT MINIVANS VEHICLES ONE YEAR OF OPERATING ASSISTANCE FUNDS FOR PREVENTIVE MAINTENANCE TO KEEP FIXED ASSETS IN A GOOD STATE OF REPAIR THE INSTALLATION OF A BACK-UP GENERATOR A PHONE SYSTEM UPGRADE AND FUNDING FOR THE PURCHASE OF FOUR REPLACEMENT NON-REVENUE ELECTRIC VEHICLES.; ACTIVITIES PERFORMED: FUNDS WILL BE USED TO COVER TRANSIT PLANNING ACTIVITIES FOR THE DEVELOPMENT AND UPDATE OF OUR SERVICE PLANS TRANSPORTATION IMPROVEMENT PROGRAMS ONGOING ANALYSIS AND EVALUATION OF POLICIES PROCEDURES AND STANDARDS IN THE AREAS OF SERVICE. FUNDS WILL BE USED FOR ARCHITECTURE AND ENGINEERING DESIGN TO ASSIST WRTA STAFF WITH SPECIFICATION DEVELOPMENT AND PROJECT OVERSIGHT ON VARIOUS TECHNICAL AND CONSTRUCTION PROJECTS. FUNDS WILL BE USED FOR PREVENTIVE MAINTENANCE TO KEEP OUR ASSETS IN A GOOD STATE OF REPAIR FUNDS WILL BE USED FOR THE PURCHASE OF THREE REPLACEMENT MINIVAN VEHICLES AND FOUR REPLACEMENT NON-REVENUE VEHICLES. FUNDS WILL BE USED FOR THE CONSTRUCTION OF THE EXPANSION OF OFFICE SPACE AND MAINTENANCE BAYS TO ACCOMMODATE THE GROWTH IN OUR WORKFORCE. FUNDS WILL BE USED FOR THE INSTALLATION OF A BACK-UP GENERATOR AT OUR DOWNTOWN PASSENGER TERMINAL AND FUNDS WILL BE USED TO REPLACE OUR BEYOND USEFUL LIFE PHONE SYSTEM.; EXPECTED OUTCOMES: THE BENEFITS FROM THESE FUNDS WILL ALLOW WRTA TO PLAN AND DEVELOP ROUTES TO BETTER SERVE OUR COMMUNITY ASSIST IN THE CONSTRUCTION OF THE EXPANSION OF OUR ADMIN/MAINTENANCE FACILITY. THE PURCHASE OF REPLACEMENT MINIVANS VEHICLES WILL REPLACE VEHICLES THAT ARE BEYOND THEIR USEFUL LIFE SO THAT WRTA CAN PROVIDE A BETTER SERVICE WITH NEWER VEHICLES FOR OUR PASSENGERS. THE REPLACEMENT OF BEYOND USEFUL LIFE NON-REVENUE VEHICLES WITH NEWER MORE ENVIRONMENTALLY SUSTAINABLE VEHICLES. THE INSTALLATION OF A BACK-UP GENERATOR TO MAKE SURE OUR TRANSIT CENTER CAN REMAIN OPERATING DURING POWER OUTAGES. THE CONTINUED MAINTENANCE OF OUR ASSETS IN A STATE OF GOOD REPAIR. WITH THE UPGRADE TO THE PHONE SYSTEM WE WILL HAVE A MORE RELIABLE SYSTEM ALONG WITH ADDITIONAL FEATURES TO MAKE IT EASIER TO ANSWER CALLS FOR SERVICE.; INTENDED BENEFICIARIES: WRTA AND OUR PASSENGERS THAT RELY ON OUR SERVICE WILL BENEFIT FROM CONTINUED SERVICES PERMITTING WORKERS TO GET TO JOBS MEDICAL TRIPS EDUCATION OPPORTUNITIES SHOPPING AND OTHER DESTINATIONS. PLUS WRTA WILL BE ABLE TO REDUCE OUR CARBON FOOTPRINT THAT WILL HELP THE ENVIRONMENT.; SUBRECIPIENT ACTIVITIES: NONE
Corporation for National and Community Service
$7.6M
AMERICORPS*STATE
Department of Health and Human Services
$7.6M
HEMODIALYSIS FISTULA MATURATION CONSORTIUM DATA COORDINATING CENTER
Department of Health and Human Services
$7.6M
TISSUE INJURY AND INFLAMMATION IN MULTIPLE SCLEROSIS
Department of Health and Human Services
$7.5M
MOLECULAR DISSECTION OF CYTOKINE CROSSTALK IN THE TUMOR MICROENVIRONMENT - PROJECT SUMMARY DESPITE RECOGNITION OF THE BROAD CONSEQUENCES OF INFLAMMATION IN CANCER BIOLOGY, THE MECHANISTIC IMPACT ON THE TUMOR LANDSCAPE REMAINS INCOMPLETELY UNDERSTOOD. INDEED, INNATE AND ADAPTIVE IMMUNE FUNCTIONS IN CANCER CAN BE BENEFICIAL OR DETRIMENTAL AND THE OPPOSING ROLES HIGHLIGHT THE GAP OF KNOWLEDGE IN OUR UNDERSTANDING OF HOW INFLAMMATION SCULPTS THE TUMOR MICROENVIRONMENT (TME). THIS PROGRAM PROJECT WILL ADDRESS THIS GAP OF KNOWLEDGE BY DEFINING AND DELINEATING HOW CYTOKINES MODULATE THE FUNCTIONS OF THE MULTIPLE CELL TYPES COMPOSING THE TUMOR MICROENVIRONMENT. OUR PREVIOUS WORK HAS REVEALED THE POTENTIAL FOR THESE INFLAMMATORY CYTOKINES TO REGULATE A SPECTRUM OF CANCER CELL PHENOTYPES, INCLUDING THEIR SELF-RENEWAL AND CELLULAR HIERARCHY OR STEMNESS, THAT ARE ASSOCIATED WITH THE EPITHELIAL-MESENCHYMAL TRANSITION (EMT). MOREOVER, THESE PHENOTYPES ARE COMMONLY ASSOCIATED WITH CANCER PROGRESSION THROUGH MODULATION OF DIFFERENTIATION POTENTIAL, CELL-CELL INTERACTIONS AND MOBILITY, FIBROSIS, AND SENSITIVITY TO MULTIPLE THERAPEUTIC MODALITIES. THE PROGRAM IS NOW CENTERED ON TWO MAJOR THEMES. THE FIRST IS TO DEFINE THE SIGNALING MECHANISMS THAT GOVERN HOW CYTOKINES (TYPE I IFNS, IL- 17,TGFSS) MODULATE (BOTH POSITIVELY AND NEGATIVELY) THE EMT PROCESS. THE CELLULAR TARGETS INCLUDE STEM-LIKE TUMOR CELLS AS WELL AS THE NON-TUMOR DERIVED POPULATIONS, INCLUDING FIBROBLASTS AND IMMUNE CELLS. THE SECOND THEME RELATES THESE CELL-SPECIFIC EMT RESPONSES TO SPECIFIC EFFECTS ON METASTASIS, FIBROSIS, AND RESISTANCE TO MULTIPLE THERAPEUTIC STRATEGIES. OUR MAJOR GOAL IS TO PARLAY OUR IMPROVED UNDERSTANDING OF CYTOKINE EFFECTS IN THE TME INTO SPECIFIC IMPROVEMENTS IN CANCER THERAPY. COLLECTIVELY THE THREE PROJECTS IN THE APPLICATION WILL TEST THE FOLLOWING OVERARCHING HYPOTHESIS: CYTOKINE SIGNALS HAVE DISTINCT AND SOMETIMES CONFLICTING MECHANISTIC ROLES IN CANCER PROGRESSION THOUGH ALTERATIONS IN EMT AND CANCER STEM CELL DEVELOPMENT. SUCH MECHANISMS LEAD TO CRITICAL PHENOTYPIC PROPERTIES RESPONSIBLE FOR CONTINUOUS METASTATIC SPREAD AND RESISTANCE TO MULTIPLE THERAPEUTIC MODALITIES (CHEMOTHERAPY, IMMUNE THERAPY). THIS HYPOTHESIS WILL BE TESTED BY (1) DEFINING THE SIGNALING EVENTS INITIATED BY TGFSS, IL-17, AND/OR TYPE I IFNS AND THE ENDPOINT CHANGES IN SPECIFIC GENE EXPRESSION THAT ARE CAUSALLY LINKED WITH CONTROL OF TME AND CANCER CELL PHENOTYPES, (2) DETERMINATION OF HOW THESE SPECIFIC SIGNALING PATHWAYS AND GENE EXPRESSION EVENTS ARE MECHANISTICALLY RESPONSIBLE FOR ACQUISITION OF THERAPEUTIC RESISTANCE AND (3) EVALUATION OF THE DISTINCT CELL TYPE CONTRIBUTIONS TO TUMOR PHENOTYPES AND THERAPEUTIC RESISTANCE, WITH EMPHASIS ON TUMOR CELL INTRINSIC MECHANISMS, IMMUNE CELL INFILTRATES AND ACTIVITIES, AND STROMAL CELL CONTROL OF TUMOR ACCESS.
Department of Health and Human Services
$7.5M
PROGNOSIS AND PREDICTORS OF ACL RECONSTRUCTION: A MULTICENTER COHORT STUDY
Department of Defense
$7.5M
MOLECULAR MECHANISMS AND PATHWAYS FOR GAS TRANSPORT ACROSS BIOLOGICAL MEMBRANES AND IMPLICATIONS FOR PHYSIOLOGY AND PERFORMANCE MURI 2016
Corporation for National and Community Service
$7.4M
GRANTS WILL BE AWARDED TO ORGANIZATIONS PROPOSING TO ENGAGE AMERICORPS MEMBERS TO STRENGTHEN COMMUNITIES.
Department of Health and Human Services
$7.4M
CYCLE-AD: RANDOMIZED CONTROLLED TRIAL TO ASSESS THE EFFICACY OF INDOOR CYCLING IN SLOWING DISEASE PROGRESSION IN HEALTHY OLDER PERSONS AT GENETIC RISK FOR ALZHEIMER?S DISEASE - PROJECT SUMMARY/ABSTRACT THE APOLIPOPROTEIN E EPSILON 4 (APOE 4) ALLELE IS THE MOST IMPORTANT GENETIC RISK FACTOR FOR LATE ONSET ALZHEIMER'S DISEASE (AD). A RECENT REVIEW BY THE WORLD HEALTH ORGANIZATION HIGHLIGHTED THE POTENTIAL PROTECTIVE ROLE OF PHYSICAL ACTIVITY AND EXERCISE AGAINST COGNITIVE DECLINE, ALL-CAUSE DEMENTIA, AD, AND VASCULAR DEMENTIA IN HEALTHY INDIVIDUALS. IN AN 18-MONTH LONGITUDINAL OBSERVATIONAL STUDY, WE SHOWED THAT SEDENTARY 4 CARRIERS EXPERIENCE SIGNIFICANT DECLINES IN EPISODIC MEMORY AND HIPPOCAMPAL VOLUME COMPARED TO 4 CARRIERS WHO ENGAGED IN MODERATE PA. IMPORTANTLY, AMONG 4 NON-CARRIERS, NO SIGNIFICANT LONGITUDINAL CHANGES IN COGNITION AND BRAIN IMAGING WERE OBSERVED WHETHER THE NON-CARRIERS WERE SEDENTARY OR ENGAGED IN MODERATE PA, SUGGESTING THAT PA HAS A SPECIFIC NEUROPROTECTIVE ROLE IN DELAYING THE PROGRESSION OF AD IN 4 CARRIERS. BASED ON OUR RESULTS, A PRAGMATIC, RANDOMIZED CONTROLLED TRIAL WITH BLINDED CLINICAL AND IMAGING OUTCOMES IS PROPOSED TO DETERMINE THE IMPACT OF A HOME BASED, HIGH INTENSITY EXERCISE INTERVENTION IN HEALTHY, COGNITIVELY INTACT 4 CARRIERS BETWEEN THE AGES OF 65 AND 80 YEARS. THE CYCLE-AD (CYCLING TO CEASE OR LIMIT THE EFFECTS OF ALZHEIMER'S DISEASE) TRIAL WILL RECRUIT OTHERWISE HEALTHY SEDENTARY CARRIERS RANDOMIZED TO ONE OF TWO GROUPS (N=75 EACH): 1) AN INDOOR CYCLING (IC) GROUP THAT PARTICIPATES IN HIGH-INTENSITY INTERVAL TRAINING (HIIT; 60-90% OF HEART RATE RESERVE) IN THEIR HOME VIA THE COMMERCIALLY AVAILABLE PELOTON® CYCLING SYSTEM OR 2) A USUAL AND CUSTOMARY CARE (UCC) GROUP, IN WHICH PARTICIPANTS ENGAGE IN THEIR HABITUAL LEVEL OF PA. WE HYPOTHESIZE THAT AN 18-MONTH HIGH-INTENSITY AEROBIC EXERCISE REGIMEN WILL SLOW AD-RELATED DISEASE PROGRESSION IN SEDENTARY ELDERS AT GENETIC RISK FOR AD. PARTICIPANTS IN THE INTERVENTION GROUP WILL ENGAGE IN EXERCISE 3X/WEEK (MINIMUM 90 MINUTES/WEEK) FOR 18 MONTHS. PRIMARY OUTCOME MEASURES, OBTAINED AT STUDY ENTRY AND AT 18 MONTHS, WILL INCLUDE COMPREHENSIVE COGNITIVE TESTING AND BRAIN MR IMAGING TO ASSESS DISEASE PROGRESSION AND A COMPREHENSIVE PA/FITNESS ASSESSMENT TO MEASURE THE DEGREE OF CHANGE IN PHYSICAL FITNESS DUE TO HIGH INTENSITY AEROBIC EXERCISE. THE OVERALL GOAL OF THE CYCLE-AD TRIAL IS TO DETERMINE THE ROLE OF LONG-TERM, HIGH INTENSITY EXERCISE IN SLOWING OR DELAYING THE ONSET OF COGNITIVE AND AD-RELATED BRAIN CHANGES IN 4 CARRIERS. SUCCESSFUL TRANSLATION AND DEMONSTRATION OF THE EFFECTIVENESS OF A SCALABLE HOME-BASED EXERCISE INTERVENTION CAPABLE OF SLOWING OR DELAYING DISEASE ONSET WILL TRANSFORM AD TREATMENT, IMPROVE PATIENT OUTCOMES AND QUALITY OF LIFE, AND REDUCE HEALTH CARE COSTS.
Department of Veterans Affairs
$7.4M
HOMELESS PREVENTION
Department of Health and Human Services
$7.3M
POST-TRANSPLANT INFLAMMATORY RESPONSE
Corporation for National and Community Service
$7.3M
ENGAGES AMERICORPS MEMBERS IN FULL AND PART-TIME SERVICE TO MEET COMMUNITY NEEDS IN EDUCATION, THE ENVIRONMENT, HEALTH, VETERANS, AND OTHER AREAS. NA
Department of Health and Human Services
$7.3M
CAPTURING SPATIAL PATTERNS OF NEW M. TUBERCULOSIS INFECTION IN KAMPALA, UGANDA
Department of Veterans Affairs
$7.3M
CARES 2.0 FUNDING FOR COVID19. THE SSVF PROGRAM'S PURPOSE IS TO PROVIDE SUPPORTIVE SERVICES GRANTS TO PRIVATE NON-PROFIT ORGANIZATIONS AND CONSUMER COOPERATIVES, WHO WILL COORDINATE OR PROVIDE SUPPORTIVE SERVICES TO VERY LOW-INCOME VETERAN FAMILIES WHO ARE RESIDING IN PERMANENT HOUSING, ARE HOMELESS AND SCHEDULED TO BECOME RESIDENTS OF PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD; OR AFTER EXITING PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD, ARE SEEKING OTHER HOUSING THAT IS RESPONSIVE TO SUCH VERY LOW-INCOME VETERAN FAMILY'S NEEDS AND PREFERENCES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES.
Corporation for National and Community Service
$7.3M
N/A
Department of Transportation
$7.2M
WRTA SECTION 5307 ARPA OPERATING ASSISTANCE
Department of Health and Human Services
$7.1M
MULTI-FUNCTIONAL NEUROPROSTHETIC SYSTEMS FOR RESTORATION OF MOTOR FUNCTION
Department of Health and Human Services
$7.1M
CENTRAL VEIN SIGN: A DIAGNOSTIC BIOMARKER IN MULTIPLE SCLEROSIS
Department of Health and Human Services
$7.1M
INVOLVING COMMUNITIES IN DELIVERING AND DISSEMINATING HEALTH DISPARITY INTERVENTIONS
Department of Health and Human Services
$7.1M
REGULATION OF GENE EXPRESSION DURING STRESS
Department of Health and Human Services
$7.1M
CASE WESTERN RESERVE UNIVERSITY/CLEVELAND CLINIC CTSA (KL2)
Department of Health and Human Services
$7.1M
MOLECULAR BASIS OF ILK SIGNALING IN CELL ADHESION
Department of Health and Human Services
$7M
TOWARDS PRECISION IMMUNO-ONCOLOGY: UNRAVELING THE GENOMIC DETERMINANTS AND MECHANISMS UNDERLYING IMMUNOTHERAPY EFFICACY AND RESISTANCE
Department of Health and Human Services
$7M
NEI CENTER CORE GRANT FOR VISION RESEARCH
Agency for International Development
$7M
THE GORILLA COFFEE ALLIANCE BRINGS TOGETHER DEVELOPMENT AND CONSERVATION ORGANIZATIONS IN PARTNERSHIP WITH AGRICULTURE COMPANIES TO IDENTIFY INNOVATIVE AND SCALABLE SOLUTIONS THAT ENHANCE THE WAYS THAT COMMUNITIES AROUND KAHUZI BIEGA NATIONAL PARK BENEFIT FROM THE REGION’S PRODUCTION POTENTIAL WHILE PROTECTING THE PARK’S VULNERABLE SPECIES AND LANDSCAPES.
Department of Transportation
$7M
CAPITAL PLANNING VEHICLE PURCHASE
Department of Health and Human Services
$6.9M
PATHOGENESIS OF NEUROLOGICAL DISABILITY IN PRIMARY DISEASES OF MYELIN
Department of Veterans Affairs
$6.9M
THE SSVF PROGRAM'S PURPOSE IS TO PROVIDE SUPPORTIVE SERVICES GRANTS TO PRIVATE NON-PROFIT ORGANIZATIONS AND CONSUMER COOPERATIVES, WHO WILL COORDINATE OR PROVIDE SUPPORTIVE SERVICES TO VERY LOW-INCOME VETERAN FAMILIES WHO ARE RESIDING IN PERMANENT HOUSING, ARE HOMELESS AND SCHEDULED TO BECOME RESIDENTS OF PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD; OR AFTER EXITING PERMANENT HOUSING WITHIN A SPECIFIED TIME PERIOD, ARE SEEKING OTHER HOUSING THAT IS RESPONSIVE TO SUCH VERY LOW-INCOME VETERAN FAMILY'S NEEDS AND PREFERENCES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES. GRANTEES WILL USE SUPPORTIVE SERVICES GRANT FUNDS TO PROVIDE SUPPORTIVE SERVICE. ALL GRANTEES ARE REQUIRED TO PROVIDE OUTREACH SERVICES, CASE MANAGEMENT SERVICES, ASSISTANCE IN OBTAINING VA BENEFITS AND ASSISTANCE IN OBTAINING AND COORDINATING OTHER PUBLIC BENEFITS. IN ADDITION TO THE REQUIRED SERVICES, GRANTEES MAY ALSO PROVIDE TEMPORARY FINANCIAL ASSISTANCE PAID DIRECTLY TO A THIRD PARTY ON BEHALF OF A PARTICIPANT FOR CHILD CARE, EMERGENCY HOUSING ASSISTANCE, TRANSPORTATION, RENTAL ASSISTANCE, UTILITY-FEE PAYMENT ASSISTANCE, SECURITY DEPOSITS, UTILITY DEPOSITS, MOVING COSTS, AND GENERAL HOUSING STABILITY ASSISTANCE (WHICH INCLUDES EMERGENCY SUPPLIES), IN ACCORDANCE WITH 38 CFR PART 62. ADDITIONAL OPTIONAL SUPPORTIVE SERVICES MAY INCLUDE LEGAL ASSISTANCE AND FINANCIAL MANAGEMENT SERVICES.
Department of Health and Human Services
$6.9M
INSTITUTIONAL CAREER DEVELOPMENT CORE
Department of Health and Human Services
$6.8M
MOLECULAR DETERMINANTS OF CORONARY ARTERY DISEASE
Department of Veterans Affairs
$6.8M
HOMELESS PREVENTION
Department of Health and Human Services
$6.7M
PREVENTION RESEARCH CENTER FOR HEALTHY NEIGHBORHOODS
Department of Health and Human Services
$6.7M
IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM
Department of Health and Human Services
$6.7M
CLEVELAND CLINIC CARDIOTHORACIC COLLABORATIVE CLINICAL CENTER (C6)
Department of Health and Human Services
$6.6M
PATHWAYS OF INJURY AND REPAIR IN BARRETT'S CARCINOGENESIS - PROGRAM SUMMARY THE CENTRAL HYPOTHESIS OF THIS PROGRAM PROJECT IS THAT “ALTERED SQUAMOUS EPITHELIAL INTEGRITY (PRJ 1) AND INFLAMMATORY INJURY (PRJ 2) ACTIVATE SIGNALING PATHWAYS INCLUDING EPHB2 (PRJ 3) THAT AFFECT PRECURSOR CELLS AT THE SQUAMOCOLUMNAR JUNCTION (SCJ) TRANSITION, ESOPHAGEAL SUBMUCOSAL GLAND (ESMG), AND BASAL SQUAMOUS NICHES, RESULTING IN THE ALTERATION OF REGULATORY FACTORS THAT INCLUDE NOTCH, MYC, P63, AND SOX9, LEADING TO ACINAR DUCTAL METAPLASIA (ADM), MULTI-LAYERED EPITHELIUM (MLE), BARRETT'S ESOPHAGUS (BE), AND ULTIMATELY ESOPHAGEAL ADENOCARCINOMA (EAC).” THE SPECIFIC AIMS OF OUR PROGRAM ARE: 1) TO ELUCIDATE SIGNALING PATHWAYS BY WHICH MUTATED VSIG10L ALTERS EPITHELIAL INTEGRITY LEADING TO MLE AND BE LIKE METAPLASIA ON NOVEL MOUSE MODELS. 2) TO DEFINE THE SPATIAL AND TEMPORAL PATTERN OF CXCL8 (IL-8) IN ESMG FOLLOWING ESOPHAGEAL INJURY AND PHENOTYPE THE INFLAMMATORY INFILTRATE THAT LEADS TO THE DEVELOPMENT OF ACINAR DUCTAL METAPLASIA (ADM) IN ESMG ASSOCIATED WITH BE/EAC. 3)TO IDENTIFY MEDIATORS OF EPHB2 SIGNALING THAT LEAD TO C-MYC ACTIVATION AND METAPLASTIC CELLULAR DIFFERENTIATION AFTER INJURY IN THE DEVELOPMENT OF BE AND ITS PROGRESSION TO EAC. 4) TO DEFINE HOW ALTERED EPITHELIAL INTEGRITY, INFLAMMATORY CELLS, AND ALTERATION OF SIGNALING MOLECULES THAT CONTROL DIFFERENTIATION (EPHB2) LEAD TO METAPLASIA BY ALTERING TRANSCRIPTION FACTORS. 5) INTEGRATE PROJECTS BY PROVIDING INVESTIGATORS EFFECTIVE SUPPORT THROUGH CORE RESOURCES WITH STATE-OF-THE-ART BIOREPOSITORY, BIOINFORMATICS, AND ADMINISTRATIVE SERVICES. THESE OBJECTIVES BUILD AND SYNERGIZE ON THE CONSIDERABLE CLINICAL, BASIC SCIENCE, AND TRANSLATIONAL EXPERTISE AVAILABLE AT OUR INSTITUTIONS, 1) TO FOCUS LABORATORY RESEARCH ON UNDERSTANDING THE GENETIC SUSCEPTIBILITY AND MOLECULAR CHANGES THAT INFLUENCE THE DEVELOPMENT OF BE AND EAC; AND 2) TO THEN TRANSLATE LABORATORY DISCOVERIES INTO CLINICAL APPLICATIONS FOR EFFECTIVE DETECTION, MOLECULAR RISK STRATIFICATION, AND PREVENTION OF PROGRESSION FROM BE TO EAC.
Department of Health and Human Services
$6.6M
TARGETING 15-PROSTAGLANDIN DEHYDROGENASE (15-PGDH) IN CANCER RISK, PREVENTION, AND TREATMENT
Department of Health and Human Services
$6.5M
SIGNIFICANCE OF CYP46A1 AND OTHER P450S IN RETINAL FUNCTION
Department of Health and Human Services
$6.5M
PSORIASIS CENTER OF RESEARCH TRANSLATION
Department of Health and Human Services
$6.5M
PHOTOTRANSDUCTION IN HEALTH AND DISEASE
Department of Health and Human Services
$6.4M
OPTICAL TOOLS TO ASSESS THE ROLE OF HEMODYNAMICS IN THE DEVELOPMENT OF CONGENITAL HEART DEFECTS
Department of Health and Human Services
$6.4M
TRANSLATIONAL RESEARCH IN CYSTIC FIBROSIS
Department of Health and Human Services
$6.4M
CIRCUIT ARCHITECTURE AND DYNAMICS REPRESENTATION IN ODOR PERCEPTION
Department of Health and Human Services
$6.4M
PROTECTIVE GENETIC VARIANTS FOR ALZHEIMER DISEASE IN THE AMISH - RENEWAL - ALZHEIMER DISEASE (AD) IS A DEVASTATING NEURODEGENERATIVE DISORDER THAT AFFECTS MILLIONS OF INDIVIDUALS IN THE U.S. IT HAS SO FAR RESISTED ATTEMPTS TO DEVELOP EFFECTIVE THERAPIES DESPITE NUMEROUS (FAILED) CLINICAL TRIALS BASED ON KNOWN TARGETS, MOST IDENTIFIED OVER 20 YEARS AGO. WHILE GENOMIC RESEARCH (E.G. THE ALZHEIMER’S DISEASE SEQUENCING PROJECT; ADSP) HAS IDENTIFIED NUMEROUS ADDITIONAL RISK LOCI, THESE RESULTS DERIVE PRIMARILY FROM CASE- CONTROL DATASETS. IN CONTRAST, COHORTS DESIGNED TO IDENTIFY VARIANTS THAT MAY PROTECT FROM AD, AND THOSE USING COMPLEMENTARY STUDY DESIGNS, ARE FEW. WE USED OUR EXTENSIVE EXPERIENCE WITH THE AMISH COMMUNITIES IN INDIANA AND OHIO TO ESTABLISH A COHORT OF OLDER INDIVIDUALS AT HIGH RISK OF DEVELOPING AD BUT WHO ARE COGNITIVELY UNIMPAIRED (CU). THE AMISH PROVIDE A UNIQUE OPPORTUNITY TO IDENTIFY PROTECTIVE VARIANTS FOR AD BECAUSE OF THEIR REDUCED BACKGROUND GENETIC VARIATION AND ENVIRONMENTAL RISK FACTORS. THEIR SMALL FOUNDING POPULATION AND ENDOGAMY PROVIDES ENRICHMENT FOR RARE VARIANTS. FOUNDER POPULATIONS ALSO ENABLE TESTING FOR NON-ADDITIVE ALLELIC EFFECTS AND CAN MAGNIFY SUB-SIGNIFICANT ASSOCIATION SIGNALS IDENTIFIED IN CASE-CONTROL STUDIES. THE STABILITY AND ENGAGEMENT OF OUR AMISH PARTICIPANTS ENABLES LONGITUDINAL ASSESSMENTS OF COGNITION AND BIOMARKERS. OUR PRIMARY GOALS ARE TO IDENTIFY AD PROTECTIVE LOCI AND CHARACTERIZE PRE-CLINICAL BIOMARKERS OF PROGRESSION TO COGNITIVE IMPAIRMENT. BUILDING ON OUR EXISTING LARGE COHORT, OUR REPLICATED PROTECTIVE LOCUS AND SEVERAL SUGGESTIVE PROTECTIVE LOCI, AND OUR EXISTING BIOBANK OF DNA AND PLASMA AND DATABANK OF GWAS AND WGS, WE PROPOSE TO: 1) PERFORM LONGITUDINAL ASSESSMENT OF COGNITION IN OUR FAMILY-BASED AMISH COHORT; 2) IDENTIFY PROTECTIVE FACTORS FOR AD AND PREDICTORS OF PROGRESSION TO COGNITIVE IMPAIRMENT BY ANALYZING GENOMIC AND LONGITUDINAL COGNITIVE, BIOMARKER, AND SDOH DATA; AND 3) EXAMINE THE FUNCTIONAL IMPLICATIONS OF CURRENT AND NOVEL GENES AND VARIANTS BY PRIORITIZING LOCI USING IN SILICO ANNOTATION FOR FUNCTIONAL CONSEQUENCES FOLLOWED BY IN VITRO FUNCTIONAL CHARACTERIZATION. OUR RESULTS WILL IDENTIFY POTENTIAL DRUGGABLE TARGETS AND ACCELERATE THE DEVELOPMENT OF BETTER TREATMENTS FOR AD.
Corporation for National and Community Service
$6.3M
AMERICORPS STATE
Department of Health and Human Services
$6.3M
GENOMIC AND MICROENVIRONMENTAL DETERMINANTS, TEMPORAL DYNAMICS, AND TREATMENT EFFICACY OF RADIATION-BASED COMBINATION THERAPIES - PROJECT SUMMARY OVERALL SECTION OUR ROBIN CENTER FOCUSES ON ELUCIDATING THE GENOMIC AND MICROENVIRONMENTAL DETERMINANTS, AND TEMPORAL DYNAMICS UNDERLYING EFFICACY OF RADIATION-BASED COMBINATION THERAPIES. RADIOTHERAPY (RT), ALONE OR IN COMBINATION WITH OTHER TREATMENTS, IS USED TO TREAT ABOUT TWO-THIRDS OF ALL CANCER PATIENTS. DESPITE THE WIDESPREAD USE OF RADIATION THERAPY IN ONCOLOGY, OUR UNDERSTANDING OF THE MECHANISMS DRIVING RESPONSE AND RESISTANCE REMAINS POOR. OUR LONG-TERM GOAL IS TO UNDERSTAND THE MECHANISMS THAT UNDERLIE EFFICACY AND RESISTANCE OF RADIATION-BASED THERAPIES. NEW EFFORTS TO IMPROVE TREATMENT FOR MANY CANCER TYPES NOW FOCUS ON USING COMBINATION THERAPIES IN WHICH RADIATION IS USED WITH SYSTEMIC AGENTS, HIGHLIGHTING THE URGENT NEED TO UNDERSTAND THE DRIVERS OF EFFICACY. AMONG THE MOST PROMISING NEW BIOLOGICS BEING STUDIED FOR USE WITH RADIATION ARE ANTIBODY-DRUG CONJUGATES (ADC) AND IMMUNE CHECKPOINT INHIBITORS (ICI). WE WILL USE AN INNOVATIVE MOLECULAR CHARACTERIZATION TRIAL TESTING RADIATION PLUS ADC IN BLADDER CANCER AND RADIATION PLUS ICI IN HEAD AND NECK CANCER TO CHARACTERIZE THE MECHANISTIC DRIVERS UNDERLYING THESE NEXT GENERATION RT-BASED COMBINATIONS. THE CENTRAL HYPOTHESIS OF THIS U54 APPLICATION IS THAT SPECIFIC GENETIC AND IMMUNOLOGIC MECHANISMS UNDERLIE SENSITIVITY AND RESISTANCE TO RADIATION-BASED COMBINATION THERAPIES. WE WILL ADDRESS THESE QUESTIONS THROUGH 3 SPECIFIC AIMS. IN AIM 1, WE WILL WORK TO UNDERSTAND THE MOLECULAR MECHANISMS THAT UNDERLIE EFFICACY OF TREATMENT WITH RADIATION PLUS ADC. HERE, OUR WORKING HYPOTHESIS IS THAT SPECIFIC GENETIC AND IMMUNOLOGIC EVENTS UNDERLIE RESPONSE TO RT PLUS SACITUZUMAB GOVITECAN (SG) TREATMENT. WE WILL LEVERAGE OUR MOLECULAR CHARACTERIZATION TRIAL (PART A) INVESTIGATING THE USE OF RT AND SACITUZUMAB FOR BLADDER PRESERVATION THERAPY. WE WILL DETERMINE THE DIFFERENTIAL MOLECULAR EFFECTS WITH STANDARD-OF-CARE RT + CISPLATIN VERSUS RT + SG. IN AIM 2, WE WILL IMPROVE IDENTIFICATION OF PATIENTS WHO ARE SENSITIVE OR RESISTANT TO RT-BASED THERAPIES BASED ON NEW INSIGHTS INTO TRANSCRIPTIONAL DYNAMICS AND TEMPORAL REPROGRAMMING DURING TREATMENT WITH RADIATION-BASED THERAPIES. HERE, WE WILL LEVERAGE OUR MOLECULAR CHARACTERIZATION TRIAL TREATING HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) OR BLADDER CANCER PATIENTS WITH RT + CHEMOTHERAPY VERSUS RT + SG OR ICI. WE WILL BUILD ON RECENT EXPERIMENTAL AND CLINICAL BREAKTHROUGHS LED BY OUR RESEARCH GROUPS, WHICH HAVE IDENTIFIED HIGHLY REFINED GENE EXPRESSION PROGRAMS ASSOCIATED WITH RT SENSITIVITY AND DELTA RADIOMICS. IN AIM 3, WE WILL IDENTIFY THE DIFFERENTIAL MECHANISMS UNDERLYING THE ANTI-TUMOR ACTIVITIES OF RT + CISPLATIN VERSUS RT + IMMUNE CHECKPOINT BLOCKADE. HERE, USING OUR HEAD AND NECK TRIAL (PART B), WE WILL UNCOVER THE UNIQUE GENETIC AND IMMUNOLOGIC FACTORS THAT GOVERN RESPONSE TO RT WHEN COMBINED WITH THESE TWO CLASSES OF AGENTS. WE WILL ELUCIDATE THE DIFFERENTIAL MOLECULAR EFFECTS OF THE TWO APPROACHES, IMMUNE REPROGRAMMING, AND MECHANISMS OF ACQUIRED RESISTANCE. OUR STUDIES WILL HELP BUILD A FOUNDATION TO OPTIMIZE MULTIMODAL, RADIATION- BASED DEFINITIVE TREATMENT STRATEGIES.
Department of Health and Human Services
$6.3M
MULTIDRUG RESISTANT ACINETOBACTER BAUMANNII,
Department of Health and Human Services
$6.2M
A FAMILIAL STUDY OF SEVERE PHONOLOGY DISORDERS
Agency for International Development
$6.2M
1-INCREASE THE TOTAL ESTIMATED AMOUNT OF THE AGREEMENT BY $256,000.00 FROM $9,608,453.00 TO $9,864,453.00;2-PROVIDE INCREMENTAL FUNDING IN THE AMOU
Department of Transportation
$6.2M
PURPOSE: REHABILITATE RUNWAY. ACTIVITIES TO BE PERFORMED/EXPECTED OUTCOMES: THIS PROJECT REHABILITATES 9,003 FEET OF EXISTING PAVED RUNWAY 14/32 TO MAINTAIN THE STRUCTURAL INTEGRITY AND MINIMIZE FOREIGN OBJECT DEBRIS TO EXTEND ITS USEFUL LIFE. THIS GRANT FUNDS PHASE 3, WHICH CONSISTS OF REHABILITATION OF 4,575 FEET OF PAVEMENT. INTENDED BENEFICIARY: THIS GRANT WILL PROVIDE FEDERAL FUNDING FOR AIRPORTS ASSOCIATED WITH YOUNGSTOWN, OHIO.
Department of Health and Human Services
$6.1M
MOLECULAR BASIS OF KSHV ONCOGENESIS
Department of Health and Human Services
$6.1M
MECHANISMS OF TUBULAR ATROPHY IN RENAL DISEASE
Department of Defense
$6.1M
AN INTEGRATED COMPUTATIONAL AND EXPERIMENTAL APPROACH TOWARD THE DESIGN OF MATERIALS FOR FUEL CELLS SYSTEMS
Department of Health and Human Services
$6.1M
FUNCTIONAL GENOMICS OF ATRIAL FIBRILLATION IN HUMAN ATRIA
Department of Health and Human Services
$6M
CWRU CASE COMPREHENSIVE CANCER CENTER NCTN LEAD ACADEMIC PARTICIPATING SITE
Department of Health and Human Services
$6M
BEAR-MOON: A TWO ARM NONINFERIORITY BLINDED RANDOMIZED CLINICAL TRIAL COMPARING ACL REPAIR WITH BEAR DEVICE VS. STANDARD OF CARE AUTOGRAFT PATELLAR TENDON ACL RECONSTRUCTION
Department of Health and Human Services
$6M
RANDOMIZED TRIAL OF ASSISTED AMBULATION TO IMPROVE HEALTH OUTCOMES FOR OLDER MEDICAL INPATIENTS - PROJECT SUMMARY/ABSTRACT FOR OLDER ADULTS, PROLONGED HOSPITALIZATION CAN LEAD TO A DEVASTATING LOSS OF MOBILITY AND INDEPENDENCE. EACH YEAR, 12 MILLION ADULTS OVER THE AGE OF 65 ARE HOSPITALIZED, AND 30% ARE DISCHARGED TO A POST-ACUTE CARE FACILITY. ONE OF THE RISKS OF HOSPITALIZATION IS BED REST, WHICH IS ASSOCIATED WITH A NUMBER OF HOSPITAL-ACQUIRED COMPLICATIONS, INCLUDING FALLS, DELIRIUM, VENOUS THROMBOSIS AND SKIN BREAKDOWN. HOSPITAL MOBILITY PROGRAMS ATTEMPT TO AMBULATE PATIENTS UP TO THREE TIMES DAILY, BUT THIS WORK IS GENERALLY ASSIGNED TO NURSES, WHO HAVE MANY COMPETING AND OFTEN MORE PRESSING TASKS. CONSEQUENTLY, AMBULATING PATIENTS IS THE MOST FREQUENTLY OVERLOOKED NURSING DUTY. THIS PROBLEM HAS BEEN EXACERBATED BY THE COVID-19 PANDEMIC AND THE RESULTING NURSING SHORTAGE. SMALL STUDIES HAVE EXAMINED THE BENEFITS OF MOBILITY TECHNICIANS (MTS), WHOSE SOLE JOB IS TO SAFELY AMBULATE PATIENTS. THESE STUDIES HAVE DEMONSTRATED THAT MTS CAN INCREASE STEPS TAKEN, BUT THEY ARE TOO SMALL TO PROVE THE IMPACT OF MTS ON OTHER OUTCOMES, SUCH AS WHETHER PATIENTS HAVE IN-HOSPITAL COMPLICATIONS OR WHETHER THEY CAN GO HOME INSTEAD OF TO A POST-ACUTE CARE FACILITY. HOSPITALS ARE HESITANT TO ADOPT MT PROGRAMS BECAUSE THEY PERCEIVE THEM TO BE EXPENSIVE AND UNPROVEN. WE PROPOSE TO CONDUCT A LARGE RANDOMIZED TRIAL TO TEST THE IMPACT OF MTS ON SHORT AND INTERMEDIATE TERM OUTCOMES FOR 3000 PATIENTS AGED 65 YEARS AND OLDER AT 5 HOSPITALS IN 2 HEALTH SYSTEMS. PATIENTS WILL BE RANDOMIZED TO RECEIVE SUPERVISED AMBULATION UP TO 3 TIMES DAILY WITH A MT OR TO RECEIVE USUAL CARE. ALL PARTICIPANTS WILL WEAR AN ACCELEROMETER ON THEIR WRIST TO TRACK THEIR MOVEMENT THROUGHOUT THE HOSPITAL STAY. THE STUDY HAS 3 AIMS. FIRST, WE WILL COMPARE THE MOBILITY OF PATIENTS AT DISCHARGE (OR 10 DAYS) TO ASSESS THE IMPACT OF THE MTS ON THIS OUTCOME. WE ARE PARTICULARLY INTERESTED IN WHETHER THE USE OF MTS WILL INCREASE THE PROPORTION OF PATIENTS WHO CAN GO HOME VS. POST-ACUTE CARE, AND WHETHER THE IMPROVEMENTS IN MOBILITY ARE SUSTAINED AT 30 DAYS. SECOND, WE WILL USE PREDICTIVE MODELING TO IDENTIFY WHICH PATIENTS ARE MOST LIKELY TO BENEFIT FROM THIS INTERVENTION. THIRD, WE WILL ASSESS THE IMPACT OF THE INTERVENTION ON OVERALL COSTS ASSOCIATED WITH THE EPISODE OF CARE, INCLUDING INPATIENT COSTS AND THE 30 DAYS AFTER DISCHARGE. THIS INFORMATION WILL BE IMPORTANT TO CONVINCE HEALTH SYSTEMS TO ADOPT THIS APPROACH.
Department of Health and Human Services
$6M
TISSUE ENGINEERED CARTILAGE REPAIR
Department of Health and Human Services
$5.9M
ENSURING PATIENTS' INFORMED ACCESS TO NONINVASIVE PRENATAL TESTING
Department of Health and Human Services
$5.9M
FUNCTION OF THE PET-1 ETS FACTOR IN THE MAMMALIAN 5-HT SYSTEM
Department of Health and Human Services
$5.8M
ACTIVATION OF BLOOD AND ENDOTHELIAL CELL A5B3 INTEGRIN
Corporation for National and Community Service
$5.7M
ENGAGES AMERICORPS MEMBERS IN FULL AND PART-TIME SERVICE TO MEET COMMUNITY NEEDS IN EDUCATION, THE ENVIRONMENT, HEALTH, VETERANS, AND OTHER AREAS. CO
Department of Health and Human Services
$5.7M
BASIC AND COMPARATIVE STUDIES OF CCR5 INHIBITION TO PREVENT HIV TRANSMISSION
Corporation for National and Community Service
$5.7M
AMERICORPS*STATE
Department of Health and Human Services
$5.7M
EFFECTS OF IL-6 BLOCKADE IN TREATED HIV INFECTION
Department of Health and Human Services
$5.6M
DEFINING THE VIRAL PTMOME: TOWARDS THE DEVELOPMENT OF NOVEL ANTIVIRAL APPROACHES - PROJECT SUMMARY OVER THE PAST SEVERAL DECADES, THE TRADITIONAL APPROACH TO COMBATING VIRAL INFECTIOUS DISEASES HAS BEEN TO TARGET THE VIRUS ITSELF, IN MOST CASES BY EITHER BLOCKING VIRUS-ENCODED ENZYMES THAT ARE REQUIRED FOR VIRAL REPLICATION, OR BY PREVENTING THE VIRUS FROM ENTERING HOST CELLS. ONE OF THE MAJOR CAVEATS OF THESE APPROACHES HAS BEEN THE ABILITY OF THE VIRUS TO READILY MUTATE AND THEREBY BECOME RESISTANT TO THESE CLASSICAL TYPES OF ANTIVIRAL THERAPIES. IN FACT, THIS IS A SERIOUS PROBLEM FOR THE THERAPY OF RNA VIRUS INFECTIONS, SUCH AS HIV OR INFLUENZA VIRUS, WHICH ARE KNOWN TO RAPIDLY MUTATE AND THEREBY ESCAPE ANTIVIRAL DRUGS. ADDITIONALLY, TRADITIONAL ANTIVIRAL APPROACHES ARE DESIGNED TO TARGET A SPECIFIC VIRUS, AND THEREFORE ARE INEFFECTIVE AGAINST ANY NEW VIRUS THAT MAY EMERGE IN THE FUTURE, AND IT IS IMPOSSIBLE TO PREDICT WHAT VIRUS WILL CAUSE THE NEXT OUTBREAK OR PANDEMIC. THEREFORE, THERE IS THE URGENT NEED TO DEVELOP NEW WAYS FOR TARGETING VIRAL PATHOGENS, WHICH WILL REQUIRE CREATIVE AND INNOVATIVE RESEARCH. LIKE HUMAN PROTEINS, VIRAL PROTEINS ROBUSTLY UNDERGO POSTTRANSLATIONAL MODIFICATIONS (PTMS) FOR THEIR REGULATION AND PROPER FUNCTIONING IN THE VIRUS LIFE CYCLE. IN MOST CASES, VIRAL PTMS ARE DYNAMICALLY REGULATED BY HUMAN ENZYMES, SUCH AS KINASES/PHOSPHATASES, UBIQUITIN E3 LIGASES/DEUBIQUITINATING ENZYMES, OR ACETYL TRANSFERASES/DEACETYLASES. THUS, CELLULAR ENZYMES PLAY AN IMPORTANT ROLE IN CONTROLLING THE ABILITY OF THE VIRUS TO REPLICATE AND TO CAUSE DISEASE. THIS PROPOSAL’S OVERARCHING GOAL IS TO COMPREHENSIVELY MAP THE ‘VIRAL PTMOME’ TO IDENTIFY THE PTMS THAT ARE ESSENTIAL FOR VIRUS REPLICATION AND PATHOGENESIS. WE WILL COMBINE PROTEOMICS SCREENS AND MOLECULAR VIROLOGY APPROACHES INCLUDING REVERSE GENETICS TECHNIQUES WITH CUTTING- EDGE MOLECULAR, BIOCHEMICAL AND BIOPHYSICAL STUDIES. THIS WILL ALLOW US TO IDENTIFY AND CHARACTERIZE VIRAL PTMS AND THE RESPONSIBLE HOST MODIFYING ENZYMES, AS WELL AS TO DETERMINE THEIR ROLES FOR EFFECTIVE VIRAL REPLICATION AND PATHOGENESIS. THIS POWERFUL APPROACH, COMBINED WITH COLLABORATIVE STUDIES TO DESIGN AND TEST CHEMICAL INHIBITORS TO BLOCK THE ENZYMES THAT REGULATE CRITICAL VIRAL PTMS, WILL NOT ONLY PROVIDE UNIQUE MECHANISTIC INSIGHT INTO HOST CONTROL OF VIRUS REPLICATION BUT WILL ALSO LAY THE GROUNDWORK FOR DEVELOPING NEW ANTIVIRALS FOR A RANGE OF EMERGING VIRAL INFECTIOUS DISEASES.
Department of Health and Human Services
$5.6M
NERVE RESHAPING FOR IMPROVED ELECTRODE SELECTIVITY
Department of Health and Human Services
$5.6M
EFFECT OF CORNEAL PRESERVATION TIME ON LONG-TERM GRAFT SUCCESS (CPTS)
Department of Health and Human Services
$5.6M
UNDERSTANDING NEURAL CONTROL OF THE OCULAR SURFACE - PROJECT SUMMARY CURRENTLY OUR UNDERSTANDING OF HOW THE NERVOUS SYSTEM MAINTAINS OCULAR SURFACE HOMEOSTASIS IS EXTREMELY LIMITED. NEW TECHNOLOGIES, METHODS AND MODELS ARE NEEDED TO ADVANCE OUR SCIENTIFIC UNDERSTANDING AND ADDRESS KNOWLEDGE GAPS. THE OCULAR SURFACE AND TEAR FILM-SECRETING GLANDS (INCLUDING THE LACRIMAL AND MEIBOMIAN GLANDS, AS WELL AS THE GOBLET CELLS) ARE CAREFULLY CONTROLLED TO PROVIDE AN OPTICALLY SMOOTH, LOW-SCATTERING SURFACE WITH APPROPRIATE IMMUNE AND INJURY RESPONSES. SENSORY FEEDBACK TO MAINTAIN THE STRUCTURAL AND FUNCTIONAL INTEGRITY OF THE OCULAR SURFACE IS PROVIDED BY THE CORNEAL NERVES, WHICH SEND FEEDBACK FROM STIMULI (CHEMICAL, THERMAL, MECHANICAL) TO GANGLIA (E.G., TRIGEMINAL) AND BRAIN REGIONS (E.G., VENTRAL POSTEROMEDIAL THALAMUS) TO DRIVE PRODUCTION OF TEAR FILM COMPONENTS AS WELL AS THE BLINK REFLEX. THIS DELICATE BALANCE OF NEURAL CONTROL IS DISRUPTED BY DAMAGE, PERIPHERAL NEUROPATHIES, INFLAMMATION AND FURTHER COMPLICATED BY A WIDE ARRAY OF IMMUNE RESPONSES TO VARIOUS DISEASES. DYSFUNCTION OF THIS FEEDBACK LOOP CAN LEAD TO A DOWNWARD SPIRAL OF FURTHER DYSREGULATION. ABERRANT NEURAL CONTROL OF THE OCULAR SURFACE CAN LEAD TO ABNORMAL SENSATION AND PAIN, WHICH IN THE WORST CASES CAN BE DISABLING. TO FIND REMEDIES, IT IS FIRST ESSENTIAL TO UNDERSTAND THE UNDERLYING NEURAL CONTROL SYSTEM AND HOW IT ADAPTS TO ITS ENVIRONMENT. IN THIS PROPOSAL, WE AIM TO BRING NEW TOOLS AND MODELS TO STUDY MOLECULAR, CELLULAR, AND FUNCTIONAL INTERACTIONS ACROSS SYSTEMS RESPONSIBLE FOR NEURAL CONTROL OF THE OCULAR SURFACE AND EXAMINE HOW THEY CHANGE UNDER DIFFERENT INFLAMMATORY AND PAIN CONDITIONS. WE HAVE ASSEMBLED AN EXCELLENT TEAM WITH EXPERTISE ACROSS MULTIPLE FIELDS INCLUDING ADVANCED 3D MICROSCOPY, NEUROSCIENCE, ELECTROPHYSIOLOGY, PAIN, OCULAR IMMUNOLOGY, OCULAR LIPID METABOLISM, OCULAR SURFACE DISORDERS, SPATIAL STATISTICS, AND MACHINE/DEEP LEARNING. HERE, WE WILL UTILIZE CUTTING EDGE TECHNIQUES AND TECHNOLOGIES INCLUDING OPTICAL CLEARING, TRACT TRACING, ETHOLOGICALLY-VALID BEHAVIOR ANALYSIS, MACHINE/DEEP LEARNING, SPATIAL STATISTICS, GENETICALLY ENCODED CALCIUM IMAGING, LIGHT-SHEET MICROSCOPY, MULTIPLEXED 3D FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IMAGING, AND MULTI-ARRAY ELECTRODES IMPLANTED IN THE BRAIN. THESE TOOLS WILL HELP US ASSESS MOLECULAR, CELLULAR, AND FUNCTIONAL INTERACTIONS ACROSS ORGANS AND BEGIN TO UNDERSTAND OCULAR SURFACE CONTROL AT THE ORGANISM LEVEL. WE WILL ALSO EMPLOY SEVERAL RELEVANT ANIMAL MODELS TO ASSESS OCULAR SURFACE CONTROL UNDER DIFFERENT INFLAMMATORY AND PAIN CONDITIONS. MODELS INCLUDE AWAT2 DEFICIENT MICE THAT MIMIC EVAPORATIVE DRY EYE DISEASE (DED), DIABETIC MICE, AN EPITHELIAL DEBRIDEMENT MODEL WITH PSEUDOMONAS AERUGINOSA THAT MIMICS BACTERIAL KERATITIS, AND HUMAN DONOR EYES. THE MOUSE MODELS ALL HAVE GCAMP6F EXPRESSED IN CORNEAL NERVES ALLOWING FUNCTIONAL IMAGING OF CALCIUM TRANSIENTS. WITH THESE MODELS WE WILL STUDY BOTH INNATE AND ADAPTIVE IMMUNITY AS WELL AS NOCICEPTIVE AND NEUROPATHIC PAIN RESPONSES. IN ADDITION, WE WILL APPLY NERVE GROWTH FACTOR (NGF) TO OUR MODELS TO STUDY HOW A POTENTIAL TREATMENT OPTION ALTERS THE OCULAR SURFACE CONTROL SYSTEM.
Department of Health and Human Services
$5.6M
ACTIVATION OF THE BETA-3 INTEGRINS: ROLE OF THE KINDLINS
Department of Health and Human Services
$5.5M
MULTI-LEVEL INTERVENTIONS TO REDUCE CARIES DISPARITIES IN PRIMARY CARE SETTINGS
Department of Transportation
$5.5M
APPLICATION PURPOSE: THE PURPOSE OF THIS AWARD IS TO PROVIDE ASSISTANCE FOR ONE YEAR OF OPERATING PLANNING ASSISTANCE PREVENTIVE MAINTENANCE ADA SERVICE LEASE OF CAPITAL MAINTENANCE ITEMS AND ARCHITECTURE AND ENGINEERING DESIGN THE PURCHASE OF FOUR REPLACEMENT VEHICLES FUND TO REHAB BUS STOP SIGNS PURCHASE OF COMPUTER EQUIPMENT AND SOFTWARE.; ACTIVITIES PERFORMED: FUNDS WILL BE USED TO COVER TRANSIT PLANNING ACTIVITIES FOR THE DEVELOPMENT AND UPDATE OF OUR SERVICE PLANS TRANSPORTATION IMPROVEMENT PROGRAMS ONGOING ANALYSIS AND EVALUATION OF POLICIES PROCEDURES AND STANDARDS IN THE AREAS OF SERVICE. FUNDS WILL BE USED FOR ARCHITECTURE AND ENGINEERING DESIGN TO ASSIST WRTA STAFF WITH SPECIFICATION DEVELOPMENT AND PROJECT OVERSIGHT ON VARIOUS TECHNICAL AND CONSTRUCTION PROJECTS. FUNDS WILL BE USED FOR THE PURCHASE OF COMPUTER HARDWARE AND SOFTWARE. FUNDS WILL BE USED TO SUPPORT OPERATING AND ADA SERVICES. FUNDS WILL BE USED FOR PREVENTIVE MAINTENANCE TO KEEP OUR ASSETS IN A GOOD STATE OF REPAIR FUNDS WILL BE USED FOR THE PURCHASE OF FOUR REPLACEMENT VEHICLES.; EXPECTED OUTCOMES: THE BENEFITS FROM THESE FUNDS WILL ALLOW WRTA TO PLAN AND DEVELOP ROUTES TO BETTER SERVE OUR COMMUNITY ASSIST IN THE CONSTRUCTION OF THE EXPANSION OF OUR ADMIN/MAINTENANCE FACILITY. THE PURCHASE OF REPLACEMENT VEHICLES WILL REPLACE VEHICLES THAT ARE BEYOND THEIR USEFUL LIFE SO THAT WRTA CAN PROVIDE A BETTER SERVICE WITH NEWER VEHICLES FOR OUR PASSENGERS. THE CONTINUED MAINTENANCE OF OUR ASSETS IN A STATE OF GOOD REPAIR. CONTINUED ABILITY TO MAINTAIN ADA AND FIXED ROUTE SERVICE.; INTENDED BENEFICIARIES: WRTA AND OUR PASSENGERS THAT RELY ON OUR SERVICE WILL BENEFIT FROM CONTINUED SERVICES PERMITTING WORKERS TO GET TO JOBS MEDICAL TRIPS EDUCATION OPPORTUNITIES SHOPPING AND OTHER DESTINATIONS. PLUS WRTA WILL BE ABLE TO REDUCE OUR CARBON FOOTPRINT THAT WILL HELP THE ENVIRONMENT.; SUBRECIPIENT ACTIVITIES: NONE
Department of Transportation
$5.5M
APPLICATION PURPOSE: THE PURPOSE OF THIS AWARD IS TO PROVIDE FUNDING THE PURCHASE OF THREE REPLACEMENT BATTERY ELECTRIC LTV BUSES CHARGING EQUIPMENT TO BE INSTALLED IN A BUS STORAGE BARN PROJECT ADMINISTRATION AND BUS BARN RENOVATION.; ACTIVITIES PERFORMED: FUNDS WILL BE USED FOR THE PURCHASE OF THREE REPLACEMENT BATTERY ELECTRIC LTV BUSES CHARGING EQUIPMENT TO BE USED TO FUEL ELECTRIC VEHICLES PROJECT ADMINISTRATION AND THE RENOVATION OF A BUS BARN.; EXPECTED OUTCOMES: THE BENEFITS FROM THESE FUNDS WILL ALLOW WRTA TO BEGIN THE CONVERSION OF OUR FLEET FROM DIESEL TO A MORE SUSTAINABLE POWER SOURCE THAT WILL REDUCE CARBON EMISSIONS. THE PURCHASE OF REPLACEMENT BATTERY ELECTRIC LTV BUSES WILL REPLACE VEHICLES THAT ARE BEYOND THEIR USEFUL LIFE SO THAT WRTA CAN PROVIDE A BETTER SERVICE WITH NEWER VEHICLES FOR OUR PASSENGERS. THE REPLACEMENT OF BEYOND USEFUL LIFE REVENUE VEHICLES WITH NEWER MORE ENVIRONMENTALLY SUSTAINABLE VEHICLES. THE RENOVATION OF OLD UNDERUTILIZED BUS BARN TO PROVIDE ADDITIONAL BUS STORAGE.; INTENDED BENEFICIARIES: WRTA AND OUR PASSENGERS THAT RELY ON OUR SERVICE WILL BENEFIT FROM CONTINUED SERVICES PERMITTING WORKERS TO GET TO JOBS MEDICAL TRIPS EDUCATION OPPORTUNITIES SHOPPING AND OTHER DESTINATIONS. PLUS WRTA WILL BE ABLE TO REDUCE OUR CARBON FOOTPRINT THAT WILL HELP THE ENVIRONMENT.; SUBRECIPIENT ACTIVITIES: N/A
Department of Health and Human Services
$5.5M
NOVEL THERAPIES FOR ALCOHOLIC HEPATITIS
Department of Health and Human Services
$5.4M
DATA COORDINATING CENTER FOR PILOT STUDIES OF CANDIDATE THERAPIES FOR CKD
Department of Health and Human Services
$5.4M
DEVELOPMENT OF NETWORKED IMPLANTABLE NEUROPROSTHESES
Department of Health and Human Services
$5.3M
AUTOMATIC CONTROL OF STANDING BALANCE WITH FNS
Department of Health and Human Services
$5.3M
THERAPEUTIC IMPLICATIONS OF MOLECULAR DEFECTS IN BONE MARROW FAILURE
Department of Health and Human Services
$5.3M
LOCAL CIRCUITS IN THE OLFACTORY BULB
Department of Transportation
$5.2M
CAPITAL PLANNING
Department of Health and Human Services
$5.2M
NIAMS: CORT (PSORIASIS CENTER OF RESEARCH TRANSLATION)
Department of Health and Human Services
$5.1M
ER-TO-GOLGI TRANSPORT OF COAGULATION FACTORS V AND VIII
Department of Health and Human Services
$5.1M
INTERDISCIPLINARY BIOMEDICAL IMAGING TRAINING PROGRAM
Department of Health and Human Services
$5.1M
LRP4 SIGNALING IN NEUROMUSCULAR JUNCTION FORMATION
Source: Federal Audit Clearinghouse (fac.gov)
No federal single audit records found for this organization.
Single audits are required for entities expending $750,000+ in federal awards annually.
Tax Year 2025 · Source: IRS e-Filed Form 990
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2024IRS e-File | $2.6M | $939.4K | $2.7M | $1.6M | $892.5K |
| 2023 | $2.5M | $1.3M | $2.6M | $788.6K | $603K |
| 2022 | $2.3M | $1.1M | $2.3M | $830.8K | $619.1K |
| 2021 | $2.4M | $1.2M |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
| Tax Year | Form Type | Source | Documents |
|---|---|---|---|
| 2025 | 990 | IRS e-File | PDF not yet published by IRSView Filing → |
| 2024 | 990 | IRS e-File | PDF not yet published by IRSView Filing → |
| 2023 | 990 | DataIRS e-File |
Financial data: IRS e-Filed Form 990 (Tax Year 2024)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2025)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Collin Clement X | VP | 1 | $0 | $0 | $0 | $0 |
| Amanda Gowin X | Sec | 1 | $0 | $0 | $0 | $0 |
| Brandon Ruediger X | Treas | 5 | $0 | $0 | $0 | $0 |
| Don Soph X | President | 1 | $0 | $0 | $0 | $0 |
Collin Clement X
VP
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Amanda Gowin X
Sec
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Brandon Ruediger X
Treas
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Don Soph X
President
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Bill Ladwig X | Member | 5 | $0 | $0 | $0 | $0 |
| Bill Nigue X | Member | 1 | $0 | $0 | $0 | $0 |
| Jennifer Brady X | Member | 1 | $0 | $0 | $0 | $0 |
| Katherine Christensen X | Member | 1 | $0 | $0 | $0 | $0 |
| Melissa Anderson X | Member | 5 | $0 | $0 | $0 | $0 |
| Tana Real X | Member |
Bill Ladwig X
Member
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Bill Nigue X
Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Jennifer Brady X
Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
| $2.1M |
| $817.8K |
| $591.4K |
| 2020 | $2.3M | $1.1M | $2.3M | $784.5K | $324.3K |
| 2019 | $2.5M | $1.2M | $2.5M | $640.9K | $411.4K |
| 2018 | $2M | $989.9K | $2.1M | $605.3K | $353.5K |
| 2017 | $1.8M | $1.7M | $1.9M | $553.9K | $476.5K |
| 2016 | $2.1M | $1.9M | $1.9M | $567.3K | $501.9K |
| 2015 | $1.8M | $1.5M | $1.8M | $422.5K | $364.9K |
| 2014 | $1.9M | $1.7M | $1.9M | $399.1K | $339K |
| 2013 | $1.9M | $551.4K | $2M | $369.2K | $305.9K |
| 2012 | $927.5K | $420.4K | $882K | $470.4K | $367.3K |
| 2011 | $1.7M | $190.9K | $1.7M | $456.8K | $350K |
| 2022 | 990 | DataIRS e-File |
| 2021 | 990 | Data | PDF not yet published by IRS |
| 2020 | 990 | Data |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | Data |
| 2010 | 990 | — |
| 2009 | 990 | — |
| 2008 | 990 | — |
| 2007 | 990 | — |
| 2006 | 990 | — |
| 2005 | 990 | — |
| 2004 | 990 | — |
| 2003 | 990 | — |
| 2002 | 990 | — |
| 2001 | 990 | — |
| 5 |
| $0 |
| $0 |
| $0 |
| $0 |
| William Bill Hinchie X | Member | 1 | $0 | $0 | $0 | $0 |
Katherine Christensen X
Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Melissa Anderson X
Member
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Tana Real X
Member
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
William Bill Hinchie X
Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0